paclitaxel has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 413 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 187 (45.28) | 24.3611 |
| 2020's | 226 (54.72) | 2.80 |
| Authors | Studies |
|---|---|
| Ham, J; Hwang, GS; Jang, HJ; Kang, KS; Kim, HY; Kim, KH; Kwak, JH; Kwak, JY; Lee, D; Park, EH; Park, HJ; Park, JY; Yamabe, N | 1 |
| Chen, LJ; Cheng, W; Huang, M; Jiao, Y; Li, GB; Li, YP; Lin, WT; Lin, XD; Wei, YQ; Wu, XA; Xiang, R; Yang, J; Yang, SY; Zhang, CH; Zhang, RJ; Zhao, YL; Zheng, MW; Zhong, L | 1 |
| Cichewicz, RH; Du, L; Mooberry, SL; Robles, AJ | 1 |
| Chen, K; Han, JH; Huang, SZ; Jiao, Y; Li, LL; Li, YP; Lin, WT; Lu, GW; Peng, B; Song, CL; Wei, YQ; Xiang, R; Yang, J; Yang, SY; Zhang, CH; Zhang, RJ; Zheng, MW; Zhong, L | 1 |
| Hu, R; Kim, D; Lee, JY; Lee, SK; Luu, TT; Park, HJ; Wang, CY | 1 |
| Al Moustafa, AE; Alali, F; Cyprian, FS; El Sayed, K; Elkhalifa, D; Khalil, A; Qusa, M; Siddique, AB | 1 |
| Chen, ZS; Li, D; Lin, A; Liu, J; Ma, X; Wu, H; Xie, S; Xu, J; Xu, S; Yang, DH; Yao, H | 1 |
| Cao, S; Li, C; Liu, N; Liu, S; Liu, T; Liu, X; Liu, Y; Lu, C; Sheng, P; Sun, Y; Wang, Q; Wei, M; Wei, Y; Yang, C; Yang, G; Yang, Y; Zhou, Y | 1 |
| Kok Meng, C; Kok Wai, L; Li, H; Poh Yen, K; Stanslas, J; Wang, X; Zhang, T | 1 |
| Bian, ZX; Fan, BM; Guo, XM; Hao, CW; Huang, T; Khan, M; Lin, CY; Wu, J; Yadav, MB | 1 |
| Njar, VCO; Purushottamachar, P; Thankan, RS; Thomas, E | 1 |
| Fu, Q; Hu, C; Lv, H; Zhao, D | 1 |
| Ajarim, D; Al-Sayed, A; Al-Tweigeri, T; Cabangon, L; Eiada, R; Ghebeh, H; Suleman, K; Tulbah, A | 1 |
| Beebe, DJ; Burkard, ME; Hu, Y; Humayun, M; Jin, N; Lera, RF; Manasrah, BK; McGregor, SM; Norman, RX; O'Regan, RM; Scribano, CM; Tevaarwerk, AJ; Tucker, JB; Weaver, BA; Wilke, LG; Wisinski, KB; Yan, RE | 1 |
| Choi, J; Han, J; Heo, W; Jung, JG; Kang, W; Kim, JH; Kim, JI; Lee, C; Lee, KJ; Li, S; Moon, HG; Na, D; Noh, DY; Quan, M; Ryu, HS; Son, HY; Yun, J | 1 |
| Cao, J; Gong, C; Hu, S; Hu, X; Li, T; Li, Y; Tao, Z; Wang, B; Wang, L; Xie, Y; Zhang, J; Zhao, Y | 1 |
| Huang, YQ; Li, PP; Li, RG; Lu, JP; Wang, ZY; Zhang, WJ | 1 |
| Adélaïde, J; Bertucci, F; Birnbaum, D; Boher, JM; Carbuccia, N; Chaffanet, M; Charafe-Jauffret, E; Dalenc, F; Garnier, S; Gonçalves, A; Guille, A; Isambert, N; Levy, C; Pakradouni, J; Popovici, C; Provansal, M; Rezai, K; Robert, M; Sabatier, R; Sfumato, P; Vicier, C | 1 |
| Morita, A; Nohara, Y; Ono, S; Sato, T; Takagi, S; Tanaka, M; Yamashita, S; Yoshinaga, Y | 1 |
| Guo, B; Meng, F; Qiu, X; Qu, Y; Zheng, H; Zhong, Z | 1 |
| Fiegl, H; Hackl, H; Haschka, MD; Karbon, G; Parson, W; Rocamora-Reverte, L; Soratroi, C; Villunger, A | 1 |
| Andersen, J; Bermejo, B; Calvo, I; Ciruelos, EM; Gallagher, RI; Gil-Gil, MJ; Isakoff, SJ; Nowicka, M; Nuciforo, PG; Oliveira, M; Passos-Coelho, JL; Petricoin, EF; Pratt, DA; Saura, C; Shi, Z; Villagrasa, P; Wongchenko, MJ; Wulfkuhle, J | 1 |
| DeBerardinis, RJ; Fan, C; Glodowski, CR; Kaushik, A; Liao, C; Liu, J; Locasale, JW; McBrayer, SK; Mott, KR; Perou, CM; Vu, H; Zhang, Q | 1 |
| Jamal, MA; Jiao, D; Qing, Y; Wei, HJ; Xiong, Z; Xu, A; Xu, K; Zhao, H; Zhao, HY; Zhu, W; Zou, D | 1 |
| Chen, L; Li, L; Liu, W; Wang, Y; Zhang, Z | 1 |
| Ballman, K; Bellon, JR; Campbell, JD; Carey, LA; Collyar, D; Fan, C; Fernandez-Martinez, A; Golshan, M; Hahn, OM; Hoadley, KA; Hu, Z; Hudis, CA; Hyslop, T; Kuzma, C; Li, Y; Ma, C; Mamounas, E; Parker, JS; Partridge, A; Perou, CM; Polley, MC; Port, ER; Selitsky, S; Shepherd, JH; Sikov, WM; Singh, B; Soloway, MG; Somlo, G; Spears, PA; Tolaney, SM; Winer, EP | 1 |
| Bernard, B; Chang, S; Chun, B; Conlin, AK; Conrad, V; Fields, PA; Kim, I; Koguchi, Y; McArthur, HL; Nikitin, B; Page, DB; Polaske, N; Pucilowska, J; Rajamanickam, V; Redmond, WL; Schmidt, M; Urba, WJ | 1 |
| Dunbar, M; Geyer, CE; Golshan, M; Harkness, C; Huober, J; Loibl, S; Lorenzo, JP; Maag, D; McIntyre, K; Metzger, O; O'Shaughnessy, J; Rastogi, P; Rugo, HS; Sikov, WM; Sohn, JH; Symmans, WF; Untch, M; Wolmark, N; Wright, GS; Yardley, D; Young, R | 1 |
| Al-Wahsh, H; Ferraiuolo, RM; Fifield, BA; Gupta, R; Hamm, C; Hussein, A; Kay, A; Kulkarni, S; Mailloux, E; Mathews, J; Porter, LA | 1 |
| Ge, X; Jiang, Q; Liang, Y; Mi, Y; Shen, Y; Song, S; Wang, J; Ye, Q; Zhang, D | 1 |
| Anton, A; Bermejo, B; Bianchini, G; Ciruelos, EM; Colleoni, M; Del Mastro, L; Egle, D; Gianni, L; Greil, R; Huang, CS; Kelly, C; Maffeis, I; Mariani, G; Russo, S; Semiglazov, V; Thill, M; Valagussa, P; Viale, G; Zamagni, C; Zambelli, S | 1 |
| Banala, RR; Bodlapati, R; Devraj, VM; Halder, S; Jana, K; Mallarpu, CS; Mukherjee, S; Neerudu, UK; Rachamalla, HK; Thakkumalai, M; Vemuri, SK; Venkata, GRA; Venkata, SGP | 1 |
| Cao, AY; Chai, WJ; Chen, CM; Chen, L; Chen, X; Di, GH; Fan, L; Guo, X; Hou, YF; Hu, X; Hu, Z; Huang, XY; Jiang, YZ; Li, JJ; Liu, GY; Ma, XY; Shao, ZM; Sun, XJ; Wang, ZH; Wu, J; Wu, SY; Xu, Y; Yang, WT; Yu, KD; Zhao, S; Zhu, XY; Zou, JJ | 1 |
| Huang, X; Ni, J; Xi, X; Yang, F; Yuan, H | 1 |
| Alfón, J; Domènech, C; Lizcano, JM; Megías-Roda, E; Muñoz-Guardiola, P; Perez-Montoyo, H; Polonio-Alcalá, E; Puig, T; Ruiz-Martínez, S; Solé-Sánchez, S; Yeste-Velasco, M | 1 |
| Okines, A; Turner, N | 1 |
| Downey, K; Foulser, PFG; Hart, PE; McGrath, SE; Senthivel, N | 1 |
| Box, GM; Burmi, RS; Court, WJ; Davies, JA; Eccles, SA; Harvey, AJ; Hussain, HA; Jiang, WG; Mokbel, K; Wazir, U | 1 |
| Bai, Y; Blenman, KRM; Denkert, C; Foldi, J; Gunasekharan, V; Ibrahim, EY; Karn, T; Li, X; Loibl, S; Marczyk, M; Park, T; Pusztai, L; Qing, T; Reisenbichler, E; Rimm, DL; Rozenblit, M; Silber, A; Sinn, BV; Wolf, DM; Yaghoobi, V | 1 |
| Bilbao, M; Linden, KM; Morgan, AB; Ostrovsky, O; Sookram, J; Zheng, A | 1 |
| Geyer, CE; Loibl, S; Sikov, WM | 1 |
| Dong, L; Fan, Y; Li, Q; Luo, Y; Ma, F; Wang, J; Wang, X; Xiu, M; Xu, B; Yuan, P; Zhang, P | 1 |
| Bai, Y; Chen, M; Chen, Y; Cheng, P; Deng, S; Hou, L; Liang, Q; Lv, Y; Ma, C; Pu, L; Wang, D; Wang, S; Zhang, K; Zhou, Y | 1 |
| Loi, S; Salgado, R | 1 |
| He, J; He, Q; Li, J; Li, M; Long, Y; Qiu, Y; Ren, K; Wang, X; Xu, Z; Yang, Y; Zang, S; Zhang, Z | 1 |
| Chowdhury, M; Das, PK; Ghosh, A; Ghosh, AK | 1 |
| Chen, H; Deng, S; Hartman, KL; Krutilina, RI; Li, W; Lukka, PB; Ma, D; Mahmud, F; Meibohm, B; Miller, DD; Parke, DN; Seagroves, TN; Wang, R | 1 |
| Baldassarre, G; Belletti, B; Manfioletti, G; Pegoraro, S; Pellarin, I; Piazza, S; Ros, G; Sgarra, R; Sgubin, M | 1 |
| Blohmer, JU; Denkert, C; Engels, K; Fasching, PA; Hanusch, C; Huober, J; Jackisch, C; Just, M; Link, T; Loibl, S; Nekljudova, V; Reinisch, M; Rhiem, K; Schneeweiss, A; Seiler, S; Seither, F; Solbach, C; Stötzer, O; Thill, M; Untch, M; Wimberger, P | 1 |
| Jang, HJ; Kwon, H; Lee, HJ; Lee, HY; Min, HY; Moon, HG; Pei, H; Suh, YA; Yun, HJ | 1 |
| Chakraborti, A; Kundrapu, DB; Malla, R; Marni, R | 1 |
| Futamura, M; Iwasa, T; Kawabata, H; Kitano, S; Masuda, N; Matsumoto, K; Minami, H; Mukohara, T; Ozaki, Y; Takahashi, M; Takano, T; Tanabe, Y; Tsurutani, J; Yoshimura, K | 1 |
| Czerwonka, A; Luszczki, J; Okon, E; Stepulak, A; Wawruszak, A | 1 |
| Hasegawa, A; Hattori, M; Hayashi, N; Ito, M; Kiyama, K; Kobayashi, K; Masuda, N; Nakagawa, S; Niikura, N; Ohsumi, S; Saji, S; Yamashita, T | 1 |
| Chang, S; Chen, SJ; Chen, ST; Dai, MS; Huang, CS; Kuo, SH; Lee, YH; Lin, PH; Liu, LC; Lo, C; Tan, KT; Tseng, LM; Wang, MY; Yeh, DC | 1 |
| Bruzzese, F; Budillon, A; Caputo, R; Ciardiello, C; Cocco, S; Costantini, S; De Laurentiis, M; Leone, A; Lombardi, R; Piezzo, M; Roca, MS; Sisalli, MJ | 1 |
| Chen, L; Cheng, Q; Duan, Y; Fan, W; Huang, B; Li, D; Liu, J; Ma, T; Wang, P; Yu, M; Zhu, C | 1 |
| Crews, P; Johnson, TA; Morris, JD; Risinger, AL; Takahashi-Ruiz, L | 1 |
| Cai, L; Guo, X; Hu, X; Jiang, Z; Luo, J; Pan, Y; Shao, Z; Sun, T; Teng, YE; Wang, B; Wang, S; Wang, X; Wang, Z; Wu, J; Yan, M; Zhang, J; Zhao, Y | 1 |
| Bhargavi, N; Chaudhari, D; Date, T; Ghadi, R; Jain, S; Katari, O; Kuche, K | 1 |
| Czerwonka, A; Luszczki, J; Okon, E; Telejko, I; Wawruszak, A | 1 |
| Adrada, BE; Boge, M; Candelaria, RP; Elshafeey, N; Huo, L; Jarrett, AM; Litton, JK; Ma, J; Mohamed, RMM; Rauch, GM; Son, JB; Tripathy, D; Valero, V; White, JB; Wu, C; Yam, C; Yankeelov, TE; Zhou, Z | 1 |
| Ishizaka, T; Kimura, A; Matsuda, T; Nishida, S; Okada, A; Sakamoto, C; Takeda, T; Takefuji, H; Tsubaki, M; Tsurushima, K | 1 |
| Lukong, KE; Mandapati, A | 1 |
| Bharti, S; Dhiman, S; Goswami, A; Manhas, D; Mir, KB; Nandi, U; Sharma, DK; Tripathi, N; Wazir, P | 1 |
| Bairaktari, E; Kordias, D; Kostara, CE; Magklara, A; Papadaki, S; Verigos, J | 1 |
| Ahmed, AY; Ahmed, SK; Habashy, DA; Khaled, RM; Magdy, H; Mansour, AM; Radacki, K; Tharwat, EK; Zeinhom, A | 1 |
| Anderson, DH; Boulet, A; Hammond, SA; Kendall, S; Mellor, P; Plaza, K; Plett, R; Vizeacoumar, FJ; Vizeacoumar, FS | 1 |
| Aiso, T; Hasegawa, S; Igarashi, Y; Kimura, Y; Nihei, Y; Ohnishi, K; Ohtake, H; Sai, Y; Satou, T; Takasu, N | 1 |
| Arpino, G; Awada, A; Bartsch, R; Campone, M; Cortes, J; Curigliano, G; De Placido, P; De Placido, S; Del Mastro, L; Denys, H; Generali, D; Gennari, A; Giuliano, M; Gligorov, J; Harbeck, N; Jerusalem, G; Lambertini, M; Lüftner, D; Martín, M; Mustacchi, G; Onesti, CE; Paris, I; Pinato, DJ; Prat, A; Schettini, F; Tjan-Heijnen, V; Van Dam, P; Venturini, S; Wildiers, H; Zaman, K | 1 |
| Du, Y; Gao, F; Guo, Q; He, Y; Liu, Y; Qiu, Y; Yang, C; Zhang, G | 1 |
| Cunningham, K; Haynes, BM; Shekhar, MPV | 1 |
| Bago-Horvath, Z; Bartsch, R; Deutschmann, C; Gschwantler-Kaulich, D; Leser, C; Marhold, M; Pfeiler, G; Seifert, M; Singer, CF | 1 |
| Aye, SN; Basavaraj, AK; Sharmni Vishnu, K; Win, TT | 1 |
| Anastasiadis, P; Carney, CP; Chen, C; Kapur, A; Kim, AJ; Ritzel, RM; Winkles, JA; Woodworth, GF | 1 |
| Amato, O; Bria, E; Canino, F; Carbognin, L; Cumerlato, E; Dieci, MV; Fassan, M; Garufi, G; Genovesi, E; Giannarelli, D; Giorgi, CA; Griguolo, G; Guarneri, V; Lo Mele, M; Massa, D; Michieletto, S; Miglietta, F; Piacentini, F; Saibene, T; Tornincasa, A; Trudu, L; Zarrilli, G | 1 |
| Dong, Q; Du, F; Gao, L; Huo, X; Li, Z; Liu, Z; Ren, D; Shen, G; Wang, M; Xie, Q; Xin, Y; Zhao, F; Zhao, J; Zhao, Y | 1 |
| Fan, L; Liu, Y; Shao, ZM; Wang, ZH | 1 |
| Cai, J; Chen, J; Huang, C; Li, C; Li, M; Wang, B; Wang, J; Zhang, JV; Zhang, P; Zhou, W | 1 |
| Andriani, L; Chen, C; Deng, L; Hu, SY; Li, DQ; Liao, L; Ma, XY; Shao, ZM; Yang, SY; Zhang, FL; Zhang, YL | 1 |
| Caner, A; Cumaoğlu, A; Önal, MG; Sezer, G | 1 |
| Cogan, NG; Davenport, AA; Gallegos, CA; Heinzman, KA; Lu, Y; Massicano, AVF; Song, PN; Sorace, AG | 1 |
| Bian, Y; Chen, P; Hu, X; Luo, S; Wen, Q; Yu, L; Zeng, X | 1 |
| Bianchi, GV; Cantarelli, B; Capri, G; de Braud, F; Depretto, C; Fucà, G; Leporati, R; Ligorio, F; Lobefaro, R; Manoukian, S; Mariani, L; Peverelli, G; Presti, D; Pruneri, G; Rametta, A; Scaperrotta, G; Vernieri, C; Vingiani, A; Zattarin, E | 1 |
| Chen, L; Chen, Q; Huang, P; Li, H; Liang, Y; Lu, H; Luo, T; Wu, G; Xie, H; Zuo, Q | 1 |
| He, Y; Luo, W; Shi, J; Song, K; Zhang, X; Zhang, Y; Zhu, Z | 1 |
| Fu, W; Gu, J; Guo, G; Huang, Q; Lu, K; Ma, R; Zheng, S; Zhou, J | 1 |
| Han, G; Hu, D; Huang, J; Yao, G; Yuan, F; Zhang, Q | 1 |
| Aguilar, MLÁ; Bernabeu, E; Chiappetta, DA; Fuentes, P; Lauretta, P; Martínez Vivot, R; Medina, VA; Moretton, MA; Nicoud, MB; Ospital, IA; Riedel, J; Rubinstein, MR; Salgueiro, MJ; Speisky, D; Táquez Delgado, MA | 1 |
| Appleman, LJ; Belani, CP; Beumer, JH; Chen, AP; Chu, E; Ding, F; Emens, LA; Giranda, VL; Ivy, SP; Kiesel, BF; Lee, JJ; Lin, Y; Malhotra, MK; Pahuja, S; Puhalla, S; Shepherd, SP; Stoller, RG; Tawbi, HA | 1 |
| Belleville, E; Brucker, SY; Erber, R; Fasching, PA; Fehm, TN; Häberle, L; Hack, CC; Hartkopf, AD; Hartmann, A; Hein, A; Janni, W; Kolberg, HC; Rübner, M; Theuser, AK; Uhrig, S; Untch, M | 1 |
| Jiang, H; Lu, L; Wang, F; Wang, L; Zhang, X; Zhao, C | 1 |
| Bao, J; Dai, X; Dai, Y; Gu, H; Li, H; Liu, C; Lv, L; Wang, O; Wang, X; Wang, Z; Wu, H; Wu, Z; Xia, E; Yan, C | 1 |
| Alessandri, G; Bonaffini, L; Cazzaniga, ME; Cerrito, MG; Coccè, V; Cordani, N; Giannì, A; Lisini, D; Marcianti, A; Mauri, M; Meanti, R; Mologni, L; Paglia, G; Paino, F; Pessina, A; Tettamanti, P; Torsello, A; Villa, C | 1 |
| Bano, A; Gustafsson, JÅ; Modi, PS; Stevens, JH; Strom, AM | 1 |
| Fan, Z; He, Y; Li, J; Ouyang, T; Wang, J; Wang, T; Wang, X | 1 |
| Bozoghlanian, M; Cui, Y; Frankel, PH; Martinez, N; Murga, M; Patel, N; Ruel, C; Schmolze, D; Stewart, D; Tang, A; Tumyan, L; Vora, L; Waisman, J; Yost, SE; Yuan, Y | 1 |
| Adrada, BE; Candelaria, RP; Clayborn, A; Damodaran, S; Ding, QQ; Garber, HR; Huo, L; Ibrahim, N; Karuturi, M; Layman, RM; Litton, JK; Mittendorf, EA; Moulder, SL; Murthy, RK; Prabhakaran, S; Ramirez, D; Rauch, GM; Ravenberg, E; Sun, R; Symmans, WF; Thompson, AM; Tripathy, D; Valero, V; White, JB; Yam, C | 1 |
| Chen, Z; Cheng, Y; Gong, R; Jiang, S; Jiang, T; Sun, X; Xu, P; Yang, J; Yi, W; Zhong, C; Zhou, W; Zhu, J | 1 |
| Hong, G; Liu, H; Liu, T; Liu, Y; Mao, L; Su, Z | 1 |
| Jin, Z; Ma, X; Ni, R; Pan, Y; Wu, Q; Yang, G | 1 |
| Li, Q; Li, X; Liu, X; Luo, K; Sun, Q; Xie, L; Yan, C; Yang, L; Zhao, Y | 1 |
| Adorno-Cruz, V; Almubarak, HF; Azadi, P; Cobb, BA; Colley, KJ; Cristofanilli, M; D'Amico, P; Dandar, T; Dashzeveg, NK; El-Shennawy, L; Gerratana, L; Gradishar, WJ; Hoffmann, AD; Jia, Y; Liu, H; Manai, M; Muller, WA; Patel, P; Platanias, LC; Ramos, EK; Reduzzi, C; Scholten, D; Schuster, EJ; Shah, AN; Shajahan, A; Sokolowski, MT; Taftaf, R; Zhang, Q; Zhang, Y | 1 |
| Hao, D; Jing, X; Li, C; Lu, S; Meng, Q; Pei, Q; Xiang, X; Xie, Z | 1 |
| Cho, WCS; Lin, ZX; Wu, YL; Xian, YF; Xu, HX; Zhang, J | 1 |
| Bhatt, S; Chand, J; Dash, A; Dhiman, S; Goswami, A; Jamwal, A; Nandi, U; Singh, B; Wazir, P | 1 |
| Olivier, T; Prasad, V | 1 |
| Denkert, C; Fasching, PA; Furlanetto, J; Heinmöller, E; Jackisch, C; Karn, T; Loibl, S; Mairinger, T; Marme, F; Müller, V; Nekljudova, V; Schem, C; Schmatloch, S; Schneeweiss, A; Shen, C; Soon-Shiong, P; Stickeler, E; Szeto, CW; Untch, M; van Mackelenbergh, MT; Weber, KE; Williams, TM | 1 |
| Aceto, N; Gvozdenovic, A | 1 |
| Li, N; Liu, H; Liu, Y; Wang, M; Zhang, GQ | 1 |
| Akpan, UM; Borbor-Sawyer, SM; Nwazojie, CC; Obayemi, JD; Odusanya, OS; Onwudiwe, KC; Onyekanne, CE; Oparah, JC; Salifu, AA; Soboyejo, WO; Uzonwanne, VO | 1 |
| Hedayat, M; Jafari, R; Khezri, MR; Majidi Zolbanin, N; Malekinejad, H | 1 |
| Alexandre, M; Bidard, FC; Bourien, H; Chaumard-Billotey, N; Dabakuyo, S; de Moura, A; Dohollou, N; Frenel, JS; Grenier, J; Hajjaji, N; Ladoire, S; Lafayolle de la Bruyère, C; Loirat, D; Nicolai, V; Patsouris, A; Pierga, JY; Renouf, B; Vaflard, P; Vuagnat, P | 1 |
| Akers, KG; Cortes, J; Fasching, PA; Frederickson, AM; Haiderali, A; Huang, M; O'Shaughnessy, J; Pan, W; Park, JE; Schmid, P | 1 |
| Belfiore, A; de Braud, F; Depretto, C; Ferraris, C; Ficchì, A; Formisano, B; Franza, A; Fucà, G; Ligorio, F; Lobefaro, R; Martinetti, A; Nasca, V; Provenzano, L; Pruneri, G; Salvadori, G; Scaperrotta, G; Sottotetti, E; Sposetti, C; Vernieri, C; Vingiani, A; Zanenga, L | 1 |
| Chai, Y; He, M; Jiang, M; Li, Q; Liu, J; Luo, Y; Ma, F; Ou, K; Qi, L; Wang, X; Wang, Y; Xu, B; Yuan, P; Zhang, P | 1 |
| Alečković, M; Foidart, P; Garrido-Castro, AC; Garza, K; Guerriero, JL; Huang, XY; Kesten, N; Li, R; Li, Z; Lim, K; Long, HW; Lulseged, B; Polyak, K; Qi, J; Qiu, X; Shu, S; Zhou, N | 1 |
| Amiji, M; Dolare, S; Milane, LS; Ren, G | 1 |
| Bruque, CD; Bruzzone, A; Jabloñski, M; Lüthy, IA; Pérez Piñero, C; Rivero, EM; Rodríguez, MS; Vanzulli, S | 1 |
| Dong, B; Li, L; Lu, J; Sun, H; Xu, H; Yin, X; Zhou, K | 1 |
| Chen, Q; Lin, Z; Liu, J; Zhang, Y; Zhao, H | 1 |
| Elangovan, S; Muduli, K; Pradhan, J; Samant, M; Upreti, S | 1 |
| Clark, RF; Coombs, MRP; Fernando, W; Hoskin, DW; Rupasinghe, HPV | 1 |
| Aftimos, P; Agostinetto, E; Barthélémy, P; Bonnefoi, H; Buisseret, L; Canon, JL; Catteau, X; Clatot, F; Craciun, L; de Azambuja, E; Debien, V; Denis, Z; Duhoux, FP; Eiger, D; Ferrero, JM; Ghiringhelli, F; Goncalves, A; Ignatiadis, M; Isambert, N; Kristanto, P; Larsimont, D; Loirat, D; Mansi, L; Maurer, C; Paesmans, M; Piccart-Gebhart, M; Poncin, R; Punie, K; Romano, E; Rothé, F; Salgado, R; Sotiriou, C; Stagg, J; Taylor, D; Van den Mooter, T; Venet, D | 1 |
| Adriaenssens, E; Bourette, RP; Fovez, Q; Ghesquiere, B; Guette, C; Hondermarck, H; Kluza, J; Laine, W; Le Bourhis, X; Nait Eldjoudi, A; Winter, M | 1 |
| Bajaj, PS; Chui, SY; Falgas, A; Hasnain, W; Hsieh, AF; Kurian, AW; Luhn, P; Mecke, A; Ton, TG; Yi, J | 1 |
| Fan, C; Lee, BH; Mo, C; Shetti, D; Wei, K; Zhang, B | 1 |
| Cai, Z; Lai, H; Li, S; Li, Y; Liu, Y; Shi, Q; Wang, R | 1 |
| Alfieri, R; Bonelli, M; Cavazzoni, A; Cretella, D; Digiacomo, G; Fumarola, C; Galetti, M; Generali, D; La Monica, S; Petronini, PG | 1 |
| Sui, Y; Tao, Y; Wang, Y | 1 |
| Fu, Q; Guo, L; Peng, Y; Pu, Y; Wu, Y; Yue, Q; Zhang, H; Zhao, Y | 1 |
| Anderhub, SJ; Blagg, J; Burke, R; Drosopoulos, K; Eccles, SA; Faisal, A; Filosto, S; Gurden, MD; Hayes, A; Hoelder, S; Innocenti, P; Linardopoulos, S; Mak, GW; Naud, S; Raynaud, FI; Saville, H; Theofani, E; van Montfort, RLM; Walsh, K; Westwood, IM; Woodward, HL | 1 |
| Hasegawa, A; Inoue, K; Ito, Y; Iwata, H; Kaneko, K; Kuratomi, H; Nakagawa, S; Tamura, K; Tsugawa, K | 1 |
| Beischlag, TV; Khamenehfar, A; Li, PCH; Parekh, K; Payer, RTM; Sharifi, H | 1 |
| Al Sayed, AD; Al-Tweigeri, T; Elshenawy, MA; Ghebeh, H; Tulbah, A | 1 |
| Balolong-Garcia, JC; Cruz-Ordinario, MVB; Pandy, JGP; Que, FVF | 1 |
| Baradaran, B; Darabi, M; Javadian, M; Kazemi, T; Mansoori, B; Maralbashi, S; Mohammadi, A; Shanehbandi, D; Shekari, N; Soltani-Zangbar, MS | 1 |
| Bago, JR; Batrakova, EV; Haney, MJ; Jin, YS; Kabanov, AV; Klyachko, NL; Li, SM; Zhao, Y | 1 |
| Berreth, H; Hausser, A; Lieb, WS; Lungu, C; Olayioye, MA; Rathert, P; Storz, P; Tamas, R | 1 |
| Adams, S; Barrios, CH; Chui, SY; Diéras, V; Emens, LA; Henschel, V; Husain, A; Iwata, H; Loi, S; Maiya, V; Molinero, L; Rugo, HS; Schmid, P; Schneeweiss, A; Winer, EP | 1 |
| Woodward, WA | 1 |
| Fremd, C; Jäger, D; Mavratzas, A; Schneeweiss, A; Seitz, J; Smetanay, K | 1 |
| Killock, D | 1 |
| Bleilevens, A; Li, X; Maurer, J; Stickeler, E; Strietz, J | 1 |
| Badawi, M; Carson, W; Cherian, M; Grever, M; Kassem, M; Layman, R; Ling, Y; Lustberg, M; Morgan, E; Mrozek, E; Phelps, M; Ramaswamy, B; Reinbolt, R; Sardesai, S; Stephens, J; Stover, D; VanDeusen, J; Wei, L; Wesolowski, R; Williams, N | 1 |
| Amiri-Kordestani, L; Beaver, JA; Bloomquist, E; Blumenthal, GM; Fu, W; Gao, JJ; Ghosh, S; Goldberg, KB; Gong, Y; Hou, S; Ibrahim, A; Kalavar, S; King-Kallimanis, BL; Kluetz, PG; Liu, J; Narayan, P; Pazdur, R; Philip, R; Song, P; Sridhara, R; Tang, S; Theoret, MR; Wahby, S; Xu, Y | 1 |
| Guo, X; Huang, P; Huang, X; Li, H; Lin, S; Rao, X; Weng, X | 1 |
| Anstine, LJ; Avril, S; Keri, RA; Piemonte, KM; Roberts, MS; Sahni, JM; Schrock, MS; Seachrist, DD; Singh, S; Sizemore, ST; Summers, MK; Varadan, V; Weber-Bonk, KL | 1 |
| Chiu, W; Dong, Y; Evers, BM; Guo, P; Guo, S; Hu, S; Li, S; Li, X; Sparreboom, A; Vieweger, M; Wang, H; Yin, H; Zhang, K | 1 |
| Fujiwara-Tani, R; Goto, K; Kawahara, I; Kishi, S; Kondoh, M; Kuniyasu, H; Luo, Y; Mori, S; Mori, T; Nishiguchi, Y; Ohmori, H; Sasaki, T | 1 |
| Dang, HX; Datla, US; Jones, CN; Lawrence, CB; Maher, CA; Menon, N; Moarefian, M | 1 |
| Aktan, G; Bergh, J; Cardoso, F; Cortes, J; Denkert, C; Dent, R; Fasching, PA; Foukakis, T; Harbeck, N; Hui, R; Jia, L; Karantza, V; Kümmel, S; McArthur, H; O'Shaughnessy, J; Park, YH; Pusztai, L; Schmid, P; Takahashi, M; Untch, M; Zhao, J | 1 |
| Bos, MEMM; Bouma, JM; Claessens, AKM; de Graaf, H; Erdkamp, FLG; Honkoop, AH; Lopez-Yurda, M; Rademaker-Lakhai, JM; Tjan-Heijnen, VCG | 1 |
| Adams, S; Barrios, CH; Chui, SY; Diéras, V; Emens, LA; Henschel, V; Iwata, H; Loi, S; Patel, S; Rugo, HS; Schmid, P; Schneeweiss, A; Winer, EP | 1 |
| Gong, Y; Huang, P; Liu, H; Ren, X; Wang, J; Weng, M; Yang, X; Yu, Z; Zheng, L; Zheng, Q | 1 |
| Ishii, T; Itou, J; Sato, F; Tanaka, S; Toi, M | 1 |
| Kang, C; Syed, YY | 1 |
| Bhargava, R; Hu, Y; Lee, S; Lewis, MT; Loo, SK; Tan, Y; Wang, XS | 1 |
| Devi, S; Gupta, N; Jagadish, N; Suri, A; Suri, V | 1 |
| Bamezai, RN; Chattopadhyay, S; Iqbal, MA; Khan, A; Prakasam, G; Siddiqui, FA; Siddiqui, S; Sultana, S; Ur Rehman, A | 1 |
| Chen, S; Gong, Y; Ji, P; Shao, ZM; Wang, RX | 1 |
| Bouvet, M; Endo, I; Higuchi, T; Hoffman, RM; Hozumi, C; Inubushi, S; Kurebayashi, J; Lim, H; Miyake, K; Murata, T; Nishino, H; Nomura, T; Shimoya, K; Singh, SR; Sugisawa, N; Sun, YU; Tanino, H; Tashiro, Y; Yamamoto, J | 1 |
| Brown, M; Fassl, A; Ge, JY; Gulvady, A; Heavey, GA; Jovanović, B; Kuang, Y; Kwon, M; Luoma, A; McDonald, TO; Michor, F; Murphy, K; Paweletz, C; Pellman, D; Polyak, K; Qi, J; Shu, S; Sicinski, P; Thorner, AR; Trinh, A; Wucherpfennig, KW | 1 |
| Huang, X; Lang, T; Lee, RJ; Li, Y; Teng, L; Wang, G; Yin, Q; Zheng, Z | 1 |
| Dai, Z; Guo, H; Li, J; Liu, M; Qin, T; Sun, H; Xu, X; You, X; Zhang, Z; Zhu, H | 1 |
| Aieta, M; Bordonaro, R; Borsellino, N; Bozza, G; Ciccarese, M; Cilenti, G; Cinieri, S; Colucci, G; Febbraro, A; Fedele, P; Forcignanò, R; Lorusso, V; Maiello, E; Orlando, L; Pisconti, S; Riccardi, F; Rinaldi, A; Romito, S; Saracino, V; Schiavone, P; Surico, G | 1 |
| Jin, X; Lu, X; Lv, H; Zhang, Z | 1 |
| Agrawal, N; Burande, AS; Jha, A; Mahto, SK; Mehata, AK; Muthu, MS; Poddar, S; Shaik, A; Viswanadh, MK | 1 |
| Cortés, J; Gion, M; Pérez-García, J; Racca, F; Soberino, J; Stradella, A | 1 |
| Chen, L; Jiang, J; Li, J; Lu, P; Zhang, T; Zhao, J | 1 |
| Arrowsmith, CH; Ba-Alawi, W; Cescon, DW; De Carvalho, DD; Deblois, G; Ettayebi, I; Fedor, AN; Fortier, AM; Grillo, G; Guilhamon, P; Haibe-Kains, B; Kao, YI; Kuasne, H; Lima-Fernandes, E; Liu, X; Locasale, JW; Lupien, M; Martinez, C; Murison, A; Park, M; Savage, P; Tai, F; Tonekaboni, SAM | 1 |
| Li, F; Li, Y; Liang, C; Lu, A; Wu, X; Yu, Y; Zhang, B; Zhang, G; Zhao, C | 1 |
| Abdul Aziz, MI; Lee, SC; Ng, K; Phua, LC | 1 |
| Cai, R; Chen, S; Chen, X; Chen, Y; Fan, Y; Guan, Y; Lan, B; Li, Q; Luo, Y; Ma, F; Mo, H; Wang, J; Xu, B; Zhang, P; Zhao, W | 1 |
| Lambertini, M; Perachino, M; Poggio, F | 1 |
| Byerly, JH; Irie, HY; Port, ER | 1 |
| Pei, J; Wang, B; Wang, Z; Yang, X; Zhang, J; Zhao, L | 1 |
| Berindan-Neagoe, I; Braicu, C; Ciocan-Cârtiţă, CA; Cojocneanu, R; Irimie, A; Jurj, A; Moldovan, C; Pop, LA; Pop-Bica, C; Raduly, L; Trif, M; Zanoaga, O | 1 |
| Chen, J; Deng, Q; Huang, J; Xia, J; Xu, R; Zhu, M; Zou, L | 1 |
| Li, H; Meng, R; Rui, M; Shang, Y; Shi, F | 1 |
| Han, ZX; Huang, JG; Liu, JY; Lv, D; Ren, HW; Shi, XY; Wang, H; Xu, DQ; Zhang, YN | 1 |
| Altini, M; Bravaccini, S; Maltoni, R; Palleschi, M; Parrella, P; Puccetti, M; Ravaioli, S; Rocca, A; Tumedei, MM | 1 |
| Chen, CL; Chen, YL; Kuei, CH; Lee, HH; Lin, CH; Lin, HY; Lin, YF | 1 |
| Ding, J; Hu, X; Jiang, L; Jiang, YZ; Kaklamani, V; Liu, Y; Ma, D; Shao, ZM; Stover, DG; Verschraegen, C; Wang, ZH; Xiao, Y; Zhu, X; Zou, J; Zuo, WJ | 1 |
| Cross, V; Dircksen, C; Felten, A; Hahn, S; Johnson, T; Klein, P; Leamon, CP; Lu, J; Nelson, M; Parham, G; Pugh, M; Qi, L; Reddy, JA; Santhapuram, HK; Vaughn, JF; Vetzel, M; Vlahov, IR; Wang, K; Westrick, E | 1 |
| Di, GH; Fan, L; He, M; He, PQ; Hou, YF; Lin, XY; Liu, GY; Ma, D; Mo, M; Ricci, F; Shao, ZM; Shen, ZZ; Song, CG; Toss, A; Wang, C; Wang, J; Wu, J; Wu, KJ; Ye, FG; Yu, KD; Zeng, XH; Zhuang, ZG | 1 |
| Abramson, V; Carey, L; Componeschi, K; Falkson, C; Jankowitz, R; Krop, I; Marcom, PK; Mayer, EL; Miller, K; Perou, C; Richardson, AL; Rimawi, M; Specht, J; Stearns, V; Tan-Wasielewski, Z; Timms, K; Traina, T; Trippa, L; Tung, N; Winer, EP; Wolff, AC | 1 |
| Brailoiu, GC; Chen, G; Chen, QH; Kurtz, M; Lakshmikuttyamma, A; Lawson, S; Modi, K; Rekhtman, I; Tumuluri, D | 1 |
| Abramson, VG; Axelrod, ML; Balko, JM; Bergman, RE; Donaldson, J; Garrido-Castro, AC; Gonzalez-Ericsson, PI; Jansen, VM; Krop, IE; Loi, S; Mackay, S; Mallal, S; Marotti, JD; Mayer, IA; McDonnell, WJ; Miller, TW; Nixon, MJ; Opalenik, SR; Pilkinton, MA; Rexer, BN; Salgado, R; Sanchez, V; Sanders, ME; Shee, K; Tolaney, SM; Zhou, J | 1 |
| Jusu, SM; Nwazojie, CC; Obayemi, JD; Odusanya, OS; Salifu, AA; Soboyejo, WO; Uzonwanne, V | 1 |
| Cristofaro, I; Di Bari, M; Español, AJ; Salem, A; Sales, ME; Sanchez, Y; Tata, AM | 1 |
| Adams, S; Almonte, C; Bagdatlioglu, E; Deng, J; Heguy, A; Klar, N; Krogsgaard, M; Labbe, K; Marier, C; Meyn, P; Perou, CM; Shah, S; Thennavan, A; Wong, KK; Zhang, Y | 1 |
| Chambers, K; Corral, J; Gaur, S; Konstantinidis, I; McCallum, R; Philipovskiy, A | 1 |
| Jing, D; Lei, L; Zhang, Q | 1 |
| Sidaway, P | 1 |
| Ge, LP; Gou, ZC; Jiang, W; Jiang, YZ; Liu, XY; Ma, D; Shao, ZM; Xu, XE; Yang, YS | 1 |
| Frankel, PH; Jones, V; Kruper, L; Lee, JS; Li, SM; Martinez, N; Menicucci, A; Mortimer, J; Robinson, K; Ruel, C; Schmolze, D; Somlo, G; Stewart, D; Tang, A; Uygun, S; van der Baan, B; Waisman, J; Yeon, C; Yim, JH; Yoder, E; Yost, SE; Yuan, Y | 1 |
| Ahn, JH; Cheon, DH; Chong, SE; Hyun, S; Jang, J; Lee, Y; Nam, SH; Yu, J | 1 |
| Bai, X; Bei, Y; Cheng, N; Shen, P; Shu, Y; Song, Y; Xu, L; Yang, N; Zhang, W | 1 |
| Agrawal, R; Lam, KS; Li, Y; Liu, Q; Luo, Y; Suby, N; Vu, M; Xiao, K; Xiao, W; Zhang, H | 1 |
| Mano, M; Masuda, N; Masuyama, M; Mizutani, M; Mori, K; Morikawa, N; Otani, Y; Yasojima, H | 1 |
| Guo, R; He, J; He, Q; Li, J; Li, M; Liu, Y; Mei, L; Qiu, Y; Ren, K; Tang, J; Wei, J; Xu, S; Yu, Q; Zhang, Z; Zhao, W | 1 |
| Dowling, P; Halasz, M; Higgins, MJ; Irwin, JA; Kavanagh, EL; Lindsay, S; McCann, A; Rudd, PM; Saldova, R; Withers, J | 1 |
| Slater, H | 1 |
| Shao, ZM; Yu, KD | 1 |
| Arora, S; Batra, A; Kumar, A | 1 |
| Alain, T; Chambers, J; Côté, M; Cui, J; D'Costa, VM; Ekker, M; El-Sahli, S; Farah, E; Gadde, S; Hua, K; Lee, SH; Li, L; Li, X; Liu, D; McGarry, S; Sulaiman, A; Wang, L; Zheng, P | 1 |
| Han, H; Li, YT; Lin, LF; Lin, SG | 1 |
| Guo, GL; Huang, QD; Zhang, ZT; Zheng, SR; Zheng, ZH | 1 |
| Gote, V; Pal, D; Sharma, AD | 1 |
| Adams, S; Barrios, CH; Chui, SY; Diéras, V; Emens, LA; Husain, A; Iwata, H; Loi, S; Molinero, L; Nechaeva, M; Nguyen-Duc, A; Rugo, HS; Schmid, P; Schneeweiss, A; Winer, EP | 1 |
| Bian, Z; Liu, W; Liu, ZR; Mishra, F; Satyanarayana, G; Sharma, M; Sun, L; Turaga, RC; Yang, J; Yuan, Y | 1 |
| Emens, LA; Ma, H; Popel, AS; Sové, RJ; Wang, H | 1 |
| Ansell, PJ; Asad, S; Bae, J; Cherian, M; Collier, K; Denkert, C; Filho, OM; Geyer, CE; Golshan, M; Huober, JB; Loibl, S; Maag, D; O'Shaughnessy, J; Rastogi, P; Rugo, HS; Sikov, WM; Stover, DG; Symmans, WF; Untch, M; von Minckwitz, G; Watson, M; Wolmark, N | 1 |
| Chen, C; Duan, Y; Fu, H; Guo, Q; Liao, H; Shen, M; Yu, J | 1 |
| Chen, Y; Dai, T; Jiang, L; Li, A; Lu, L; Wang, L; Zhang, L; Zhou, Y | 1 |
| Abraham, DT; Andrews, AG; Backianathan, S; Balakrishnan, R; Chacko, RT; Chandramohan, J; Cherian, AJ; Georgy, JT; Joel, A; John, AO; Manipadam, MT; Paul, MJ; Rebekah, G; Sigamani, E; Singh, A; Thumaty, DB | 1 |
| Fang, K; Gao, X; Guo, D; Hu, S; Ji, C; Ji, H; Jiang, S; Li, G; Peng, L; Si, H; Song, X; Wang, J; Zhang, J; Zuo, R | 1 |
| Chisaki, Y; Kuwada, Y; Matsumura, C; Yano, Y | 1 |
| Aruga, T; Bando, H; Haga, H; Ishiguro, H; Kadoya, T; Kasai, H; Kataoka, TR; Kawabata, H; Kikawa, Y; Masuda, N; Morita, S; Nagai, SE; Ohno, S; Ohtani, S; Suzuki, E; Takahashi, M; Toi, M; Uozumi, R; Yamanaka, T; Yasojima, H | 1 |
| Balasubramaniam, J; Chandrasekaran, J; Ravi, A; Sellamuthu, A | 1 |
| Battista, R; Coluccio, V; Grandi, G; Guidotti, I; Monari, F; Moscetti, L; Neri, I; Piombino, C; Torcetta, F; Toss, A | 1 |
| Bonetti, A; Giuliani, J; Mantoan, B | 1 |
| Chandrani, P; Ghosh, D; Jondhale, M; Kumar Panda, C; Mukherjee, N; Roychowdhury, A; Saldanha, E | 1 |
| Abu-Irmaileh, B; Al-Majawleh, M; Al-Qirim, T; Bustanji, Y; Hamadneh, L; Jarrar, Y | 1 |
| Chang, YJ; Chou, CW; Huang, CY; Huang, YM; Hung, CS | 1 |
| Chakravarti, A; Cole, MW; Das, M; Knoblaugh, SE; Lian, AW; Ostrowski, MC; Ray, A; Richardson, DS; Schafer, RE; Shakya, R; Sizemore, GM; Sizemore, ST; Spehar, JM; Steck, SA; Thies, KA; Timmers, CD | 1 |
| Gyawali, B; Van Wambeke, S | 1 |
| Adriaenssens, E; Angrand, PO; Bidan, N; Chopin, V; Lagadec, C; Le Bourhis, X; Meignan, S; Toillon, RA; Völkel, P; Winter, M | 1 |
| Andrade, L; André, F; Barata, T; Barrios, C; Cameron, D; Gligorov, J; Kaen, D; Kaul, M; Miles, D; Morales, L; O'Shaughnessy, J; Patel, S; Patel, SL; Patre, M; Reinisch, M; Schneeweiss, A; Semiglazov, V; Wardley, A; Xu, B | 1 |
| Dong, W; Jin, Y; Li, L; Li, R; Liao, H; Liu, Y; Qin, C; Shen, Q; Sun, T; Wang, H; Wang, Y; Xia, X; Xu, X; Yang, Y; Ye, J | 1 |
| Chen, M; Gan, Y; Guo, L; Miao, Y; Qian, K; Qiu, Y; Wang, R; Zhang, X; Zhou, X | 1 |
| Blau, S; Bradley, D; Dent, R; Espié, M; Im, SA; Isakoff, SJ; Kim, SB; Mani, A; Oliveira, M; Reilly, SJ; Saura, C; Tan, AR; Wongchenko, MJ; Xu, N | 1 |
| Adams, S; Barrios, CH; Chui, SY; Diéras, V; Emens, LA; Henschel, V; Iwata, H; Kaul, M; Loi, S; Molinero, L; Patel, S; Rugo, HS; Schmid, P; Schneeweiss, A; Swat, A; Winer, EP | 1 |
| Guo, Y; Jiang, C; Li, F; Teng, B; Wang, X; Wang, Z; Zeng, Q; Zhao, Y | 1 |
| Gan, L; Peng, C; Xia, B; Yi, M | 1 |
| Gangapuram, M; Mazzio, EA; Redda, KK; Soliman, KFA | 1 |
| Amini, M; Arman, SY; Ashourpour, M; Kazerouni, F; Mostafavi Hosseini, F; Saeedian Moghadam, E; Shahsavari, Z | 1 |
| Aggarwal, AK; Baker, SJ; Bartkowski, A; Cosenza, SC; Domingo-Domenech, J; Irie, HY; Padgaonkar, AA; Port, ER; Ramana Reddy, MV; Rechkoblit, O; Reddy, EP; Sato, K; Subbaiah, DRCV | 1 |
| Astarita, EM; Berkeley, BJ; Hoover, CA; Maloney, SM; Nair, TM; Prosperi, JR; VanKlompenberg, MK | 1 |
| Abdelfattah, ON; Bakri, HM; Eid, S; Mohamed, RF | 1 |
| Asselain, B; Berger, F; Beuzeboc, P; Bidard, FC; Cottu, PH; Dieras, V; Dujaric, ME; Escalup, L; Laurence, V; LE Tourneau, C; Pierga, JY; Piperno-Neumann, S; Pop, S; Robain, M | 1 |
| Chen, C; Dong, X; Liang, X; Liu, F; Liu, T; Shao, B; Sun, B; Sun, H; Wang, M; Wang, Y; Zhu, D | 1 |
| Baldacchino, S; Carlisi, D; Caruana-Dingli, G; De Blasio, A; Debono, J; Degaetano, J; Di Fiore, R; Drago-Ferrante, R; Giordano, A; Grech, G; Pentimalli, F; Saliba, C; Scerri, C; Tesoriere, G; Vento, R | 1 |
| Bianco, R; Cantile, M; Chambery, A; Cicatiello, V; Ciciola, P; Collina, F; D'Amato, V; De Falco, S; De Placido, S; Di Bonito, M; Di Mauro, C; Formisano, L; Marciano, R; Orsini, RC; Rosa, R; Servetto, A; Veneziani, BM | 1 |
| Al-Kassas, R; Cerqueira, BBS; Lasham, A; Shelling, AN | 1 |
| Arrowsmith, ER; Bosserman, LD; Brufsky, A; Bubis, JA; Burris, HA; Bury, M; Daniel, BR; Drosick, DR; Eakle, J; Goble, SA; Gravenor, DS; Hainsworth, JD; Harwin, WN; Inhorn, RC; Keaton, MR; Kudrik, F; Manalo, Y; Pendergrass, K; Priego, VM; Rodriguez, GI; Silver, C; Yardley, DA; Young, RR | 1 |
| Babbs, B; Barton, VN; Butterfield, K; Christenson, JL; D'Amato, NC; Elias, A; Gordon, MA; Greene, LI; Richer, JK; Rogers, TJ; Spoelstra, NS | 1 |
| Feng, S; Huang, J; Lin, W; Ma, W; Xie, Y; Yuan, Z | 1 |
| Ding, H; Jiang, Q; Wei, W; Yan, L; Yang, S; Zhou, Z; Zou, Y | 1 |
| Blohmer, JU; Burchardi, N; Denkert, C; Eiermann, W; Engels, K; Fasching, PA; Gerber, B; Hanusch, C; Hilfrich, J; Huober, J; Jackisch, C; Klare, P; Kümmel, S; Loibl, S; Paepke, S; Schem, C; Schneeweiss, A; Untch, M; von Minckwitz, G | 1 |
| Bandyopadhyay, S; Bukhsh, MA; Gorski, DH; Jafry, WS; Sexton, RE; Speyer, CL | 1 |
| Baselga, J; Blau, S; Chan, WY; Dent, R; Espié, M; Im, SA; Isakoff, SJ; Kapp, AV; Kim, SB; Maslyar, DJ; Oliveira, M; Saura, C; Singel, SM; Tan, AR; Wongchenko, MJ | 1 |
| Denkert, C; Forstbauer, H; Hoffmann, G; Karn, T; Kohls, A; Köhne, CH; Linn, SC; Loibl, S; Marmé, F; Möbus, VJ; Nekljudova, V; Schem, C; Schmatloch, S; Schouten, PC; Solbach, C; Thomssen, C; van Rossum, AGJ; von Minckwitz, G; Weber, KE | 1 |
| Davoodi, P; Ng, WC; Srinivasan, MP; Wang, CH | 1 |
| Chatterji, U; Chattopadhyay, D; Gupta, A; Mukherjee, P | 1 |
| He, W; Huang, S; Ji, D; Lan, H; Li, L; Li, Z; Liu, X; Wang, Y; Wu, Z; Xu, J; Yang, F; Zhang, W; Zhou, W | 1 |
| Bignon, L; Caron, O; Faivre, L; Fricker, JP; Gesta, P; Gladieff, L; Hamimi, A; Lasset, C; Lortholary, A; Mari, V; Mouret-Fourme, E; Nogues, C; Petit, T; Stoppa-Lyonnet, D; Velten, M | 1 |
| Bakrania, AK; Patel, SS; Rathod, LV; Variya, BC | 1 |
| Cairns, J; Hankemeier, T; Joore, J; Kramer, B; Lanz, HL; Ng, CP; Saleh, A; Trietsch, SJ; Vulto, P; Wang, L; Weinshilboum, R; Yu, J | 1 |
| Bai, Z; Du, P; Li, S; Tian, Q; Yang, Y; Zeng, J | 1 |
| Christofillakis, C; Georgoulias, V; Kalbakis, K; Kentepozidis, N; Kourousis, C; Mavroudis, D; Nikolaou, M; Pistamaltzian, N; Polyzos, A; Saloustros, E; Vamvakas, L | 1 |
| Aktas, B; Bangemann, N; Braun, M; Christgen, M; Clemens, M; Forstbauer, H; Gluz, O; Grischke, EM; Hackmann, J; Harbeck, N; Kates, R; Kohls, A; Kreipe, HH; Kuemmel, S; Liedtke, C; Lindner, C; Nitz, U; Potenberg, J; Schumacher, C; Schumacher, J; Staib, P; Uleer, C; von Schumann, R; Warm, M; Wuerstlein, R | 1 |
| Hirakawa, K; Ikeda, K; Ishikawa, T; Kashiwagi, S; Kawajiri, H; Kudoh, S; Mizuyama, Y; Nishimori, T; Nishimura, S; Noda, S; Ogawa, Y; Ohira, M; Onoda, N; Sunami, T; Takada, M; Takashima, T; Tei, S; Tezuka, K; Tokunaga, S; Yamagata, S | 1 |
| Asano, Y; Goto, W; Hatano, T; Hirakawa, K; Kashiwagi, S; Motomura, H; Ohira, M; Ohsawa, M; Takada, K; Takahashi, K; Takashima, T; Tanaka, S; Tomita, S | 1 |
| Chen, C; Chen, Y; Jiang, X; Li, S; Shi, F; Wang, X; Xiong, H; Yan, T; Zhang, W; Zhu, Y | 1 |
| Chiu, HW; Chiu, IJ; Kuo, CJ; Lin, HY; Lin, YF; Tseng, IJ | 1 |
| Almanza, A; Dolan, S; Gorman, AM; Hillis, J; Jaafar, R; Logue, SE; Mnich, K; Samali, A | 1 |
| Chen, LQ; Fang, WS; Gao, ZG; Huang, W; Jin, MJ; Yu, L; Zhang, ZM | 1 |
| Geyer, CE; Golshan, M; Huober, J; Liu, X; Loibl, S; Maag, D; McIntyre, K; McKee, MD; Metzger Filho, O; O'Shaughnessy, J; Ponce Lorenzo, JJ; Rastogi, P; Rugo, HS; Sikov, WM; Sullivan, D; Symmans, WF; Untch, M; von Minckwitz, G; Wolmark, N | 1 |
| Çeti N, İL; Kolusayin Ozar, MÖ; Özbaş Turan, S; Topçul, M | 1 |
| Bernöster, K; Häder, T; Herbener, P; Schönfeld, K; Schüttrumpf, J; Uherek, C; Zuber, C | 1 |
| Belloli, S; Bogni, A; Bombardieri, E; Daidone, MG; Moresco, RM; Pascali, C; Presotto, L; Raccagni, I; Russo, G; Stefano, A; Tortoreto, M; Valtorta, S; Zaffaroni, N | 1 |
| Ali, H; Barton, D; Bengala, C; Brufsky, A; Coleman, R; Conte, P; Cortes, J; de la Cruz-Merino, L; Eakel, J; Glück, S; Harbeck, N; Li, H; Miller, J; O'Shaughnessy, J; Schneeweiss, A; Shtivelband, M; Wilks, S; Yardley, DA; Young, R | 1 |
| Bianchi, G; Capri, G; Cona, MS; de Braud, F; Ferrari, B; Huber, V; Maggi, C; Manoukian, S; Mariani, G; Mennitto, A; Milano, M; Prisciandaro, M; Rinaldi, L; Rivoltini, L; Vernieri, C | 1 |
| Cao, J; Hu, XC; Lin, Y; Luo, JF; Shao, ZM; Sun, XJ; Tao, ZH; Wang, BY; Wang, LP; Wang, ZH; Wu, J; Yang, WT; Zhang, J; Zhang, S | 1 |
| Lebert, JM; Lester, R; McCarthy, J; Powell, E; Seal, M | 1 |
| Cidlowski, JA; Helle, TM; Krutilina, RI; Lange, CA; Ma, S; Ostrander, JH; Peng, Y; Perez Kerkvliet, C; Raj, GV; Regan Anderson, TM; Schwertfeger, KL; Seagroves, TN | 1 |
| Clemons, M; Fergusson, D; Hilton, J; Hutton, B; Mazzarello, S; Stober, C; Vandermeer, L | 1 |
| Alwagdani, H; Kolta, MG; Mendonca, P; Messeha, SS; Soliman, KFA; Zarmouh, NO | 1 |
| Fu, P; Wang, S; Wang, W; Yao, M; Yao, Y | 1 |
| Cheney, EM; Clifton, EM; Dawson, MR; Ghosh, D; Xuan, B | 1 |
| Almanza, A; Chevet, E; Cleary, P; Dwyer, RM; Godey, F; Gorman, AM; Greene, S; Jäger, R; Legembre, P; Leuzzi, B; Logue, SE; Madden, EC; McGrath, EP; Mnich, K; Obacz, J; Oommen, A; Patterson, JB; Samali, A; Zeng, Q | 1 |
| Chen, S; Ji, R; Li, C; Tang, P; Wang, Q; Wen, J | 1 |
| Bovenzi, V; Chemtob, S; Côté, J; Dubuc, C; Geha, S; Gobeil, F; Lessard, A; Neugebauer, W; Savard, M | 1 |
| Diao, K; Dong, Y; Liu, Y; Mi, X; Su, L; Zhao, L | 1 |
| Cao, Z; Chen, Q; Chen, X; Guo, Q; Guo, Z; Jiang, C; Li, C; Liang, D; Lu, Y; Sun, T; Zhang, Y; Zhou, W | 1 |
| Clor, ZJ; Kelts, JL; Wilhelm, CA | 1 |
| Dong, X; Han, B; Han, J; Hao, J; Pang, H; Shen, Q; Wu, X | 1 |
| Chen, Y; Jiang, C; Li, CY; Lin, MH; Liu, LY; Miao, KL; Zhao, GB | 1 |
| Blohmer, JU; Braun, S; Denkert, C; Elkin, EP; Fasching, PA; Gerber, B; Hahnen, E; Hartman, AR; Jackisch, C; Klare, P; Kümmel, S; Lederer, B; Loibl, S; Nekljudova, V; Paepke, S; Penn, S; Reid, J; Rezai, M; Rhiem, K; Salat, CT; Schem, C; Schmutzler, R; Schneeweiss, A; Timms, KM; Untch, M; von Minckwitz, G; Weber, KE; Zahm, DM | 1 |
| Adams, S; Barrios, CH; Chui, SY; Diéras, V; Emens, LA; Funke, R; Hegg, R; Henschel, V; Husain, A; Im, SA; Iwata, H; Loi, S; Molinero, L; Rugo, HS; Schmid, P; Schneeweiss, A; Shaw Wright, G; Winer, EP | 1 |
| Adams, S; Chang, CW; Diamond, JR; Foster, PG; Funke, R; Hamilton, E; Iizuka, K; Molinero, L; Pohlmann, PR; Powderly, J; Tolaney, SM; Zhang, W | 1 |
| Hock, TT; Kalaimani, JK; Karupiah, S; Kit, NS; Krishnan, S; Palanimuthu, VR; Sankarankutty, S; Venugopal, V | 1 |
| Chen, Q; Chen, X; Cheng, J; Guo, Q; He, X; Jiang, C; Li, C; Liu, L; Lu, Y; Ruan, C; Sun, T; Zhang, J; Zhang, Y | 1 |
| Chen, X; Li, Y; Song, Z; Wang, S; Wei, X; Zhang, J; Zhang, S | 1 |
| Ali, S; Bakdounes, K; Dai, M; Hachim, IY; Jean-Claude, B; Khadang, B; Lebrun, JJ; Moamer, A; Raffa, FA; Tian, J | 1 |
| Gong, Y; Hao, S; Jiang, YZ; Jin, X; Ren, YX; Shao, ZM; Ye, FG | 1 |
| Imanishi, S; Kagara, N; Kim, SJ; Miyake, T; Naoi, Y; Noguchi, S; Shimazu, K; Shimoda, M; Tanei, T | 1 |
| Chow, A; Hilberg, F; Kerbel, RS; Man, S; Reguera-Nuñez, E; Xu, P | 1 |
| Chao, JI; Chen, C; Ho, Y; Liao, WS; Lin, YW; Liu, KK; Lu, KP; Naveen Raj, E; Zhou, XZ | 1 |
| Anderson, J; Baker, K; Gadi, V; Garrison, M; Gralow, J; Jenkins, I; Korde, L; Kurland, B; Linden, H; Redman, M; Rodler, E; Smith, J; Specht, J; Symonds, L; Van Haelst, C; Wu, QV | 1 |
| Ashley, D; Baron-Hay, S; Chisanga, D; Collins, I; Khasraw, M; Liao, Y; Lindeman, G; Mukaro, V; Murphy, C; Muscat, A; Patil, S; Shi, W; West, L | 1 |
| Berger, T; Cappello, P; Cescon, DW; Chu, MF; Duncan, G; Garcia-Valero, M; Gorrini, C; Hodgson, K; Jafari, SM; Mak, TW; McGaha, TL; Palomero, L; Pujana, MA; Roux, C; Shinde, R; Silvester, J; Wakeham, A | 1 |
| Alsayed, A; He, C; Karginova, O; Lee, SS; Olopade, OI; Raoul, A; Weekley, CM; Wu, T | 1 |
| Cao, Y; Chen, X; Fu, S; Lin, HJ; Lin, J; Lo, HW; Pan, L; Tian, J; Wu, X; Xiao, H; Zhang, R; Zhang, Y | 1 |
| Aksoy, S; Aktas, BY; Taban, H | 1 |
| Collins, D; O'Reilly, S; O'Sullivan, H | 1 |
| Altundag, K | 1 |
| Chui, SY; Emens, LA; Schmid, P | 1 |
| Hsieh, YL; Liou, JP; Pan, SL; Tu, HJ; Yang, CR | 1 |
| Ciurana, J; Feliu, L; Giró-Perafita, A; Planas, M; Puig, T; Rabionet, M; Ruiz-Martínez, S | 1 |
| Doucey, P; Jacquin, JP; Magné, N; Mery, B; Rowinski, E; Simoens, X; Vallard, A | 1 |
| Blohmer, JU; Burchardi, N; Denkert, C; Engels, K; Fasching, PA; Furlanetto, J; Grischke, EM; Hanusch, C; Huober, J; Jackisch, C; Kümmel, S; Loibl, S; Rautenberg, B; Rezai, M; Rhiem, K; Schmitt, WD; Schneeweiss, A; Sinn, BV; Tesch, H; Thomalla, J; Untch, M; von Minckwitz, G; Weber, K | 1 |
| Andersen, J; Bermejo, B; Calvo, I; Ciruelos, E; de la Peña, L; Gil Gil, M; Isakoff, SJ; Nuciforo, P; Oliveira, M; Passos-Coelho, JL; Patt, DA; Saura, C; Shi, Z; Singel, SM; Wongchenko, M; Xu, N | 1 |
| Bechade, D; Blaye, C; Chassaigne, F; Grellety, T; Italiano, A; Kind, M; Lafon, M | 1 |
| Badana, AK; Kumari, S; Malla, RR; Mohan, MG; Shailender, G | 1 |
| Du, FS; Ke, HL; Li, ZC; Yu, L | 1 |
| Harper, NW; Hodges, KB; Huang, B; O'Connor, KL; Romond, EH; Stewart, RL; Wu, J | 1 |
| Futsuhara, K; Hata, S; Inoue, K; Kimizuka, K; Kojima, M; Kuroda, T; Nagai, SE; Saito, T; Sakurai, T; Yamada, H; Yamazaki, Y | 1 |
| Ahmad, R; Hata, T; Hiraki, M; Hong, D; Jin, C; Kufe, D; Kui, L; Li, W; Maeda, T; Miyo, M; Rajabi, H; Samur, M; Suzuki, Y; Takahashi, H; Yamamoto, M; Yasumizu, Y; Zhang, Y | 1 |
| Alain, T; Chambers, J; Côté, M; Cron, GO; El-Sahli, S; Figeys, D; Gadde, S; Le, Y; Lee, SH; Li, L; Liu, S; McGarry, S; Phan, A; Sulaiman, A; Wang, L | 1 |
| Chen, Y; Gong, C; Liu, M; Wang, X; Xu, R | 1 |
| Huang, D; Kamran, M; Liu, Q; Wang, C; Wang, J; Wang, Z; Xu, B; Yan, M; Yang, N | 1 |
| Cai, RG; Li, Q; Wang, JY; Wang, X; Xu, BH; Xu, XZ; Yin, Y; Yuan, P; Zhang, BL; Zhang, P | 1 |
| Aitini, E; Bighin, C; Bisagni, G; Clavarezza, M; De Placido, S; Del Mastro, L; Durando, A; Galli, A; Garrone, O; Levaggi, A; Restuccia, E; Saracchini, S; Scalamogna, R; Turazza, M | 1 |
| Cataruozolo, PE; Cesari, R; Collier, M; Cortés, J; Curigliano, G; Elias, A; Goldhirsch, A; Huang, X; Kern, KA; Khosravan, R; Pivot, X | 1 |
| Bergh, J; Carlsson, L; Einbeigi, Z; Hatschek, T; Lidbrink, E; Linderholm, BK; Norberg, B; Olsson, ME; Svensson, H; Tallroth, E; von Wachenfeldt, A; Wilking, N | 1 |
| Bush, TL; Chung, G; Friberg, G; Hanestad, K; Heller, S; Kendall, RL; Loberg, R; Payton, M; Radinsky, R; Rottman, JB; Saffran, D | 1 |
| Cai, Y; Conzen, SD; Goyal, A; Hall, BA; Kocherginsky, M; Skor, MN; Wonder, EL | 1 |
| Carmichael, J; Chan, A; Clemons, M; Dent, RA; Lindeman, GJ; Lowe, ES; McCarthy, NJ; Singer, CF; Watkins, CL; Wildiers, H | 1 |
| Blackwell, K; Broadwater, G; Hamilton, E; Hopkins, J; Kimmick, G; Marcom, PK; Rocha, G; Welch, R | 1 |
| Inagaki, A; Iwao, H; Izumi, Y; Miura, K; Nagayama, K; Shiota, M; Takahashi, K; Tanaka, M; Wanibuchi, H | 1 |
| Blohmer, JU; Eggemann, H; Eidtmann, H; Fasching, PA; Gerber, B; Hanusch, C; Hauschild, M; Huober, J; Jackisch, C; Kittel, K; Kreienberg, R; Kunz, G; Loibl, S; Nekljudova, V; Rezai, M; Schrader, I; Solbach, C; Tesch, H; Untch, M; von Minckwitz, G | 1 |
| Abu-Khalaf, M; Chang, B; James, E; Sokhn, J | 1 |
| Barranger, E; Bertheau, P; Bousquet, G; de Bazelaire, C; Ferreira, I; Feugeas, JP; Janin, A; Jourdan, N; Vercellino, L | 1 |
| Du, ZG; Gao, WC; Li, QQ; Ma, ZY; Yin, B; Zhao, ZH; Zhou, ZW | 1 |
| Printz, C | 1 |
| Balci, S; Cascione, L; Croce, CM; Fassan, M; Gasparini, P; Guler, G; Huebner, K; Irkkan, C; Lovat, F; Morrison, C; Shapiro, CL | 1 |
| Awada, A; Bakshi, AV; Bondarenko, IN; Bonneterre, J; Ferrero, JM; Nowara, E; Piccart, M; Wilke, C | 1 |
| Akcakanat, A; Brewster, AM; Chen, H; Crawford, D; Do, KA; Dryden, MJ; Flores, P; Giordano, SH; Gonzalez-Angulo, AM; Green, MC; Hortobagyi, GN; Ibrahim, NK; Koenig, KB; Litton, JK; Liu, S; Meric-Bernstam, F; Mills, GB; Moore, J; Moulder-Thompson, S; Murray, JL; Palla, SL; Pusztai, L; Sahin, A; Symmans, WF; Tarco, E; Valero, V | 1 |
| Doi, M; Fudaba, Y; Ikeda, S; Imaoka, Y; Ishimoto, T; Itamoto, T; Kohashi, T; Mashima, H; Matsugu, Y; Mizota, S; Nakahara, H; Nishisaka, T; Noma, M; Ohara, M; Oishi, K; Okimoto, S; Takakura, Y; Urushihara, T | 1 |
| Saeki, T; Ueda, S | 1 |
| Ah Lee, S; Gwe Ahn, S; Jeong, J; Min Lee, H; Woo Lee, H | 1 |
| Hamburger, T; Nechushtan, H; Peretz, T; Salmon, AY; Stainberg, H; Vainer, G | 1 |
| Higaki, K; Kuroi, K; Masuda, N; Matsunami, N; Miyamoto, T; Mizutani, M; Morimoto, T; Morita, S; Ohno, S; Ohtani, S; Takano, T; Toi, M | 1 |
| Ma, T; Tang, J; Wu, J; Zhang, J | 1 |
| D'Assoro, AB; Galanis, E; Gambino, MW; Goetz, MP; Iankov, I; Ingle, JN; Malatino, L; McCubrey, J; Opyrchal, M; Puccia, G; Salisbury, JL | 1 |
| Bellon, JR; Berry, DA; Carey, LA; Cirrincione, CT; Collyar, D; Golshan, M; Hahn, OM; Hudis, CA; Kuzma, CS; Perou, CM; Pluard, TJ; Port, ER; Sikov, WM; Singh, B; Somlo, G; Tolaney, SM; Winer, EP | 1 |
| Arpino, G; De Angelis, C; De Placido, S | 1 |
| Hirokaga, K; Maekawa, Y; Matsuo, Y; Miki, M; Takao, S; Tane, K; Yoshida, S | 1 |
| Bernemann, C; Götte, M; Hülsewig, C; Kiesel, L; Ruckert, C; von Wahlde, MK | 1 |
| Burness, ML; Obeid, EI; Olopade, OI | 1 |
| Chaturvedi, P; Gilkes, DM; Samanta, D; Semenza, GL; Xiang, L | 1 |
| Bos, MM; Boven, E; Braun, JJ; de Groot, SM; Honkoop, AH; Jager, A; Kroep, JR; Lam, SW; Linn, SC; ten Tije, AJ; van den Bosch, J; van Tinteren, H | 1 |
| Frankel, P; Kirschenbaum, M; Kruper, L; Luu, T; Shaw, S; Shinde, AM; Somlo, G; Vito, C; Vora, NL; Yim, JH; Yu, KW; Zhai, J | 1 |
| Bernabe, BP; Dokic, D; Hamdan, R; Jeruss, JS; Parimi, V; Rivas, L; Shea, LD; Tarasewicz, E; Thomas, A | 1 |
| Amith, SR; Baksh, S; Fliegel, L; Wilkinson, JM | 1 |
| Bisagni, G; Boni, C; Cagossi, K; Conte, P; Dieci, MV; Guarneri, V; Pecchi, A; Piacentini, F; Puglisi, F | 1 |
| Blanchard, Z; Craft, B; ElShamy, WM; Paul, BT | 1 |
| Anan, K; Hayashi, M; Kamata, Y; Maeda, S; Mashino, K; Matsuo, S; Mitsuyama, S; Nishimura, J; Tamura, K; Tanaka, M; Toyoshima, S; Yamaguchi, Y; Yamamoto, Y; Yoshinaga, Y | 1 |
| Fujii, K; Kan, S; Kawashima, M; Kiso, M; Takeyama, O; Tanaka, M | 1 |
| Ding, Y; Ji, T; Li, Y; Nie, G; Su, S; Tian, Y; Wu, M; Wu, Y | 1 |
| Chen, S; Guan, JL; Haas, MA; Jin, F; Sun, S; Tu, W; Wang, C; Wen, J; Yeo, S | 1 |
| Piccart, M; Sonnenblick, A | 1 |
| Abramson, VG; Aung, K; Brown, ME; Forero-Torres, A; Hayes, DF; Irvin, WJ; Kidwell, KM; Li, Y; Lin, NU; Liu, MC; Muñiz, MC; Nanda, R; Nangia, JR; Paoletti, C; Storniolo, AM; Thomas, DG; Traina, TA; Vaklavas, C; Van Poznak, CH; Wolff, AC | 1 |
| Abramson, VG; De Los Santos, JF; Forero-Torres, A; Grizzle, W; Haluska, P; Irvin, WJ; Krontiras, H; Li, Y; Lin, NU; Liu, MC; Myers, RM; Nanda, R; Nangia, JR; Patil, S; Rugo, HS; Storniolo, AM; Traina, TA; Vaklavas, C; Van Poznak, CH; Varley, KE; Wolff, AC | 1 |
| Carey, L | 1 |
| Cai, L; Feng, JF; Gu, YJ; Hu, XC; Jiang, ZF; Liu, DG; Lou, GY; Luo, JF; Pan, YY; Ragaz, J; Shao, ZM; Sun, K; Teng, YE; Tong, ZS; Wang, BY; Wang, XJ; Wang, ZH; Wu, CP; Wu, J; Xu, BH; Yin, YM; Zhang, J | 1 |
| Attar, M; Bathula, C; Cooper, KL; Davidson, NE; Flint, MS; Hochbaum, D; Nazario, L; Neumann, CA; Oesterreich, S; Reeder, A; Roy, E; Zhang, A | 1 |
| Akman, S; Cole, J; Cowherd, S; Isom, S; Lawrence, JA; Melin, SA; Miller, LD; Pullikuth, A | 1 |
| Bagnardi, V; Barberis, M; Cancello, G; Colleoni, M; Dellapasqua, S; Goldhirsch, A; Intra, M; Iorfida, M; Luini, A; Montagna, E; Sangalli, C; Sporchia, A; Veronesi, P; Viale, G | 1 |
| Chen, J; Lin, X; Liu, P; Liu, X; Song, C; Tang, H; Wang, N; Xie, X; Yang, L | 1 |
| Hainsworth, JD; Midha, R; Peacock, NW; Priego, VM; Shastry, M; Shipley, DL; Yardley, DA | 1 |
| Campone, M; Chen, M; Diéras, V; Isakoff, SJ; Koeppen, H; Mocci, S; Romieu, G; Schmid, P; Shames, DS; Valero, V; Wilson, TR; Xiao, Y; Yardley, DA | 1 |
| Berry, DA; Cirrincione, CT; Golshan, M; Hudis, C; Jasinski, S; Ollila, DW; Sikov, WM; Somlo, G; Weisberg, TF; Winer, E | 1 |
| Bullen, JW; Chen, I; Hu, H; Lu, H; Samanta, D; Semenza, GL; Xiang, L; Zhang, H | 1 |
| Bellucci, JJ; Bhattacharyya, J; Chi, JT; Chilkoti, A; Li, X; Lin, CC; McDaniel, JR; Spasojevic, I; Weitzhandler, I | 1 |
| De Laurentiis, M; Mustacchi, G | 1 |
| Chen, Z; Clinton, SK; Huang, J; Jin, VX; Lan, X; Liu, Z; Sunkel, B; Wang, Q; Wu, D; Ye, Z | 1 |
| Crozier, M; Porter, LA | 1 |
| Kanazawa, S; Kaneko, H; Kikuchi, Y; Kobayashi, M; Kubota, Y; Magoshi, S; Murakami, Y; Natori, K; Ogata, H; Osaku, T; Saito, F; Shiraga, N | 1 |
| Aksu, H; Çakır, M; Canatan, H; İskender, B; İzgi, K; Kurt, B; Şakalar, Ç; Sezen, S; Turan, A | 1 |
| Asano, Y; Hirakawa, K; Kashiwagi, S; Kawajiri, H; Kitagawa, S; Noda, S; Ohsawa, M; Onoda, N; Takashima, T | 1 |
| Amillano, K; Aura, C; Balmaña, J; Baselga, J; Bermejo, B; Bonnefoi, H; Casas, A; Charpentier, E; Delaloge, S; Di Cosimo, S; Garcia-Ribas, I; Gavilá, J; Gonzalez-Santiago, S; Harbeck, N; Llombart-Cussac, A; Manso, L; Morales, S; Radosevic-Robin, N; Roché, H; Sánchez-Rovira, P; Villanueva, C | 1 |
| Álvarez, I; Ballesteros, AI; Blanco, E; Bueno, C; Cassinello, J; Chacón López-Muñiz, I; Cortés-Funes, H; Fernández-Aramburo, A; Galán, A; Gallegos Sancho, I; Gálve, E; Garau, I; García, MJ; González, S; González, X; González-Santiago, S; Grávalos, C; Llorca, C; Llorente, R; Manso, L; Olier, C; Palomo, AG; Perelló, A; Pérez Carrión, R; Torregrosa, D | 1 |
| Caterino, M; Cognetti, F; De Vita, R; Fabi, A; Ferretti, G; Giannarelli, D; Iacorossi, L; Malaguti, P; Mottolese, M; Nisticò, C; Papaldo, P; Vari, S | 1 |
| Barton, D; Beck, RM; Brufsky, A; Coleman, RE; Conte, PF; Cortes, J; Glück, S; Harbeck, N; Ko, A; Nabholtz, JM; O'Shaughnessy, J; Renschler, MF; Yardley, DA | 1 |
| Agyeman, AS; Conzen, SD; Jun, WJ; Kim, CR; Kocherginsky, M; Proia, DA; Skor, MN | 1 |
| Algie, M; Braithwaite, AW; Fitzgerald, SJ; Hearn, JI; Hurley, DG; Lasham, A; Mehta, SY; Print, CG; Ruza, I; Shelling, AN; Woolley, AG | 1 |
| Berger, R; Catane, R; Dadiani, M; Friedman, E; Friedman, N; Golan, T; Gutman, M; Kaufman, B; Modiano, T; Paluch-Shimon, S; Papa, M; Shabtai, M; Yosepovich, A; Zippel, D | 1 |
| Dong, W; Fu, Z; Han, R; Liu, H; Liu, Y; Meng, L; Wang, R; Xia, X; Ye, J | 1 |
| Liu, SK; Sha, LY; Sui, X; Wang, T; Wang, W; Zhang, H; Zhang, Y | 1 |
| Albain, KS; Berry, DA; Boughey, JC; Buxton, MB; Chien, AJ; Chui, SY; Davis, SE; DeMichele, A; Edmiston, KK; Elias, AD; Esserman, LJ; Euhus, DM; Ewing, C; Haddad, TC; Haley, BB; Hirst, GL; Hogarth, M; Hylton, NM; Isaacs, C; Kaplan, HG; Kemmer, KA; Khan, QJ; Lang, JE; Liu, MC; Lyandres, J; Moulder, SL; Nanda, R; Northfelt, DW; Olopade, OI; Paoloni, M; Perlmutter, J; Pusztai, L; Rugo, HS; Sanil, A; Schwab, R; Symmans, WF; Tripathy, D; van 't Veer, LJ; Viscusi, RK; Wallace, AM; Wood, WC; Yau, C; Yee, D | 1 |
| Chen, S; Jin, X; Shao, ZM; Wang, RX | 1 |
| Clark, RF; McRitchie, SL; Pathmasiri, WW; Stewart, DA; Sumner, SJ; Winnike, JH | 1 |
| Cai, R; Fan, Y; Li, Q; Ma, F; Mo, H; Wang, J; Wang, X; Xu, B; Yin, Y; Yuan, P; Zhang, B; Zhang, P; Zheng, S | 1 |
| Bakrania, AK; Patel, SS; Variya, BC | 1 |
| Kennell, C; Lee, JY; Leung, YK; Tarapore, P; Zhou, Z | 1 |
| Justinger, JS; Mazur, TM; Moore, GL; Nguyen, PT; Nyabuto, GO; Tipton, AR; Trendel, JA; Vestal, DJ; Wadi, S; Wilson, JP | 1 |
| Cho, SG; Choi, EK; Choi, HS; Choi, YK; Hong, SW; Hong, YS; Hwang, IY; Jin, DH; Jung, SA; Kim, D; Kim, H; Kim, HI; Kim, JE; Kim, JH; Kim, KP; Kim, SM; Kim, TW; Kim, YS; Ko, SG; Lee, DH; Lee, EY; Lee, JS; Lee, S; Lee, WK; Moon, JH; Shin, JS | 1 |
| Arpino, G; De Placido, S; Giuliano, M; Schettini, F | 1 |
| Gujrati, M; Lu, ZR; Mack, M; Malamas, A; Snyder, D; Vaidya, AM | 1 |
| Dawood, S; Rugo, HS | 1 |
| Barbier, L; Gertler, FB; Han, S; Jonas, O; Kosciuk, T; Lauffenburger, DA; Miller, MA; Oudin, MJ; Schäfer, C | 1 |
| Bouvet, M; Fujiwara, T; Hoffman, RM; Kagawa, S; Kishimoto, H; Takehara, K; Tazawa, H; Urata, Y; Yano, S | 1 |
| Kanomata, N; Koike, Y; Kurebayashi, J; Moriya, T; Ohta, Y; Saitoh, W; Yamashita, T | 1 |
| Börries, M; Busch, H; Hu, G; Lev, S; Müller, AK; Panayotopoulou, EG | 1 |
| Jiang, H; Li, J; Liu, X; Yuan, Z; Zhu, X | 1 |
| Bai, S; Burnett, JP; Li, Y; Lim, G; Lim, R; McDermott, SP; Paholak, HJ; Shah, RB; Sun, D; Sun, L; Tsume, Y; Wicha, MS; Zhang, T | 1 |
| Bello, E; Berndt, A; Camboni, G; Cavalletti, E; Colella, G; D'Incalci, M; Damia, G; Forestieri, D; Giavazzi, R; Licandro, SA; Richter, P; Taraboletti, G; Zucchetti, M | 1 |
| DU, M; Jiang, ZF; Meng, XY; Song, ST; Wang, T; Wu, SK; Zhang, SH; Zhao, X | 1 |
17 review(s) available for paclitaxel and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
[A Case of Stage Ⅳ Triple Negative Breast Cancer(TNBC)in Which S-1 Was Successful against Armor-Like Infiltration of the Chest Wall].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Epirubicin; Female; Humans; Middle Aged; Paclitaxel; Thoracic Wall; Triple Negative Breast Neoplasms | 2022 |
Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Bayes Theorem; Bevacizumab; Humans; Network Meta-Analysis; Paclitaxel; Poly(ADP-ribose) Polymerase Inhibitors; Triple Negative Breast Neoplasms | 2022 |
Combined atezolizumab and nab-paclitaxel in the treatment of triple negative breast cancer: a meta-analysis on their efficacy and safety.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Humans; Paclitaxel; Randomized Controlled Trials as Topic; Triple Negative Breast Neoplasms | 2022 |
Impact of platinum-based chemotherapy on the prognosis of early triple-negative breast cancer: a systematic review and meta-analysis.
Topics: Anemia; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arthralgia; Breast Neoplasms; Female; Humans; Myalgia; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Platinum; Prognosis; Triple Negative Breast Neoplasms | 2023 |
Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysis.
Topics: Adjuvants, Immunologic; Anthracyclines; Bevacizumab; Carboplatin; Cyclophosphamide; Humans; Immunotherapy; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Network Meta-Analysis; Paclitaxel; Triple Negative Breast Neoplasms | 2023 |
Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Bridged-Ring Compounds; Carboplatin; Female; Humans; Mutation; Neoadjuvant Therapy; Organoplatinum Compounds; Paclitaxel; Progression-Free Survival; Randomized Controlled Trials as Topic; Taxoids; Triple Negative Breast Neoplasms | 2019 |
Atezolizumab for use in PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast cancer.
Topics: Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Clinical Trials as Topic; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Maximum Tolerated Dose; Paclitaxel; Progression-Free Survival; Triple Negative Breast Neoplasms; Tumor Escape | 2020 |
Atezolizumab (in Combination with Nab-Paclitaxel): A Review in Advanced Triple-Negative Breast Cancer.
Topics: Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Humans; Paclitaxel; Triple Negative Breast Neoplasms | 2020 |
Atezolizumab in the treatment of metastatic triple-negative breast cancer.
Topics: Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; B7-H1 Antigen; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Paclitaxel; Treatment Outcome; Triple Negative Breast Neoplasms | 2020 |
Effect of antitumor treatments on triple-negative breast cancer patients: A PRISMA-compliant network meta-analysis of randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bevacizumab; Carboplatin; Female; Humans; Paclitaxel; Randomized Controlled Trials as Topic; Survival Analysis; Triple Negative Breast Neoplasms | 2017 |
Advances in the systemic treatment of triple-negative breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Capecitabine; Chemotherapy, Adjuvant; Female; Humans; Immunotherapy; Medical Oncology; Mutation; Neoadjuvant Therapy; Paclitaxel; Triple Negative Breast Neoplasms | 2018 |
Adjuvant systemic therapy in breast cancer: quo vadis?
Topics: Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Female; Humans; Lapatinib; Mastectomy; Paclitaxel; Patient Selection; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Tamoxifen; Trastuzumab; Triple Negative Breast Neoplasms | 2015 |
The role of taxanes in triple-negative breast cancer: literature review.
Topics: Albumins; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms | 2015 |
Liver Metastasis of a Triple-Negative Breast Cancer and Complete Remission for 5 Years After Treatment With Combined Bevacizumab/Paclitaxel/Carboplatin: Case Report and Review of the Literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; BRCA2 Protein; Carboplatin; Female; Genetic Predisposition to Disease; Germ-Line Mutation; Humans; Liver Neoplasms; Paclitaxel; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Remission Induction; Triple Negative Breast Neoplasms | 2015 |
Novel targets for paclitaxel nano formulations: Hopes and hypes in triple negative breast cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Drug Delivery Systems; Humans; Ligands; Molecular Targeted Therapy; Nanotechnology; Paclitaxel; Triple Negative Breast Neoplasms | 2016 |
Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives.
Topics: Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Chemotherapy, Adjuvant; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Nanoparticles; Neoadjuvant Therapy; Paclitaxel; Triple Negative Breast Neoplasms | 2016 |
Targeting the host immune system: PD-1 and PD-L1 antibodies and breast cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Breast Neoplasms; Clinical Trials, Phase I as Topic; Humans; Paclitaxel; Programmed Cell Death 1 Receptor; Triple Negative Breast Neoplasms | 2016 |
89 trial(s) available for paclitaxel and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Weekly Paclitaxel given concurrently with Durvalumab has a favorable safety profile in triple-negative metastatic breast cancer.
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Female; Humans; Middle Aged; Paclitaxel; Progression-Free Survival; Triple Negative Breast Neoplasms; Young Adult | 2021 |
Phase II trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastases.
Topics: Adult; Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Albumins; Analysis of Variance; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Breast Neoplasms; China; Confidence Intervals; Female; Humans; Middle Aged; Neutropenia; Paclitaxel; Premenopause; Progression-Free Survival; Prospective Studies; Treatment Outcome; Triple Negative Breast Neoplasms; Viscera | 2021 |
TAKTIC: A prospective, multicentre, uncontrolled, phase IB/II study of LY2780301, a p70S6K/AKT inhibitor, in combination with weekly paclitaxel in HER2-negative advanced breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Enzyme Inhibitors; Female; Humans; Middle Aged; Paclitaxel; Proto-Oncogene Proteins c-akt; Ribosomal Protein S6 Kinases, 70-kDa; Triple Negative Breast Neoplasms | 2021 |
Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Class I Phosphatidylinositol 3-Kinases; Humans; Neoadjuvant Therapy; Paclitaxel; Phosphatidylinositol 3-Kinases; Piperazines; Proto-Oncogene Proteins c-akt; Pyrimidines; Triple Negative Breast Neoplasms | 2022 |
CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carboplatin; Female; Humans; Neoadjuvant Therapy; Neoplasm, Residual; Paclitaxel; Triple Negative Breast Neoplasms | 2022 |
Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancer.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Female; Humans; Immune Checkpoint Inhibitors; Lymphocyte Depletion; Middle Aged; Neoplasm Metastasis; Paclitaxel; Receptors, Antigen, T-Cell; T-Lymphocyte Subsets; Triple Negative Breast Neoplasms; Young Adult | 2022 |
Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Neoadjuvant Therapy; Paclitaxel; Triple Negative Breast Neoplasms | 2022 |
A prospective phase II clinical trial identifying the optimal regimen for carboplatin plus standard backbone of anthracycline and taxane-based chemotherapy in triple negative breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Canada; Carboplatin; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Prospective Studies; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms | 2022 |
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carboplatin; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Triple Negative Breast Neoplasms | 2022 |
Efficacy of Sequential Capecitabine on Adjuvant Chemotherapy of Triple-Negative Breast Cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Paclitaxel; Triple Negative Breast Neoplasms | 2022 |
Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer.
Topics: Albumins; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Transforming Growth Factor beta; Triple Negative Breast Neoplasms | 2022 |
Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Denosumab; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Treatment Outcome; Triple Negative Breast Neoplasms; Young Adult | 2022 |
Safety and efficacy of nivolumab plus bevacizumab, paclitaxel for HER2-negative metastatic breast cancer: Primary results and biomarker data from a phase 2 trial (WJOG9917B).
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers; Breast Neoplasms; Female; Humans; Ligands; Nivolumab; Paclitaxel; Receptor, ErbB-2; Triple Negative Breast Neoplasms; Vascular Endothelial Growth Factor A | 2022 |
Subgroup analysis of Japanese patients in a phase III randomized, controlled study of neoadjuvant atezolizumab or placebo, combined with nab-paclitaxel and anthracycline-based chemotherapy in early triple-negative breast cancer (IMpassion031).
Topics: Albumins; Anthracyclines; Antibiotics, Antineoplastic; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Cyclophosphamide; Doxorubicin; Humans; Japan; Neoadjuvant Therapy; Paclitaxel; Triple Negative Breast Neoplasms | 2022 |
A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Triple Negative Breast Neoplasms | 2022 |
Nab-paclitaxel Followed by Dose-dense Epirubicin/Cyclophosphamide in Neoadjuvant Chemotherapy for Triple-negative Breast Cancer: A Phase II Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Epirubicin; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Treatment Outcome; Triple Negative Breast Neoplasms | 2023 |
A phase 1 study of veliparib (ABT-888) plus weekly carboplatin and paclitaxel in advanced solid malignancies, with an expansion cohort in triple negative breast cancer (TNBC) (ETCTN 8620).
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Female; Humans; Paclitaxel; Triple Negative Breast Neoplasms | 2023 |
Pembrolizumab in combination with nab-paclitaxel for the treatment of patients with early-stage triple-negative breast cancer - A single-arm phase II trial (NeoImmunoboost, AGO-B-041).
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Platinum; Prospective Studies; Quality of Life; Treatment Outcome; Triple Negative Breast Neoplasms | 2023 |
Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboplatin; Humans; Paclitaxel; Triple Negative Breast Neoplasms | 2023 |
A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Triple Negative Breast Neoplasms | 2023 |
Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Paclitaxel; Triple Negative Breast Neoplasms | 2023 |
Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130).
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Female; Humans; Japan; Middle Aged; Paclitaxel; Progression-Free Survival; Safety; Triple Negative Breast Neoplasms | 2019 |
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Adolescent; Adult; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Double-Blind Method; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Triple Negative Breast Neoplasms; Young Adult | 2020 |
A phase I study of an oral selective gamma secretase (GS) inhibitor RO4929097 in combination with neoadjuvant paclitaxel and carboplatin in triple negative breast cancer.
Topics: Administration, Oral; Adult; Aged; Amyloid Precursor Protein Secretases; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzazepines; Carboplatin; Female; Humans; Infusions, Intravenous; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Treatment Outcome; Triple Negative Breast Neoplasms | 2020 |
FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Double-Blind Method; Drug Approval; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Survival Rate; Triple Negative Breast Neoplasms; United States; United States Food and Drug Administration; Young Adult | 2020 |
Pembrolizumab for Early Triple-Negative Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Doxorubicin; Epirubicin; Female; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Triple Negative Breast Neoplasms | 2020 |
Secondary analyses of the randomized phase III Stop&Go study: efficacy of second-line intermittent versus continuous chemotherapy in HER2-negative advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Doxorubicin; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Paclitaxel; Polyethylene Glycols; Progression-Free Survival; Receptor, ErbB-2; Time Factors; Triple Negative Breast Neoplasms | 2020 |
Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer.
Topics: Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Humans; Paclitaxel; Patient Reported Outcome Measures; Quality of Life; Triple Negative Breast Neoplasms | 2020 |
A multicenter phase II trial of nab-paclitaxel and capecitabine in HER-2 negative and triple- negative advanced breast cancer: Could be an old regimen a valid approach to a changing disease?
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Humans; Paclitaxel; Triple Negative Breast Neoplasms | 2020 |
Platinum-based chemotherapy in advanced triple-negative breast cancer: A multicenter real-world study in China.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; China; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Platinum; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome; Triple Negative Breast Neoplasms; Young Adult | 2020 |
Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial.
Topics: Adult; Aged; Albumins; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Female; Follow-Up Studies; High-Throughput Nucleotide Sequencing; Humans; Immunohistochemistry; Middle Aged; Molecular Targeted Therapy; Paclitaxel; Precision Medicine; Programmed Cell Death 1 Receptor; Prospective Studies; RNA, Messenger; Treatment Outcome; Triple Negative Breast Neoplasms | 2021 |
Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Carboplatin; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Germ-Line Mutation; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Triple Negative Breast Neoplasms | 2020 |
TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cisplatin; Homologous Recombination; Humans; Mutation; Neoadjuvant Therapy; Paclitaxel; Prospective Studies; Triple Negative Breast Neoplasms | 2020 |
Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Humans; Neoadjuvant Therapy; Paclitaxel; Treatment Outcome; Triple Negative Breast Neoplasms | 2021 |
Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study.
Topics: Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Biomarkers; Humans; Lymphocytes, Tumor-Infiltrating; Paclitaxel; Triple Negative Breast Neoplasms; Tumor Microenvironment | 2021 |
Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Immunophenotyping; Neoadjuvant Therapy; Paclitaxel; Triple Negative Breast Neoplasms | 2021 |
Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Female; Furans; Homologous Recombination; Humans; Japan; Ketones; Neoadjuvant Therapy; Paclitaxel; Treatment Outcome; Triple Negative Breast Neoplasms | 2021 |
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Humans; Paclitaxel; Progression-Free Survival; Triple Negative Breast Neoplasms | 2021 |
Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Humans; Paclitaxel; Phosphatidylinositol 3-Kinases; Piperazines; Pyrimidines; Triple Negative Breast Neoplasms | 2021 |
First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis.
Topics: Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Humans; Paclitaxel; Survival Analysis; Triple Negative Breast Neoplasms | 2021 |
Does bevacizumab carry a hope for metastatic triple-negative breast cancer in the era of immunotherapy?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carboplatin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Progression-Free Survival; Prospective Studies; Remission Induction; Triple Negative Breast Neoplasms | 2022 |
TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Epothilones; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Analysis; Treatment Outcome; Triple Negative Breast Neoplasms; Young Adult | 2017 |
Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE).
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Germany; Humans; Mastectomy; Medication Adherence; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Taxoids; Time Factors; Treatment Outcome; Triple Negative Breast Neoplasms; Young Adult | 2017 |
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Patient Selection; Placebos; Prognosis; Proportional Hazards Models; Proto-Oncogene Proteins c-akt; Risk Assessment; Survival Analysis; Treatment Outcome; Triple Negative Breast Neoplasms | 2017 |
BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Capecitabine; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Humans; Middle Aged; Myeloablative Agonists; Neoplasm Recurrence, Local; Paclitaxel; Triple Negative Breast Neoplasms | 2017 |
Efficacy of anthracycline/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers.
Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Disease-Free Survival; Docetaxel; Female; Heterozygote; Humans; Middle Aged; Mutation; Neoadjuvant Therapy; Paclitaxel; Treatment Outcome; Triple Negative Breast Neoplasms | 2018 |
Weekly Paclitaxel and Carboplatin Plus Bevacizumab as First-Line Treatment of Metastatic Triple-Negative Breast Cancer. A Multicenter Phase II Trial by the Hellenic Oncology Research Group.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Diarrhea; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Paclitaxel; Progression-Free Survival; Severity of Illness Index; Thrombocytopenia; Triple Negative Breast Neoplasms | 2018 |
Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Treatment Outcome; Triple Negative Breast Neoplasms | 2018 |
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Topics: Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Chemotherapy-Induced Febrile Neutropenia; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Double-Blind Method; Doxorubicin; Female; Genes, BRCA1; Genes, BRCA2; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Mastectomy; Middle Aged; Mutation; Neoadjuvant Therapy; Paclitaxel; Survival Rate; Thrombocytopenia; Treatment Outcome; Triple Negative Breast Neoplasms; Tumor Burden | 2018 |
nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Mastectomy; Middle Aged; Paclitaxel; Progression-Free Survival; Triple Negative Breast Neoplasms | 2018 |
The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple negative breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lymphocyte Count; Lymphocytes; Middle Aged; Neoplasm Metastasis; Neutrophils; Paclitaxel; Retrospective Studies; Survival Rate; Triple Negative Breast Neoplasms | 2018 |
Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Germ-Line Mutation; Humans; Kaplan-Meier Estimate; Models, Biological; Paclitaxel; Patient Selection; Progression-Free Survival; Prospective Studies; Risk Assessment; Treatment Outcome; Triple Negative Breast Neoplasms | 2018 |
Randomised feasibility trial to compare three standard of care chemotherapy regimens for early stage triple-negative breast cancer (REaCT-TNBC trial).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Docetaxel; Doxorubicin; Endpoint Determination; Epirubicin; Feasibility Studies; Female; Fluorouracil; Guideline Adherence; Humans; Middle Aged; Paclitaxel; Pilot Projects; Random Allocation; Surveys and Questionnaires; Triple Negative Breast Neoplasms | 2018 |
Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Breast; Bridged-Ring Compounds; Carboplatin; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Mastectomy; Middle Aged; Mutation; Neoadjuvant Therapy; Paclitaxel; Polyethylene Glycols; Prognosis; Recombinational DNA Repair; Survival Analysis; Taxoids; Triple Negative Breast Neoplasms | 2018 |
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
Topics: Adult; Aged; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Intention to Treat Analysis; Middle Aged; Paclitaxel; Progression-Free Survival; Survival Analysis; Triple Negative Breast Neoplasms | 2018 |
Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Progression-Free Survival; Time Factors; Triple Negative Breast Neoplasms; United States | 2019 |
Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer-A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Disease-Free Survival; Drug Administration Schedule; Endothelial Cells; Erlotinib Hydrochloride; Female; Humans; Induction Chemotherapy; Maintenance Chemotherapy; Middle Aged; Neoplastic Cells, Circulating; Paclitaxel; Protein Kinase Inhibitors; Triple Negative Breast Neoplasms; Tubulin Modulators | 2019 |
Tailored NEOadjuvant epirubicin, cyclophosphamide and Nanoparticle Albumin-Bound paclitaxel for breast cancer: The phase II NEONAB trial-Clinical outcomes and molecular determinants of response.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Epirubicin; Female; Follow-Up Studies; Humans; Middle Aged; Nanoparticles; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Serum Albumin, Human; Trastuzumab; Triple Negative Breast Neoplasms | 2019 |
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study.
Topics: Adult; Aged; Albumins; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Biomarkers, Tumor; Breast; Cyclophosphamide; Double-Blind Method; Epirubicin; Female; Humans; Hyperthyroidism; Hypothyroidism; Lymphocytes, Tumor-Infiltrating; Mastectomy; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Placebos; Prospective Studies; Receptor, ErbB-2; Thyroid Gland; Treatment Outcome; Triple Negative Breast Neoplasms; Young Adult | 2019 |
FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Gain of Function Mutation; Humans; Magnetic Resonance Imaging; Mastectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Patient Selection; Piperazines; Placebos; Pyrimidines; Triple Negative Breast Neoplasms | 2019 |
Adjuvant Treatment of Triple-Negative Metaplastic Breast Cancer With Weekly Paclitaxel and Platinum Chemotherapy: Retrospective Case Review From a Single Institution.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Triple Negative Breast Neoplasms | 2019 |
Unfavorable pathological complete response rate of neoadjuvant chemotherapy epirubicin plus taxanes for locally advanced triple-negative breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Epirubicin; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm, Residual; Paclitaxel; Taxoids; Treatment Failure; Treatment Outcome; Triple Negative Breast Neoplasms | 2013 |
Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma; Cyclophosphamide; Drug Therapy, Combination; Epirubicin; Female; Fluorouracil; Humans; Inflammatory Breast Neoplasms; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Treatment Outcome; Triple Negative Breast Neoplasms | 2013 |
Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Docetaxel; Fatigue; Female; Fluorouracil; Gemcitabine; Hand-Foot Syndrome; Humans; Indoles; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Pyrroles; Sunitinib; Survival Rate; Taxoids; Thrombocytopenia; Triple Negative Breast Neoplasms | 2013 |
Angiogenic factors in relation to clinical effect in a phase II trial of weekly paclitaxel.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Female; Fibroblast Growth Factor 2; Humans; Middle Aged; Paclitaxel; Receptor, ErbB-2; Time Factors; Trastuzumab; Triple Negative Breast Neoplasms; Vascular Endothelial Growth Factor A | 2013 |
Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Treatment Outcome; Triple Negative Breast Neoplasms | 2013 |
Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancer.
Topics: Adult; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Prognosis; Triple Negative Breast Neoplasms | 2013 |
Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44).
Topics: Adult; Aged; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Everolimus; Female; Humans; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Paclitaxel; Sirolimus; Treatment Outcome; Triple Negative Breast Neoplasms; Tumor Burden; Ultrasonography; Young Adult | 2013 |
A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC).
Topics: Adult; Aged; Combined Modality Therapy; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Endothelial Cells; Female; Humans; Lipids; Middle Aged; Paclitaxel; Triple Negative Breast Neoplasms | 2014 |
Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Epirubicin; Everolimus; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Triple Negative Breast Neoplasms | 2014 |
A phase 1/2 of a combination of cetuximab and taxane for "triple negative" breast cancer patients.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cetuximab; Docetaxel; ErbB Receptors; Female; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Paclitaxel; Skin Neoplasms; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms | 2014 |
A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Cyclophosphamide; Deoxycytidine; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Triple Negative Breast Neoplasms; Young Adult | 2014 |
Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (A
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Fatigue; Female; Humans; Hypertension; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neutropenia; Paclitaxel; Remission Induction; Thrombocytopenia; Treatment Outcome; Triple Negative Breast Neoplasms | 2015 |
Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome; Triple Negative Breast Neoplasms | 2014 |
Preoperative carboplatin-paclitaxel-bevacizumab in triple-negative breast cancer: final results of the phase II Ca.Pa.Be study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ductal, Breast; Contrast Media; Female; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Preoperative Care; Prognosis; Triple Negative Breast Neoplasms | 2015 |
Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019.
Topics: Adult; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Count; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Paclitaxel; Prognosis; Triple Negative Breast Neoplasms | 2015 |
TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Female; Humans; Middle Aged; Nanoparticles; Paclitaxel; Receptors, TNF-Related Apoptosis-Inducing Ligand; Retreatment; Treatment Outcome; Triple Negative Breast Neoplasms | 2015 |
Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; China; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Treatment Outcome; Triple Negative Breast Neoplasms | 2015 |
A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic triple negative breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; ErbB Receptors; Female; Gene Expression; Gene Expression Profiling; Humans; Middle Aged; Paclitaxel; Panitumumab; Triple Negative Breast Neoplasms | 2015 |
Phase II Study With Epirubicin, Cisplatin, and Infusional Fluorouracil Followed by Weekly Paclitaxel With Metronomic Cyclophosphamide as a Preoperative Treatment of Triple-Negative Breast Cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Triple Negative Breast Neoplasms | 2015 |
Phase I/II trial of neoadjuvant sunitinib administered with weekly paclitaxel/carboplatin in patients with locally advanced triple-negative breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Female; Humans; Indoles; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pyrroles; Sunitinib; Treatment Outcome; Triple Negative Breast Neoplasms | 2015 |
Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Disease-Free Survival; Female; Humans; Middle Aged; Paclitaxel; Placebos; Triple Negative Breast Neoplasms | 2015 |
Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Chemotherapy, Adjuvant; Disease-Free Survival; Doxorubicin; Female; Humans; Mastectomy, Segmental; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Patient Selection; Prognosis; Prospective Studies; Survival Analysis; Treatment Outcome; Triple Negative Breast Neoplasms; Young Adult | 2015 |
Predictive Value of Neutrophil/Lymphocyte Ratio for Efficacy of Preoperative Chemotherapy in Triple-Negative Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Immunoenzyme Techniques; Lymphocytes; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neutrophils; Paclitaxel; Preoperative Care; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate; Triple Negative Breast Neoplasms | 2016 |
SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Treatment Outcome; Triple Negative Breast Neoplasms | 2015 |
Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents, Phytogenic; Disease-Free Survival; Female; Follow-Up Studies; Humans; Middle Aged; Nanoparticles; Neoplasm Metastasis; Paclitaxel; Prospective Studies; Survival Rate; Taxoids; Triple Negative Breast Neoplasms; Young Adult | 2015 |
Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Protocols; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Research Design; Survival Analysis; Time Factors; Treatment Outcome; Triple Negative Breast Neoplasms | 2015 |
Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Benzimidazoles; Carboplatin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Poly(ADP-ribose) Polymerase Inhibitors; Triple Negative Breast Neoplasms | 2016 |
Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Epirubicin; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Recurrence; Survival Analysis; Treatment Outcome; Triple Negative Breast Neoplasms | 2016 |
307 other study(ies) available for paclitaxel and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Inhibitory effects of ginseng sapogenins on the proliferation of triple negative breast cancer MDA-MB-231 cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Drugs, Chinese Herbal; Female; Humans; Panax; Sapogenins; Triple Negative Breast Neoplasms | 2014 |
Design, Synthesis, and Structure-Activity Relationship Studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer.
Topics: Acetylene; Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Cycle; Cell Line, Tumor; Cell Movement; Drug Design; Drug Screening Assays, Antitumor; Heterografts; Humans; Male; Mice, SCID; Neoplasm Transplantation; Pyrazoles; Pyrimidines; Rats; Rats, Sprague-Dawley; src-Family Kinases; Structure-Activity Relationship; Triple Negative Breast Neoplasms | 2015 |
Maximiscin Induces DNA Damage, Activates DNA Damage Response Pathways, and Has Selective Cytotoxic Activity against a Subtype of Triple-Negative Breast Cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Cycle; Cell Proliferation; DNA Damage; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Mice; Molecular Structure; Receptor, ErbB-2; Receptors, Progesterone; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2016 |
From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as Agents for the Treatment of Triple Negative Breast Cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Mice; Mice, SCID; Molecular Structure; Neoplasms, Experimental; Pyrazoles; Pyrimidines; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Triple Negative Breast Neoplasms; Tumor Cells, Cultured; Zebrafish | 2016 |
Antitumor Activity of Vanicoside B Isolated from
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cinnamates; Cyclin-Dependent Kinase 8; Drug Screening Assays, Antitumor; Female; Humans; Mice; Mice, Nude; Molecular Structure; Polygonaceae; Triple Negative Breast Neoplasms; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2019 |
Design, synthesis, and validation of novel nitrogen-based chalcone analogs against triple negative breast cancer.
Topics: Animals; Apoptosis; Cell Cycle Checkpoints; Cell Proliferation; Cell Survival; Chalcone; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Female; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Models, Molecular; Molecular Structure; Nitrogen; Structure-Activity Relationship; Triple Negative Breast Neoplasms; Tumor Cells, Cultured | 2020 |
Identification of a Potent Oridonin Analogue for Treatment of Triple-Negative Breast Cancer.
Topics: Animals; Cell Line, Tumor; Diterpenes, Kaurane; Humans; Male; Mice; Mice, Inbred ICR; Mice, Nude; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2020 |
5α-Epoxyalantolactone Inhibits Metastasis of Triple-Negative Breast Cancer Cells by Covalently Binding a Conserved Cysteine of Annexin A2.
Topics: Annexin A2; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Humans; Lactones; Liver Neoplasms; Lung Neoplasms; Molecular Structure; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2021 |
Synthesis of small molecules targeting paclitaxel-induced MyD88 expression in triple-negative breast cancer cell lines.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Myeloid Differentiation Factor 88; Paclitaxel; Small Molecule Libraries; Structure-Activity Relationship; Toll-Like Receptor 4; Triple Negative Breast Neoplasms | 2021 |
Bradykinin-Potentiating Peptide-Paclitaxel Conjugate Directed at Ectopically Expressed Angiotensin-Converting Enzyme in Triple-Negative Breast Cancer.
Topics: Animals; Apoptosis; Bradykinin; Cell Line; Cell Line, Tumor; Female; Humans; Mice; Mice, Nude; Oligopeptides; Paclitaxel; Peptidyl-Dipeptidase A; Tissue Distribution; Triple Negative Breast Neoplasms | 2021 |
Novel deuterated Mnk1/2 protein degrader VNLG-152R analogs: Synthesis, In vitro Anti-TNBC activities and pharmacokinetics in mice.
Topics: Animals; Eukaryotic Initiation Factor-4E; Female; Humans; Mice; Paclitaxel; Protein Serine-Threonine Kinases; Signal Transduction; Triple Negative Breast Neoplasms | 2022 |
Combined chemotherapy for triple negative breast cancer treatment by paclitaxel and niclosamide nanocrystals loaded thermosensitive hydrogel.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Humans; Hydrogels; Nanoparticles; Niclosamide; Paclitaxel; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2021 |
Paclitaxel Induces Micronucleation and Activates Pro-Inflammatory cGAS-STING Signaling in Triple-Negative Breast Cancer.
Topics: Antineoplastic Agents, Phytogenic; Humans; Inflammation; Nucleotidyltransferases; Paclitaxel; Signal Transduction; Taxoids; Triple Negative Breast Neoplasms | 2021 |
JAK2 regulates paclitaxel resistance in triple negative breast cancers.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cancer-Associated Fibroblasts; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Janus Kinase 2; Mammary Neoplasms, Experimental; Mice; Nitriles; Paclitaxel; Pyrazoles; Pyrimidines; Triple Negative Breast Neoplasms; Tumor Microenvironment | 2021 |
LncRNA OTUD6B-AS1 promotes paclitaxel resistance in triple negative breast cancer by regulation of miR-26a-5p/MTDH pathway-mediated autophagy and genomic instability.
Topics: Animals; Antineoplastic Agents; Autophagy; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Genomic Instability; Humans; Membrane Proteins; Mice, Nude; MicroRNAs; Paclitaxel; RNA-Binding Proteins; RNA, Long Noncoding; Triple Negative Breast Neoplasms | 2021 |
[Paclitaxel plus Bevacizumab Therapy plus Surgical Resection Results in Local Control of Stage ⅢC Breast Cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Humans; Mastectomy; Paclitaxel; Quality of Life; Triple Negative Breast Neoplasms | 2021 |
Micellar paclitaxel boosts ICD and chemo-immunotherapy of metastatic triple negative breast cancer.
Topics: CD8-Positive T-Lymphocytes; Humans; Immunogenic Cell Death; Immunotherapy; Paclitaxel; Triple Negative Breast Neoplasms; Tumor Microenvironment | 2022 |
The BH3-only protein NOXA serves as an independent predictor of breast cancer patient survival and defines susceptibility to microtubule targeting agents.
Topics: Apoptosis Regulatory Proteins; Humans; Microtubules; Neoplasm Recurrence, Local; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Triple Negative Breast Neoplasms | 2021 |
Integrated Metabolic Profiling and Transcriptional Analysis Reveals Therapeutic Modalities for Targeting Rapidly Proliferating Breast Cancers.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biphenyl Compounds; Carboplatin; Cell Line, Tumor; Cell Proliferation; Gene Expression Profiling; Humans; Metabolomics; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Molecular Targeted Therapy; Paclitaxel; Signal Transduction; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2022 |
Inhibition of FOXO1‑mediated autophagy promotes paclitaxel‑induced apoptosis of MDA‑MB‑231 cells.
Topics: Adenine; Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; Autophagy-Related Protein 5; Beclin-1; Cell Line, Tumor; Cell Survival; Class III Phosphatidylinositol 3-Kinases; Cysteine Endopeptidases; Drug Resistance, Neoplasm; Forkhead Box Protein O1; Humans; Microtubule-Associated Proteins; Paclitaxel; Triple Negative Breast Neoplasms | 2022 |
Ratiometric co-delivery of doxorubicin and paclitaxel prodrug by remote-loading liposomes for the treatment of triple-negative breast cancer.
Topics: Cell Line, Tumor; Doxorubicin; Drug Delivery Systems; Humans; Liposomes; Paclitaxel; Prodrugs; Tissue Distribution; Triple Negative Breast Neoplasms | 2022 |
USP18 reduces paclitaxol sensitivity of triple-negative breast cancer via autophagy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; Cell Cycle; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Mice, Inbred BALB C; Paclitaxel; Triple Negative Breast Neoplasms; Ubiquitin Thiolesterase; Xenograft Model Antitumor Assays | 2022 |
Modulatory Effects of Biosynthesized Gold Nanoparticles Conjugated with Curcumin and Paclitaxel on Tumorigenesis and Metastatic Pathways-In Vitro and In Vivo Studies.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinogenesis; Cell Line; Cell Line, Tumor; Curcumin; Drug Resistance, Multiple; Female; Gold; HEK293 Cells; Humans; Metal Nanoparticles; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Paclitaxel; Triple Negative Breast Neoplasms | 2022 |
Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial.
Topics: Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Humans; Indoles; Paclitaxel; Pyrroles; Triple Negative Breast Neoplasms | 2022 |
ABTL0812 enhances antitumor effect of paclitaxel and reverts chemoresistance in triple-negative breast cancer models.
Topics: Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Linoleic Acids; Paclitaxel; Triple Negative Breast Neoplasms | 2022 |
Risk of MDS/AML with the addition of neoadjuvant carboplatin to standard chemotherapy for triple-negative breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Female; Humans; Leukemia, Myeloid, Acute; Neoadjuvant Therapy; Paclitaxel; Treatment Outcome; Triple Negative Breast Neoplasms | 2022 |
Posterior reversible encephalopathy syndrome associated with use of Atezolizumab for the treatment of relapsed triple negative breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Female; Humans; Middle Aged; Paclitaxel; Posterior Leukoencephalopathy Syndrome; Triple Negative Breast Neoplasms | 2022 |
Breast Tumour Kinase (Brk/PTK6) Contributes to Breast Tumour Xenograft Growth and Modulates Chemotherapeutic Responses In Vitro.
Topics: Cell Line, Tumor; Doxorubicin; Heterografts; Humans; Neoplasm Proteins; Paclitaxel; Protein-Tyrosine Kinases; Triple Negative Breast Neoplasms | 2022 |
Epigenetic drugs induce the potency of classic chemotherapy, suppress post-treatment re-growth of breast cancer, but preserve the wound healing ability of stem cells.
Topics: Epigenesis, Genetic; Humans; Paclitaxel; Stem Cells; Surgical Wound; Triple Negative Breast Neoplasms; Wound Healing | 2022 |
Reply to the Letter to the Editor 'Risk of MDS/AML with the addition of neoadjuvant carboplatin to standard chemotherapy for triple-negative breast cancer' by A. Okines and N. Turner.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Humans; Leukemia, Myeloid, Acute; Neoadjuvant Therapy; Paclitaxel; Triple Negative Breast Neoplasms | 2022 |
Survival outcomes for dose-dense paclitaxel plus carboplatin neoadjuvant vs standard adjuvant chemotherapy in stage II to III triple-negative breast cancer: A prospective cohort study with propensity-matched analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Humans; Male; Neoadjuvant Therapy; Paclitaxel; Prospective Studies; Testicular Neoplasms; Treatment Outcome; Triple Negative Breast Neoplasms | 2022 |
Targeted Intervention of NF2-YAP Signaling Axis in CD24-Overexpressing Cells Contributes to Encouraging Therapeutic Effects in TNBC.
Topics: CD24 Antigen; Cell Line, Tumor; Ferroptosis; Humans; Paclitaxel; Signal Transduction; Triple Negative Breast Neoplasms | 2022 |
What's in a Name? That Which We Call Immune Cells by Any Other Name Would All Smell as Sweet.
Topics: Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Humans; Indoles; Paclitaxel; Pyrroles; Triple Negative Breast Neoplasms | 2022 |
A neutrophil-mediated carrier regulates tumor stemness by inhibiting autophagy to prevent postoperative triple-negative breast cancer recurrence and metastasis.
Topics: Autophagy; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Hydroxychloroquine; Inflammation; Liposomes; Neoplasm, Residual; Neutrophils; Paclitaxel; Triple Negative Breast Neoplasms | 2022 |
Folic Acid-Functionalized Carbon Dot-Enabled Starvation Therapy in Synergism with Paclitaxel against Breast Cancer.
Topics: Carbon; Cell Line, Tumor; Folic Acid; Glucose; Glucose Oxidase; HEK293 Cells; Humans; Paclitaxel; Triple Negative Breast Neoplasms | 2022 |
Colchicine-Binding Site Agent CH-2-77 as a Potent Tubulin Inhibitor Suppressing Triple-Negative Breast Cancer.
Topics: Apoptosis; Binding Sites; Cell Line, Tumor; Cell Proliferation; Colchicine; Humans; Paclitaxel; Triple Negative Breast Neoplasms; Tubulin; Tubulin Modulators | 2022 |
HMGA1 positively regulates the microtubule-destabilizing protein stathmin promoting motility in TNBC cells and decreasing tumour sensitivity to paclitaxel.
Topics: HMGA1a Protein; Humans; Microtubules; Neoplasm Recurrence, Local; Paclitaxel; Stathmin; Triple Negative Breast Neoplasms | 2022 |
Targeting epidermal growth factor receptor in paclitaxel-resistant human breast and lung cancer cells with upregulated glucose-6-phosphate dehydrogenase.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Glucosephosphate Dehydrogenase; Humans; Lung Neoplasms; Paclitaxel; Triple Negative Breast Neoplasms | 2022 |
Insight into drug sensitizing effect of diallyl disulfide and diallyl trisulfide from Allium sativum L. on paclitaxel-resistant triple-negative breast cancer cells.
Topics: Allyl Compounds; Antioxidants; Apoptosis; Cell Line, Tumor; Disulfides; Garlic; Humans; Paclitaxel; Reactive Oxygen Species; Sulfides; Triple Negative Breast Neoplasms | 2022 |
Antagonistic Pharmacological Interaction between Sirtuin Inhibitor Cambinol and Paclitaxel in Triple-Negative Breast Cancer Cell Lines: An Isobolographic Analysis.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Humans; Naphthalenes; Paclitaxel; Pyrimidinones; Sirtuins; Triple Negative Breast Neoplasms | 2022 |
Neoadjuvant afatinib with paclitaxel for triple-negative breast cancer and the molecular characteristics in responders and non-responders.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Phosphatidylinositol 3-Kinases; Treatment Outcome; Triple Negative Breast Neoplasms | 2022 |
Inhibition of autophagy by chloroquine prevents resistance to PI3K/AKT inhibitors and potentiates their antitumor effect in combination with paclitaxel in triple negative breast cancer models.
Topics: Animals; Autophagy; Cell Line, Tumor; Cell Proliferation; Chloroquine; Drug Resistance, Neoplasm; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Paclitaxel; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Triple Negative Breast Neoplasms | 2022 |
Effective suppression of triple negative breast cancer by paclitaxel nanoparticles conjugated with transmembrane TNF-α monoclonal antibody.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Cell Line, Tumor; Humans; Mammals; Mice; Nanoparticles; Paclitaxel; Phosphatidylinositol 3-Kinases; Triple Negative Breast Neoplasms; Tumor Necrosis Factor-alpha | 2022 |
In Vivo Evaluation of (-)-Zampanolide Demonstrates Potent and Persistent Antitumor Efficacy When Targeted to the Tumor Site.
Topics: Antineoplastic Agents; Cell Line, Tumor; Humans; Macrolides; Microtubules; Paclitaxel; Triple Negative Breast Neoplasms | 2022 |
Unfolding the Potency of Adenosine in Targeting Triple Negative Breast Cancer via Paclitaxel-Incorporated pH-Responsive Stealth Liposomes.
Topics: Adenosine; Humans; Hydrogen-Ion Concentration; Liposomes; Paclitaxel; Triple Negative Breast Neoplasms | 2022 |
Additive pharmacological interaction between sirtuin inhibitor cambinol and paclitaxel in MCF7 luminal and MDA-MB-231 triple-negative breast cancer cells.
Topics: Apoptosis; Breast Neoplasms; Bromodeoxyuridine; Cell Line, Tumor; Cell Proliferation; Female; Histone Deacetylase Inhibitors; Humans; Paclitaxel; Sirtuins; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2022 |
MRI-Based Digital Models Forecast Patient-Specific Treatment Responses to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Humans; Magnetic Resonance Imaging; Neoadjuvant Therapy; Paclitaxel; Treatment Outcome; Triple Negative Breast Neoplasms | 2022 |
Dimethyl Fumarate Induces Apoptosis via Inhibition of NF-κB and Enhances the Effect of Paclitaxel and Adriamycin in Human TNBC Cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Dimethyl Fumarate; Doxorubicin; Humans; NF-kappa B; Paclitaxel; Signal Transduction; Triple Negative Breast Neoplasms | 2022 |
Triple negative breast cancer: approved treatment options and their mechanisms of action.
Topics: Docetaxel; Doxorubicin; Epirubicin; Humans; Paclitaxel; Triple Negative Breast Neoplasms; United States | 2023 |
Rottlerin promotes anti-metastatic events by ameliorating pharmacological parameters of paclitaxel: An in-vivo investigation in the orthotopic mouse model of breast cancer.
Topics: Acetophenones; Animals; Apoptosis Regulatory Proteins; Benzopyrans; Cadherins; Cell Line, Tumor; Disease Models, Animal; Epithelial-Mesenchymal Transition; Humans; Mice; Paclitaxel; Poly(ADP-ribose) Polymerase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Triple Negative Breast Neoplasms; Vimentin | 2022 |
Omics Analysis of Chemoresistant Triple Negative Breast Cancer Cells Reveals Novel Metabolic Vulnerabilities.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Paclitaxel; Triple Negative Breast Neoplasms | 2022 |
Cytotoxicity of
Topics: Cell Survival; Humans; Ligands; Paclitaxel; Triple Negative Breast Neoplasms | 2022 |
Homoharringtonine demonstrates a cytotoxic effect against triple-negative breast cancer cell lines and acts synergistically with paclitaxel.
Topics: Adenosine Triphosphatases; Antineoplastic Agents; Cell Line, Tumor; Cladribine; Doxorubicin; Excipients; Homoharringtonine; Humans; Nucleosides; Paclitaxel; Triple Negative Breast Neoplasms | 2022 |
Cell adhesion molecule CD44v10 promotes stem-like properties in triple-negative breast cancer cells via glucose transporter GLUT1-mediated glycolysis.
Topics: Cell Adhesion Molecules; Cell Line, Tumor; Cell Proliferation; Glucose Transport Proteins, Facilitative; Glucose Transporter Type 1; Glycolysis; Humans; Paclitaxel; Phosphatidylinositol 3-Kinases; Triple Negative Breast Neoplasms | 2022 |
RAD6 inhibition enhances paclitaxel sensitivity of triple negative breast cancer cells by aggravating mitotic spindle damage.
Topics: Cell Line, Tumor; Centrosome; Cyclin B1; DNA; Humans; Microtubule-Associated Proteins; Paclitaxel; Triple Negative Breast Neoplasms; Tubulin; Ubiquitin-Conjugating Enzymes | 2022 |
Atezolizumab plus nab-paclitaxel for unresectable, locally advanced or metastatic breast cancer: real-world results from a single academic center in Austria.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Austria; B7-H1 Antigen; Humans; Paclitaxel; Retrospective Studies; Triple Negative Breast Neoplasms | 2022 |
Fn14-Directed DART Nanoparticles Selectively Target Neoplastic Cells in Preclinical Models of Triple-Negative Breast Cancer Brain Metastasis.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Humans; Mice; Nanoparticles; Paclitaxel; Triple Negative Breast Neoplasms; Tumor Microenvironment | 2023 |
Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Humans; Lymphocytes, Tumor-Infiltrating; Neoadjuvant Therapy; Paclitaxel; Triple Negative Breast Neoplasms | 2023 |
Chondroitin Sulfate Targeting Nanodrug Achieves Near-Infrared Fluorescence-Guided Chemotherapy Against Triple-Negative Breast Primary and Lung Metastatic Cancer.
Topics: Animals; Chondroitin Sulfates; Disease Models, Animal; Humans; Lung; Lung Neoplasms; Mice; Nanospheres; Paclitaxel; Triple Negative Breast Neoplasms | 2022 |
Protein Phosphatase 1 Subunit PPP1R14B Stabilizes STMN1 to Promote Progression and Paclitaxel Resistance in Triple-Negative Breast Cancer.
Topics: Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Paclitaxel; Protein Phosphatase 1; Stathmin; Triple Negative Breast Neoplasms; Ubiquitin Thiolesterase | 2023 |
Morphine counteracts the effects of paclitaxel in triple-negative breast cancer cells.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; Morphine; Neoplasm Recurrence, Local; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Triple Negative Breast Neoplasms | 2022 |
Mathematical Model of Triple-Negative Breast Cancer in Response to Combination Chemotherapies.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Therapy, Combination; Humans; Mathematical Concepts; Mice; Models, Biological; Necrosis; Paclitaxel; Triple Negative Breast Neoplasms | 2022 |
Paclitaxel-loaded tumor cell-derived microparticles improve radiotherapy efficacy in triple-negative breast cancer by enhancing cell killing and stimulating immunity.
Topics: Apoptosis; Cell Line, Tumor; Cell-Derived Microparticles; Humans; Paclitaxel; Triple Negative Breast Neoplasms; Tumor Microenvironment | 2023 |
Efficacy and Safety of First-line Carboplatin-paclitaxel and Carboplatin-gemcitabine in Patients With Advanced Triple-negative Breast Cancer: A Monocentric, Retrospective Comparison.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Retrospective Studies; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms | 2023 |
10-Gingerol Enhances the Effect of Taxol in Triple-Negative Breast Cancer via Targeting ADRB2 Signaling.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Humans; Mice; Molecular Docking Simulation; Paclitaxel; Receptors, Adrenergic, beta-2; Triple Negative Breast Neoplasms | 2023 |
Growth differentiation factor 15 is required for triple-negative breast cancer cell growth and chemoresistance.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Growth Differentiation Factor 15; Humans; Mammals; Mice; Paclitaxel; Proto-Oncogene Proteins c-akt; TOR Serine-Threonine Kinases; Triple Negative Breast Neoplasms | 2023 |
LncRNA PRKCQ-AS1 regulates paclitaxel resistance in triple-negative breast cancer cells through miR-361-5p/PIK3C3 mediated autophagy.
Topics: Autophagy; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Paclitaxel; Protein Kinase C-theta; RNA, Long Noncoding; RNA, Messenger; Triple Negative Breast Neoplasms | 2023 |
Excellent response of refractory triple-negative breast cancer to sintilimab plus chemotherapy: a case report.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carboplatin; Female; Humans; Middle Aged; Paclitaxel; Triple Negative Breast Neoplasms | 2023 |
Nanomicellar Formulations Loaded with Histamine and Paclitaxel as a New Strategy to Improve Chemotherapy for Breast Cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Drug Carriers; Histamine; Humans; Mice; Mice, Inbred BALB C; Micelles; Paclitaxel; Polyethylene Glycols; Polymers; Triple Negative Breast Neoplasms | 2023 |
Transcytosable Peptide-Paclitaxel Prodrug Nanoparticle for Targeted Treatment of Triple-Negative Breast Cancer.
Topics: Cell Line, Tumor; Humans; Nanoparticle Drug Delivery System; Nanoparticles; Oligopeptides; Paclitaxel; Prodrugs; Triple Negative Breast Neoplasms | 2023 |
β, β-Dimethylacrylshikonin potentiates paclitaxel activity, suppresses immune evasion and triple negative breast cancer progression via STAT3Y705 phosphorylation inhibition based on network pharmacology and transcriptomics analysis.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Humans; Immune Evasion; Mice; Network Pharmacology; Paclitaxel; Phosphorylation; Transcriptome; Triple Negative Breast Neoplasms | 2023 |
Conditioned Medium of Mesenchymal Stromal Cells Loaded with Paclitaxel Is Effective in Preclinical Models of Triple-Negative Breast Cancer (TNBC).
Topics: Cell Line, Tumor; Culture Media, Conditioned; Humans; Mesenchymal Stem Cells; Paclitaxel; Triple Negative Breast Neoplasms | 2023 |
Estrogen Receptor β4 Regulates Chemotherapy Resistance and Induces Cancer Stem Cells in Triple Negative Breast Cancer.
Topics: Cell Line, Tumor; Estrogen Receptor beta; Humans; Ligands; Neoplastic Stem Cells; Paclitaxel; Receptors, Estrogen; Triple Negative Breast Neoplasms | 2023 |
Observation Effectiveness of Dose-Dense Neoadjuvant Anthracycline Sequential Weekly Paclitaxel for Triple-Negative Breast Cancer Patients.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Triple Negative Breast Neoplasms | 2023 |
Targeting lncRNA DDIT4-AS1 Sensitizes Triple Negative Breast Cancer to Chemotherapy via Suppressing of Autophagy.
Topics: Animals; Autophagy; Cell Line, Tumor; Humans; Mice; Paclitaxel; RNA, Long Noncoding; RNA, Messenger; RNA, Small Interfering; Transcription Factors; Triple Negative Breast Neoplasms | 2023 |
A Novel Paclitaxel Derivative for Triple-Negative Breast Cancer Chemotherapy.
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Humans; Paclitaxel; Triple Negative Breast Neoplasms; Water | 2023 |
Zhuidu Formula suppresses the migratory and invasive properties of triple-negative breast cancer cells via dual signaling pathways of RhoA/ROCK and CDC42/MRCK.
Topics: Actins; Animals; Cell Adhesion; Cell Growth Processes; Cell Movement; Cytoskeleton; Disease Models, Animal; Drug Synergism; Ethnopharmacology; Female; Humans; Matrix Metalloproteinases; MDA-MB-231 Cells; Medicine, Chinese Traditional; Mice; Myotonin-Protein Kinase; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; rho-Associated Kinases; Signal Transduction; Triple Negative Breast Neoplasms | 2023 |
A Dual-Targeting Liposome Enhances Triple-Negative Breast Cancer Chemoimmunotherapy through Inducing Immunogenic Cell Death and Inhibiting STAT3 Activation.
Topics: Animals; Cell Line, Tumor; Humans; Immunogenic Cell Death; Immunotherapy; Liposomes; Mice; Paclitaxel; STAT3 Transcription Factor; Triple Negative Breast Neoplasms; Tumor Microenvironment | 2023 |
Dynamic Glycoprotein Hyposialylation Promotes Chemotherapy Evasion and Metastatic Seeding of Quiescent Circulating Tumor Cell Clusters in Breast Cancer.
Topics: Biomarkers, Tumor; Breast Neoplasms; Female; Glycoproteins; Humans; Neoplasm Metastasis; Neoplastic Cells, Circulating; Paclitaxel; Triple Negative Breast Neoplasms | 2023 |
A Paclitaxel Prodrug with Copper Depletion for Combined Therapy toward Triple-Negative Breast Cancer.
Topics: Cell Line, Tumor; Copper; Humans; Nanoparticles; Paclitaxel; Prodrugs; Triple Negative Breast Neoplasms | 2023 |
Synergistic Anti-Tumor Effect of Toosendanin and Paclitaxel on Triple-Negative Breast Cancer via Regulating ADORA2A-EMT Related Signaling.
Topics: Animals; Cell Line, Tumor; Drugs, Chinese Herbal; Epithelial-Mesenchymal Transition; Humans; Mice; Paclitaxel; Triple Negative Breast Neoplasms; Triterpenes | 2023 |
Glabridin plays dual action to intensify anti-metastatic potential of paclitaxel via impeding CYP2C8 in liver and CYP2J2/EETs in tumor of an orthotopic mouse model of breast cancer.
Topics: Animals; Cell Line, Tumor; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2J2; Eicosanoids; Humans; Liver; Mice; Paclitaxel; Triple Negative Breast Neoplasms | 2023 |
Costs per event averted in the neoadjuvant and adjuvant settings of early triple-negative breast cancer.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Doxorubicin; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Triple Negative Breast Neoplasms | 2023 |
Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Caveolin 1; Female; Gene Expression; Humans; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Triple Negative Breast Neoplasms | 2023 |
Metastasis Unleashed: Hyposialylation Empowers Chemo-Evasive Circulating Tumor Cell Clusters in Breast Cancer.
Topics: Cell Line, Tumor; Humans; Neoplasm Metastasis; Neoplastic Cells, Circulating; Paclitaxel; Triple Negative Breast Neoplasms | 2023 |
[Ginsenoside Rg_3 based liposomes target delivery of dihydroartemisinin and paclitaxel for treatment of triple-negative breast cancer].
Topics: Cardiotoxicity; Cell Line, Tumor; Ginsenosides; Humans; Liposomes; Paclitaxel; Triple Negative Breast Neoplasms | 2023 |
Targeted drug-loaded PLGA-PCL microspheres for specific and localized treatment of triple negative breast cancer.
Topics: Animals; Cell Line, Tumor; Humans; Mice; Mice, Nude; Microspheres; Nanoparticles; Paclitaxel; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers; Prodigiosin; Triple Negative Breast Neoplasms | 2023 |
Concomitant effects of paclitaxel and celecoxib on genes involved in apoptosis of triple-negative metastatic breast cancer cells.
Topics: Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; Caspase 3; Celecoxib; Cell Line, Tumor; Female; Humans; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Triple Negative Breast Neoplasms | 2023 |
Atezolizumab and paclitaxel as first line therapy in advanced triple-negative breast cancer patients included in the French early access program.
Topics: B7-H1 Antigen; Humans; Paclitaxel; Retrospective Studies; Triple Negative Breast Neoplasms | 2023 |
Adding fasting-mimicking diet to first-line carboplatin-based chemotherapy is associated with better overall survival in advanced triple-negative breast cancer patients: A subanalysis of the NCT03340935 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials as Topic; Deoxycytidine; Fasting; Female; Humans; Paclitaxel; Prognosis; Triple Negative Breast Neoplasms | 2024 |
Efficacy and safety of apatinib combined with dose-dense paclitaxel and carboplatin in neoadjuvant therapy for locally advanced triple-negative breast cancer: A prospective cohort study with propensity-matched analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Humans; Neoadjuvant Therapy; Paclitaxel; Prospective Studies; Treatment Outcome; Triple Negative Breast Neoplasms | 2024 |
Combination Therapies to Improve the Efficacy of Immunotherapy in Triple-negative Breast Cancer.
Topics: Animals; B7-H1 Antigen; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Mice; Nuclear Proteins; Paclitaxel; Transcription Factors; Triple Negative Breast Neoplasms | 2023 |
Combination Organelle Mitochondrial Endoplasmic Reticulum Therapy (COMET) for Multidrug Resistant Breast Cancer.
Topics: Animals; Apoptosis; Cattle; Cell Line, Tumor; Drug Combinations; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Endoplasmic Reticulum; Humans; Mitochondria; Paclitaxel; Peptides; Triple Negative Breast Neoplasms; Tunicamycin | 2023 |
The Beta2-adrenergic agonist salbutamol synergizes with paclitaxel on cell proliferation and tumor growth in triple negative breast cancer models.
Topics: Adrenergic Agonists; Albuterol; Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; Mice; Mice, Nude; Paclitaxel; Propranolol; Triple Negative Breast Neoplasms | 2023 |
TRAF6 promotes chemoresistance to paclitaxel of triple negative breast cancer via regulating PKM2-mediated glycolysis.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glycolysis; Humans; Paclitaxel; TNF Receptor-Associated Factor 6; Triple Negative Breast Neoplasms | 2023 |
Investigating the Heterogeneity of Immune Cells in Triple-Negative Breast Cancer at the Single-Cell Level before and after Paclitaxel Chemotherapy.
Topics: CD8-Positive T-Lymphocytes; Humans; Immunity, Innate; Lymphocytes; Paclitaxel; Triple Negative Breast Neoplasms | 2023 |
Identification of novel inhibitors from Urtica spp against TNBC targeting JAK2 receptor for breast cancer therapy.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Female; HEK293 Cells; Humans; Janus Kinase 2; Molecular Docking Simulation; Paclitaxel; Triple Negative Breast Neoplasms | 2023 |
Phloridzin Docosahexaenoate Inhibits Spheroid Formation by Breast Cancer Stem Cells and Exhibits Cytotoxic Effects against Paclitaxel-Resistant Triple Negative Breast Cancer Cells.
Topics: Antineoplastic Agents; ATP-Binding Cassette Transporters; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Docosahexaenoic Acids; Female; Humans; Neoplastic Stem Cells; Paclitaxel; Phlorhizin; Triple Negative Breast Neoplasms | 2023 |
Mitochondrial adaptation decreases drug sensitivity of persistent triple negative breast cancer cells surviving combinatory and sequential chemotherapy.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Humans; Mice; Mitochondria; Paclitaxel; Pyruvates; Triple Negative Breast Neoplasms | 2023 |
Comparative effectiveness of first-line nab-paclitaxel versus paclitaxel monotherapy in triple-negative breast cancer.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Middle Aged; Paclitaxel; Survival Analysis; Triple Negative Breast Neoplasms | 2019 |
Low Dose of Paclitaxel Combined with XAV939 Attenuates Metastasis, Angiogenesis and Growth in Breast Cancer by Suppressing Wnt Signaling.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinogenesis; Cell Line, Tumor; Cell Movement; Epithelial-Mesenchymal Transition; Female; Heterocyclic Compounds, 3-Ring; Humans; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Triple Negative Breast Neoplasms; Wnt Signaling Pathway | 2019 |
LIN9 confers paclitaxel resistance in triple negative breast cancer cells by upregulating CCSAP.
Topics: Antineoplastic Agents; Apoptosis; Azepines; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Mitosis; Nuclear Proteins; Paclitaxel; Protein Kinase Inhibitors; Triazoles; Triple Negative Breast Neoplasms; Tumor Suppressor Proteins; Up-Regulation | 2020 |
Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Synergism; Female; Humans; Paclitaxel; Piperazines; Pyridines; Triple Negative Breast Neoplasms; Tumor Cells, Cultured | 2019 |
Gambogic acid increases the sensitivity to paclitaxel in drug‑resistant triple‑negative breast cancer via the SHH signaling pathway.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Female; Hedgehog Proteins; Humans; Paclitaxel; Signal Transduction; Triple Negative Breast Neoplasms; Xanthones | 2019 |
Dual-targeting liposomes with active recognition of GLUT
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Female; Fructose; Glucose Transporter Type 5; Humans; Integrin alphaVbeta3; Liposomes; Mice, Inbred BALB C; Molecular Targeted Therapy; Oligopeptides; Paclitaxel; Triple Negative Breast Neoplasms | 2019 |
High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers.
Topics: Animals; Biological Availability; Cell Cycle; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Chromosome Segregation; Chromosomes, Human; Drug Synergism; Humans; Mice; Paclitaxel; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; PTEN Phosphohydrolase; Pyrimidines; Spindle Apparatus; Triazoles; Triple Negative Breast Neoplasms | 2019 |
The microfluidic capture of single breast cancer cells for multi-drug resistance assays.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Equipment Design; Female; Humans; Lab-On-A-Chip Devices; Microfluidic Analytical Techniques; Optical Imaging; Paclitaxel; Single-Cell Analysis; Triple Negative Breast Neoplasms | 2019 |
Complete Response of Chemo-Refractory Metastatic Metaplastic Breast Cancer to Paclitaxel-Immunotherapy Combination.
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Female; Humans; Immunotherapy; Middle Aged; Paclitaxel; Therapies, Investigational; Triple Negative Breast Neoplasms | 2019 |
Docosahexaenoic acid suppresses migration of triple-negative breast cancer cell through targeting metastasis-related genes and microRNA under normoxic and hypoxic conditions.
Topics: Apoptosis; Biomarkers, Tumor; Cell Movement; Cell Proliferation; Docosahexaenoic Acids; Female; Gene Expression Regulation, Neoplastic; Humans; Hypoxia; MicroRNAs; Neoplasm Metastasis; Paclitaxel; Triple Negative Breast Neoplasms; Tumor Cells, Cultured; Wound Healing | 2020 |
Macrophage-Derived Extracellular Vesicles as Drug Delivery Systems for Triple Negative Breast Cancer (TNBC) Therapy.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Drug Compounding; Drug Delivery Systems; Extracellular Vesicles; Female; Humans; Liposomes; Lung Neoplasms; Macrophages; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Paclitaxel; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2020 |
The GEF-H1/PKD3 signaling pathway promotes the maintenance of triple-negative breast cancer stem cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Synergism; Female; Gene Knockdown Techniques; Humans; Mice; Neoplastic Stem Cells; Paclitaxel; Protein Kinase C; Pyrimidines; Rho Guanine Nucleotide Exchange Factors; Signal Transduction; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2020 |
Building momentum for subsets of patients with advanced triple-negative breast cancer.
Topics: Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Double-Blind Method; Humans; Paclitaxel; Triple Negative Breast Neoplasms | 2020 |
AKT inhibition improves OS in TNBC.
Topics: Humans; Paclitaxel; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Triple Negative Breast Neoplasms | 2020 |
Chemotherapeutic Stress Influences Epithelial-Mesenchymal Transition and Stemness in Cancer Stem Cells of Triple-Negative Breast Cancer.
Topics: Cell Line, Tumor; Dose-Response Relationship, Drug; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Humans; Neoplastic Stem Cells; Paclitaxel; Primary Cell Culture; Survival Analysis; Triple Negative Breast Neoplasms | 2020 |
First-Line Treatment With Atezolizumab Plus Nab-Paclitaxel for Advanced Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis.
Topics: Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; China; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Female; Humans; Markov Chains; Paclitaxel; Quality-Adjusted Life Years; Triple Negative Breast Neoplasms; United States | 2020 |
LIN9 and NEK2 Are Core Regulators of Mitotic Fidelity That Can Be Therapeutically Targeted to Overcome Taxane Resistance.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cellular Senescence; Centrosome; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Heterografts; Humans; Mitosis; Neoplasm Proteins; NIMA-Related Kinases; Nuclear Proteins; Paclitaxel; Survival Rate; Taxoids; Triple Negative Breast Neoplasms; Tumor Stem Cell Assay; Tumor Suppressor Proteins; Up-Regulation | 2020 |
Ultra-thermostable RNA nanoparticles for solubilizing and high-yield loading of paclitaxel for breast cancer therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Aptamers, Nucleotide; Cell Line, Tumor; Cryoelectron Microscopy; Drug Delivery Systems; ErbB Receptors; Female; Humans; Hydrophobic and Hydrophilic Interactions; Imaging, Three-Dimensional; Mice; Mice, Nude; Models, Molecular; Molecular Conformation; Nanoparticles; Paclitaxel; RNA; RNA Stability; Single Molecule Imaging; Solubility; Thermodynamics; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2020 |
Targeting claudin-4 enhances chemosensitivity in breast cancer.
Topics: Animals; Antibodies; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cell Line, Tumor; Cell Proliferation; Claudin-1; Claudin-4; Drug Synergism; Female; Humans; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Paclitaxel; Tamoxifen; Triple Negative Breast Neoplasms; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2020 |
Heparin-based hydrogel scaffolding alters the transcriptomic profile and increases the chemoresistance of MDA-MB-231 triple-negative breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Biomimetic Materials; Cell Proliferation; Drug Screening Assays, Antitumor; Heparin; Humans; Hydrogels; Paclitaxel; Transcriptome; Triple Negative Breast Neoplasms; Tumor Cells, Cultured; Tumor Microenvironment | 2020 |
Liuwei Dihuang pill suppresses metastasis by regulating the wnt pathway and disrupting -catenin/T cell factor interactions in a murine model of triple-negative breast cancer.
Topics: Animals; beta Catenin; Blotting, Western; Disease Models, Animal; Drugs, Chinese Herbal; Female; Fluorescent Antibody Technique; Immunoprecipitation; Mice; Paclitaxel; TCF Transcription Factors; Triple Negative Breast Neoplasms; Wnt Signaling Pathway | 2019 |
Eribulin mesylate-induced c-Fos upregulation enhances cell survival in breast cancer cell lines.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzophenones; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colchicine; Female; Furans; Gene Expression Regulation, Neoplastic; Humans; Isoxazoles; Ketones; Mice, Inbred BALB C; Mice, Nude; Microtubules; Paclitaxel; Proto-Oncogene Proteins c-fos; RNA, Messenger; Triple Negative Breast Neoplasms; Up-Regulation | 2020 |
Landscape analysis of adjacent gene rearrangements reveals BCL2L14-ETV6 gene fusions in more aggressive triple-negative breast cancer.
Topics: Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ETS Translocation Variant 6 Protein; Female; Gene Expression Regulation, Neoplastic; Gene Fusion; Gene Rearrangement; Genomics; Humans; Mutation; Neoplasms; Oncogene Proteins, Fusion; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-ets; Repressor Proteins; Triple Negative Breast Neoplasms; Whole Genome Sequencing | 2020 |
Knockdown of A-kinase anchor protein 4 inhibits proliferation of triple-negative breast cancer cells
Topics: A Kinase Anchor Proteins; Animals; Apoptosis; Biomarkers; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Female; Gene Knockdown Techniques; Gene Silencing; Humans; Immunophenotyping; Mice; Oxidative Stress; Paclitaxel; Reactive Oxygen Species; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2020 |
Silibinin induces metabolic crisis in triple-negative breast cancer cells by modulating EGFR-MYC-TXNIP axis: potential therapeutic implications.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carrier Proteins; Cell Line, Tumor; Cell Proliferation; Databases, Genetic; Datasets as Topic; Deoxyglucose; Drug Synergism; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Glycolysis; Humans; Metabolome; Paclitaxel; Proto-Oncogene Proteins c-myc; Signal Transduction; Silybin; Survival Analysis; Triple Negative Breast Neoplasms | 2021 |
Value of CXCL8-CXCR1/2 axis in neoadjuvant chemotherapy for triple-negative breast cancer patients: a retrospective pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Female; Follow-Up Studies; Humans; Interleukin-8; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pilot Projects; Prognosis; Receptors, Interleukin-8A; Receptors, Interleukin-8B; Retrospective Studies; Survival Rate; Triple Negative Breast Neoplasms | 2020 |
Eribulin Regresses a Cisplatinum-resistant Rare-type Triple-negative Matrix-producing Breast Carcinoma Patient-derived Orthotopic Xenograft Mouse Model.
Topics: Animals; Biomarkers, Tumor; Cisplatin; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Furans; Humans; Ketones; Mice; Paclitaxel; Treatment Outcome; Triple Negative Breast Neoplasms; Tumor Burden; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer.
Topics: Animals; Azepines; Cell Cycle Checkpoints; Cell Proliferation; Clone Cells; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; DNA, Neoplasm; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Mice; Models, Biological; Mutation; Paclitaxel; Piperazines; Ploidies; Proteins; Pyridines; Retinoblastoma Protein; Treatment Outcome; Triazoles; Triple Negative Breast Neoplasms; Up-Regulation | 2020 |
Calcitriol-Loaded Dual-pH-Sensitive Micelle Counteracts Pro-Metastasis Effect of Paclitaxel in Triple-Negative Breast Cancer Therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Calcitriol; Cell Line, Tumor; Drug Carriers; Humans; Hydrogen-Ion Concentration; Mice; Micelles; Paclitaxel; Triple Negative Breast Neoplasms | 2020 |
Paclitaxel/sunitinib-loaded micelles promote an antitumor response in vitro through synergistic immunogenic cell death for triple-negative breast cancer.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Cell Survival; Drug Stability; Drug Synergism; Female; Humans; Immunogenic Cell Death; Maleates; Mice; Micelles; Paclitaxel; Particle Size; Polystyrenes; Sunitinib; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2020 |
Indocyanine Green-Parthenolide Thermosensitive Liposome Combination Treatment for Triple-Negative Breast Cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Drug Delivery Systems; Endocytosis; Female; Humans; Hydrodynamics; Indocyanine Green; Liposomes; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Photosensitizing Agents; Reactive Oxygen Species; Sesquiterpenes; Temperature; Tissue Distribution; Treatment Outcome; Triple Negative Breast Neoplasms; Tumor Burden | 2020 |
EGFR Targeted Paclitaxel and Piperine Co-loaded Liposomes for the Treatment of Triple Negative Breast Cancer.
Topics: Alkaloids; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Benzodioxoles; Cell Line, Tumor; Drug Compounding; Drug Stability; Drug Synergism; ErbB Receptors; Female; Freeze Drying; Humans; Liposomes; Paclitaxel; Piperidines; Polyunsaturated Alkamides; Receptor, ErbB-2; Triple Negative Breast Neoplasms | 2020 |
Cost-effectiveness analysis of atezolizumab plus nab-paclitaxel for untreated metastatic triple-negative breast cancer.
Topics: Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Female; Humans; Neoplasm Metastasis; Paclitaxel; Quality-Adjusted Life Years; Triple Negative Breast Neoplasms | 2020 |
Epigenetic Switch-Induced Viral Mimicry Evasion in Chemotherapy-Resistant Breast Cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Chromatin Immunoprecipitation Sequencing; Disease Progression; DNA Methylation; DNA Transposable Elements; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; Epigenesis, Genetic; Female; Humans; Mice; Molecular Mimicry; Paclitaxel; RNA, Double-Stranded; Triple Negative Breast Neoplasms; Tumor Escape; Xenograft Model Antitumor Assays | 2020 |
A PD-L1 Aptamer Selected by Loss-Gain Cell-SELEX Conjugated with Paclitaxel for Treating Triple-Negative Breast Cancer.
Topics: Antibodies; Aptamers, Peptide; B7-H1 Antigen; Cell Line, Tumor; Cell Proliferation; Drug Delivery Systems; Female; Humans; Paclitaxel; Programmed Cell Death 1 Receptor; SELEX Aptamer Technique; Triple Negative Breast Neoplasms | 2020 |
Cost-effectiveness analysis of atezolizumab in advanced triple-negative breast cancer.
Topics: Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Cost-Benefit Analysis; Female; Humans; Paclitaxel; Quality-Adjusted Life Years; Singapore; Survival Analysis; Triple Negative Breast Neoplasms | 2020 |
Call for assessing treatment-induced gonadotoxicity of platinum-based chemotherapy in early breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Ovary; Paclitaxel; Primary Ovarian Insufficiency; Randomized Controlled Trials as Topic; Treatment Outcome; Triple Negative Breast Neoplasms | 2020 |
PRKCQ inhibition enhances chemosensitivity of triple-negative breast cancer by regulating Bim.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Bcl-2-Like Protein 11; Biomarkers, Tumor; Cell Line, Tumor; Doxorubicin; Female; Humans; Neoplasm Invasiveness; Paclitaxel; Protein Kinase C-theta; Triple Negative Breast Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
CELF6 modulates triple-negative breast cancer progression by regulating the stability of FBP1 mRNA.
Topics: 3' Untranslated Regions; Antineoplastic Agents, Phytogenic; CELF Proteins; Cell Line, Tumor; Cell Movement; Disease Progression; Drug Resistance, Neoplasm; Female; Fructose-Bisphosphatase; Gene Knockdown Techniques; Genes, Reporter; Humans; Neoplasm Invasiveness; Neoplasm Proteins; Paclitaxel; RNA Stability; RNA, Messenger; RNA, Neoplasm; RNA, Small Interfering; Triple Negative Breast Neoplasms; Up-Regulation | 2020 |
New Insights in Gene Expression Alteration as Effect of Paclitaxel Drug Resistance in Triple Negative Breast Cancer Cells.
Topics: Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Cell Death; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Drug Resistance, Neoplasm; Early Growth Response Protein 1; Female; Gene Expression Regulation, Neoplastic; Gene Ontology; Genomics; Humans; Interleukin-6; Interleukin-8; Intracellular Signaling Peptides and Proteins; Oligonucleotide Array Sequence Analysis; Paclitaxel; Protein Serine-Threonine Kinases; Triple Negative Breast Neoplasms; Tumor Suppressor Protein p53; Vascular Endothelial Growth Factor A | 2020 |
Long non-coding RNA LINC-PINT attenuates paclitaxel resistance in triple-negative breast cancer cells via targeting the RNA-binding protein NONO.
Topics: Cell Line, Tumor; DNA-Binding Proteins; Female; Humans; Neoplasm Proteins; Paclitaxel; RNA-Binding Proteins; RNA, Long Noncoding; RNA, Neoplasm; Triple Negative Breast Neoplasms | 2020 |
Economic Evaluation of Cisplatin Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine for the Treatment of First-Line Advanced Metastatic Triple-Negative Breast Cancer in China: Using Markov Model and Partitioned Survival Model.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; China; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Female; Gemcitabine; Humans; Markov Chains; Middle Aged; Neoplasm Metastasis; Paclitaxel; Triple Negative Breast Neoplasms | 2020 |
Neuropilin1, a novel independent prognostic factor and therapeutic target in triple-negative breast cancer.
Topics: Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Neuropilin-1; Paclitaxel; Prognosis; Triple Negative Breast Neoplasms | 2020 |
Atezolizumab Plus Nab-paclitaxel in PD-L1-Positive TNBC-Letter.
Topics: Albumins; Antibodies, Monoclonal, Humanized; B7-H1 Antigen; Humans; Paclitaxel; Triple Negative Breast Neoplasms | 2020 |
TNFSF13 upregulation confers chemotherapeutic resistance via triggering autophagy initiation in triple-negative breast cancer.
Topics: Apoptosis; Autophagy; Biomarkers, Tumor; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Paclitaxel; Triple Negative Breast Neoplasms; Tumor Necrosis Factor Ligand Superfamily Member 13; Up-Regulation | 2020 |
Pre-clinical studies of EC2629, a highly potent folate- receptor-targeted DNA crosslinking agent.
Topics: Alkylating Agents; Animals; Antineoplastic Agents; Cattle; Cisplatin; Cross-Linking Reagents; DNA; Dogs; Drug Delivery Systems; Drug Design; Drug Evaluation, Preclinical; Endometrial Neoplasms; Female; Folate Receptors, GPI-Anchored; Folic Acid; Humans; Inhibitory Concentration 50; KB Cells; Ligands; Mice; Mice, Inbred C57BL; Mice, Nude; Ovarian Neoplasms; Paclitaxel; Rats; Triple Negative Breast Neoplasms; Vinca Alkaloids; Xenograft Model Antitumor Assays | 2020 |
1-Chromonyl-5-Imidazolylpentadienone Demonstrates Anti-Cancer Action against TNBC and Exhibits Synergism with Paclitaxel.
Topics: Antineoplastic Agents; Breast; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Chromones; Down-Regulation; Drug Synergism; Epithelial Cells; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Humans; Interleukin-6; Mitochondria; Paclitaxel; Reactive Oxygen Species; Triple Negative Breast Neoplasms | 2020 |
Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; CD8-Positive T-Lymphocytes; Female; Gene Expression Regulation, Neoplastic; Humans; Lymphocytes, Tumor-Infiltrating; Middle Aged; Neoadjuvant Therapy; Neoplasm Proteins; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Programmed Cell Death 1 Receptor; Progression-Free Survival; Treatment Outcome; Triple Negative Breast Neoplasms; Tumor Microenvironment | 2020 |
Drug-encapsulated blend of PLGA-PEG microspheres: in vitro and in vivo study of the effects of localized/targeted drug delivery on the treatment of triple-negative breast cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Calorimetry, Differential Scanning; Cell Line, Tumor; Delayed-Action Preparations; Drug Carriers; Drug Delivery Systems; Drug Liberation; Female; Gonadotropin-Releasing Hormone; Humans; Ligands; Lung Neoplasms; Mice; Mice, Nude; Microscopy, Electron, Scanning; Microspheres; Neoplasm Proteins; Paclitaxel; Polyesters; Polyethylene Glycols; Receptors, LHRH; Spectroscopy, Fourier Transform Infrared; Thermodynamics; Thermogravimetry; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2020 |
The metronomic combination of paclitaxel with cholinergic agonists inhibits triple negative breast tumor progression. Participation of M2 receptor subtype.
Topics: Administration, Metronomic; Animals; Antineoplastic Combined Chemotherapy Protocols; Arecoline; ATP Binding Cassette Transporter, Subfamily G, Member 2; Carbachol; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cholinergic Agonists; Down-Regulation; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Neoplasm Proteins; Neovascularization, Pathologic; Paclitaxel; Receptor, Muscarinic M2; RNA, Small Interfering; Triple Negative Breast Neoplasms; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2020 |
Serial single-cell profiling analysis of metastatic TNBC during Nab-paclitaxel and pembrolizumab treatment.
Topics: Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Humans; Paclitaxel; Prospective Studies; Single-Cell Analysis; Triple Negative Breast Neoplasms; Tumor Microenvironment | 2021 |
Remarkable response to combined immunochemotherapy in patients with metastatic triple-negative breast cancer.
Topics: Adult; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Female; Humans; Immunotherapy; Middle Aged; Paclitaxel; Treatment Outcome; Triple Negative Breast Neoplasms | 2020 |
Knockdown of SERPINE1 reverses resistance of triple‑negative breast cancer to paclitaxel via suppression of VEGFA.
Topics: Animals; Apoptosis; Cell Proliferation; Computational Biology; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Male; MCF-7 Cells; Mice; Oncogene Proteins; Paclitaxel; Plasminogen Activator Inhibitor 1; Triple Negative Breast Neoplasms; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2020 |
Neoadjuvant therapy improves pCR rate.
Topics: Albumins; Anthracyclines; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Double-Blind Method; Humans; Neoadjuvant Therapy; Paclitaxel; Triple Negative Breast Neoplasms | 2020 |
SYTL4 downregulates microtubule stability and confers paclitaxel resistance in triple-negative breast cancer.
Topics: Adolescent; Adult; Animals; Breast; Cell Line, Tumor; Chemotherapy, Adjuvant; Disease-Free Survival; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Intravital Microscopy; Mastectomy; Mice; Microtubules; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Organoids; Paclitaxel; Prognosis; Protein Multimerization; RNA-Seq; Triple Negative Breast Neoplasms; Tubulin; Tumor Cells, Cultured; Vesicular Transport Proteins; Young Adult | 2020 |
pH-Activatable cell penetrating peptide dimers for potent delivery of anticancer drug to triple-negative breast cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell-Penetrating Peptides; Female; Humans; Hydrogen-Ion Concentration; Mice; Mice, Nude; Paclitaxel; Pharmaceutical Preparations; Triple Negative Breast Neoplasms | 2021 |
B7-H3 augments the pro-angiogenic function of tumor-associated macrophages and acts as a novel adjuvant target for triple-negative breast cancer therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; B7 Antigens; Biomarkers, Tumor; Drug Delivery Systems; Female; HEK293 Cells; Humans; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Paclitaxel; RAW 264.7 Cells; Triple Negative Breast Neoplasms; Tumor Microenvironment; Tumor-Associated Macrophages | 2021 |
LHRH-Targeted Redox-Responsive Crosslinked Micelles Impart Selective Drug Delivery and Effective Chemotherapy in Triple-Negative Breast Cancer.
Topics: Animals; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Gonadotropin-Releasing Hormone; Humans; Micelles; Oxidation-Reduction; Paclitaxel; Polyethylene Glycols; Triple Negative Breast Neoplasms; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2021 |
Rechallenge of anti-PD-1/PD-L1 antibody showed a good response to metastatic breast cancer: a case report.
Topics: Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Drug Resistance, Neoplasm; Female; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Microsatellite Instability; Middle Aged; Paclitaxel; Retreatment; Treatment Outcome; Triple Negative Breast Neoplasms | 2021 |
A "dual-guide" bioinspired drug delivery strategy of a macrophage-based carrier against postoperative triple-negative breast cancer recurrence.
Topics: Breast Neoplasms; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Female; Humans; Liposomes; Macrophages; Nanoparticles; Paclitaxel; Triple Negative Breast Neoplasms | 2021 |
N-Linked glycosylation profiles of therapeutic induced senescent (TIS) triple negative breast cancer cells (TNBC) and their extracellular vesicle (EV) progeny.
Topics: Antineoplastic Agents; Cellular Senescence; Chromatography, High Pressure Liquid; Chromatography, Liquid; Drug Resistance, Neoplasm; Extracellular Vesicles; Female; Glycosylation; Humans; Mass Spectrometry; Paclitaxel; Polysaccharides; Triple Negative Breast Neoplasms | 2021 |
FDA Approves Pembrolizumab + Chemotherapy Combination for Locally Recurrent Unresectable or Metastatic TNBC.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Double-Blind Method; Drug Approval; Gemcitabine; Humans; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Randomized Controlled Trials as Topic; Triple Negative Breast Neoplasms; United States; United States Food and Drug Administration | 2020 |
Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Early Triple-Negative Breast Cancer-Reply.
Topics: Carboplatin; Chemotherapy, Adjuvant; Humans; Neoadjuvant Therapy; Paclitaxel; Triple Negative Breast Neoplasms | 2021 |
Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Early Triple-Negative Breast Cancer.
Topics: Carboplatin; Chemotherapy, Adjuvant; Humans; Neoadjuvant Therapy; Paclitaxel; Triple Negative Breast Neoplasms | 2021 |
A triple-drug nanotherapy to target breast cancer cells, cancer stem cells, and tumor vasculature.
Topics: Animals; Apoptosis; Bibenzyls; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Combinations; Female; Humans; Mice, Nude; Nanoparticles; Neoplastic Stem Cells; Paclitaxel; Rats; Triple Negative Breast Neoplasms; Verteporfin; Zebrafish | 2021 |
MicroRNA-205-5p targets the HOXD9-Snail1 axis to inhibit triple negative breast cancer cell proliferation and chemoresistance.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Doxorubicin; Drug Resistance, Neoplasm; Female; Gene Knockdown Techniques; Homeodomain Proteins; Humans; MicroRNAs; Neoplasm Proteins; Paclitaxel; Snail Family Transcription Factors; Triple Negative Breast Neoplasms | 2021 |
circGFRA1 affects the sensitivity of triple-negative breast cancer cells to paclitaxel via the miR-361-5p/TLR4 pathway.
Topics: Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; MicroRNAs; Neoplasm Proteins; Paclitaxel; RNA, Circular; RNA, Neoplasm; Signal Transduction; Toll-Like Receptor 4; Triple Negative Breast Neoplasms | 2021 |
Hyaluronic Acid-Targeted Stimuli-Sensitive Nanomicelles Co-Encapsulating Paclitaxel and Ritonavir to Overcome Multi-Drug Resistance in Metastatic Breast Cancer and Triple-Negative Breast Cancer Cells.
Topics: Apoptosis; Cell Proliferation; Cell Survival; Drug Delivery Systems; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Hyaluronic Acid; MCF-7 Cells; Micelles; Nanoparticles; Neoplasm Metastasis; Paclitaxel; Ritonavir; Triple Negative Breast Neoplasms | 2021 |
Simultaneously targeting cancer-associated fibroblasts and angiogenic vessel as a treatment for TNBC.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Cancer-Associated Fibroblasts; Cell Line, Tumor; Doxorubicin; Endothelial Cells; Female; Humans; Hypoxia; Integrin alphaVbeta3; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Paclitaxel; Protein-Lysine 6-Oxidase; Signal Transduction; Treatment Outcome; Triple Negative Breast Neoplasms; Tumor Burden; Xenograft Model Antitumor Assays | 2021 |
Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer.
Topics: Albumins; Algorithms; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Clinical Trials as Topic; Computer Simulation; CTLA-4 Antigen; Female; Humans; Immune Checkpoint Inhibitors; Network Pharmacology; Paclitaxel; Retrospective Studies; Time Factors; Treatment Outcome; Triple Negative Breast Neoplasms; Tumor Microenvironment | 2021 |
A paclitaxel and microRNA-124 coloaded stepped cleavable nanosystem against triple negative breast cancer.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Movement; Female; Hyaluronan Receptors; Hyaluronic Acid; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Paclitaxel; Triple Negative Breast Neoplasms; Tumor Microenvironment | 2021 |
CircWAC induces chemotherapeutic resistance in triple-negative breast cancer by targeting miR-142, upregulating WWP1 and activating the PI3K/AKT pathway.
Topics: Animals; Biomarkers, Tumor; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; MCF-7 Cells; Mice; MicroRNAs; Neoplasm Transplantation; Paclitaxel; Phosphatidylinositol 3-Kinases; Prognosis; RNA, Circular; Signal Transduction; Survival Analysis; Triple Negative Breast Neoplasms; Ubiquitin-Protein Ligases; Up-Regulation | 2021 |
Pathological response and clinical outcomes in operable triple-negative breast cancer with cisplatin added to standard neoadjuvant chemotherapy.
Topics: Adult; Anemia; Antineoplastic Agents; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Retrospective Studies; Treatment Outcome; Triple Negative Breast Neoplasms; Young Adult | 2021 |
Encapsulating Halofuginone Hydrobromide in TPGS Polymeric Micelles Enhances Efficacy Against Triple-Negative Breast Cancer Cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Compounding; Female; Humans; Membrane Potential, Mitochondrial; Mice, Inbred BALB C; Mice, Nude; Micelles; Paclitaxel; Piperidines; Polymers; Quinazolinones; Reactive Oxygen Species; Treatment Outcome; Triple Negative Breast Neoplasms; Vitamin E | 2021 |
Cost-effectiveness Analysis of Atezolizumab Plus Nab-Paclitaxel for Advanced PD-L1 Positive Triple-Negative Breast Cancer in Japan.
Topics: Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Cost-Benefit Analysis; Female; Humans; Japan; Paclitaxel; Quality-Adjusted Life Years; Triple Negative Breast Neoplasms | 2021 |
An in vitro study on the reversal of epithelial to mesenchymal transition by brusatol and its synergistic properties in triple-negative breast cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Synergism; Epithelial-Mesenchymal Transition; Female; Humans; Neoplasm Invasiveness; Paclitaxel; Quassins; Reactive Oxygen Species; Triple Negative Breast Neoplasms | 2021 |
Carboplatin-paclitaxel in triple-negative metastatic breast cancer during pregnancy with neoplastic thrombosis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cesarean Section; Female; Humans; Mastectomy; Neoplasm Recurrence, Local; Paclitaxel; Pregnancy; Thrombosis; Triple Negative Breast Neoplasms; Vena Cava, Superior | 2022 |
The cost-effectiveness of atezolizumab in first-line for metastatic triple negative breast cancer is heavily linked to PD-L1 level.
Topics: Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Cost-Benefit Analysis; Humans; Paclitaxel; Randomized Controlled Trials as Topic; Triple Negative Breast Neoplasms | 2021 |
Landscape of toll-like receptors expression in tumor microenvironment of triple negative breast cancer (TNBC): Distinct roles of TLR4 and TLR8.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Computational Biology; Databases, Factual; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Ontology; Gene Regulatory Networks; Humans; Lymphocytes, Tumor-Infiltrating; Molecular Sequence Annotation; Neoplasm Proteins; Paclitaxel; Signal Transduction; Toll-Like Receptor 4; Toll-Like Receptor 8; Triple Negative Breast Neoplasms; Tumor Microenvironment | 2021 |
Doxorubicin-paclitaxel sequential treatment: insights of DNA methylation and gene expression changes of luminal A and triple negative breast cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; DNA Methylation; DNA, Neoplasm; Doxorubicin; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Paclitaxel; Triple Negative Breast Neoplasms | 2021 |
Identified the novel resistant biomarkers for taxane-based therapy for triple-negative breast cancer.
Topics: Biomarkers, Tumor; Datasets as Topic; Disease-Free Survival; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Genetic Heterogeneity; Humans; Kaplan-Meier Estimate; Neoplasm Recurrence, Local; Paclitaxel; Protein Interaction Maps; Triple Negative Breast Neoplasms; Up-Regulation | 2021 |
The small G-protein RalA promotes progression and metastasis of triple-negative breast cancer.
Topics: Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Enzyme Inhibitors; Female; Humans; Mice; Neoplasm Metastasis; Paclitaxel; Prognosis; ral GTP-Binding Proteins; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2021 |
Atezolizumab in Metastatic Triple-Negative Breast Cancer-No Contradiction in the Eyes of a Dispassionate Observer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Humans; Paclitaxel; Triple Negative Breast Neoplasms | 2021 |
Vimentin Promotes the Aggressiveness of Triple Negative Breast Cancer Cells Surviving Chemotherapeutic Treatment.
Topics: Animals; Cell Line, Tumor; Cell Movement; Cyclophosphamide; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Therapy; Epirubicin; Epithelial-Mesenchymal Transition; Female; Humans; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Paclitaxel; Triple Negative Breast Neoplasms; Vimentin; Zebrafish | 2021 |
Comparative colloidal stability, antitumor efficacy, and immunosuppressive effect of commercial paclitaxel nanoformulations.
Topics: Albumins; Animals; Antineoplastic Agents; Cell Line, Tumor; Disease Models, Animal; Drug Carriers; Emulsions; Female; Immunosuppressive Agents; Immunotherapy; Liposomes; Mice; Mice, Inbred BALB C; Mice, Nude; Nanomedicine; Nanoparticles; Paclitaxel; Triple Negative Breast Neoplasms | 2021 |
Detachable Liposomes Combined Immunochemotherapy for Enhanced Triple-Negative Breast Cancer Treatment through Reprogramming of Tumor-Associated Macrophages.
Topics: Animals; Cell Line, Tumor; Humans; Liposomes; Mice; Paclitaxel; Triple Negative Breast Neoplasms; Tumor Microenvironment; Tumor-Associated Macrophages | 2021 |
Peptide-Targeted High-Density Lipoprotein Nanoparticles for Combinatorial Treatment against Metastatic Breast Cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Carriers; Drug Combinations; Drug Liberation; Female; Humans; Lipoproteins, HDL; Mice; Nanoparticles; Paclitaxel; Pyridines; Pyrimidines; Signal Transduction; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2021 |
CXCL8 Facilitates the Survival and Paclitaxel-Resistance of Triple-Negative Breast Cancers.
Topics: Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Interleukin-8; Paclitaxel; Triple Negative Breast Neoplasms; Up-Regulation | 2022 |
Transcriptome Profile Analysis of Triple-Negative Breast Cancer Cells in Response to a Novel Cytostatic Tetrahydroisoquinoline Compared to Paclitaxel.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Benzamides; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cytostatic Agents; Drug Discovery; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Isoquinolines; Paclitaxel; Tetrahydroisoquinolines; Triple Negative Breast Neoplasms | 2021 |
Pyrazole Derivatives Induce Apoptosis via ROS Generation in the Triple Negative Breast Cancer Cells, MDA-MB-468.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Humans; Paclitaxel; Pyrazoles; Reactive Oxygen Species; Triple Negative Breast Neoplasms | 2021 |
Simultaneous CK2/TNIK/DYRK1 inhibition by 108600 suppresses triple negative breast cancer stem cells and chemotherapy-resistant disease.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Casein Kinase II; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Dyrk Kinases; Humans; Mice; Neoplastic Stem Cells; Nitrobenzenes; Paclitaxel; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Thiazines; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2021 |
Adenomatous Polyposis Coli loss controls cell cycle regulators and response to paclitaxel in MDA-MB-157 metaplastic breast cancer cells.
Topics: Adenomatous Polyposis Coli Protein; CDC2 Protein Kinase; Cell Cycle Proteins; Cell Line, Tumor; Cyclin B1; Drug Resistance, Neoplasm; Female; Humans; Metaplasia; Paclitaxel; RNA, Small Interfering; Triple Negative Breast Neoplasms | 2021 |
First-line Bevacizumab and Paclitaxel for HER2-negative Metastatic Breast Cancer: A French Retrospective Observational Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Female; France; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Prospective Studies; Receptor, ErbB-2; Retrospective Studies; Treatment Outcome; Triple Negative Breast Neoplasms | 2017 |
TRA2A Promoted Paclitaxel Resistance and Tumor Progression in Triple-Negative Breast Cancers via Regulating Alternative Splicing.
Topics: Alternative Splicing; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Gene Expression Regulation, Neoplastic; Humans; Membrane Cofactor Protein; Paclitaxel; Prognosis; Triple Negative Breast Neoplasms; Tumor Suppressor Proteins | 2017 |
Suppressive role exerted by microRNA-29b-1-5p in triple negative breast cancer through SPIN1 regulation.
Topics: Antineoplastic Agents, Phytogenic; Breast; Carcinogenesis; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Microtubule-Associated Proteins; Nanog Homeobox Protein; Neoplasm Invasiveness; Neoplastic Stem Cells; Octamer Transcription Factor-3; Paclitaxel; Phosphoproteins; Signal Transduction; SOXB1 Transcription Factors; Triple Negative Breast Neoplasms | 2017 |
Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biphenyl Compounds; Cell Proliferation; Coculture Techniques; Endothelial Cells; Female; Gene Silencing; Hedgehog Proteins; Human Umbilical Vein Endothelial Cells; Humans; MCF-7 Cells; Membrane Proteins; Mice; Mice, Nude; Middle Aged; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Pyridines; RNA, Messenger; Signal Transduction; Thrombospondin 1; Tissue Array Analysis; Transfection; Triple Negative Breast Neoplasms; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Young Adult; Zinc Finger Protein GLI1 | 2017 |
Development of biodegradable PLGA nanoparticles surface engineered with hyaluronic acid for targeted delivery of paclitaxel to triple negative breast cancer cells.
Topics: Cell Line, Tumor; Drug Carriers; Humans; Hyaluronic Acid; Lactic Acid; Nanoparticles; Paclitaxel; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Triple Negative Breast Neoplasms | 2017 |
Androgen Receptor Supports an Anchorage-Independent, Cancer Stem Cell-like Population in Triple-Negative Breast Cancer.
Topics: Androgen Receptor Antagonists; Animals; Benzamides; Cell Line, Tumor; Female; Gene Knockdown Techniques; Heterografts; Humans; Mice, Nude; Neoplastic Stem Cells; Nitriles; Paclitaxel; Phenylthiohydantoin; Receptors, Androgen; Transcriptional Activation; Triple Negative Breast Neoplasms; Up-Regulation | 2017 |
Protein kinase C inhibitor chelerythrine selectively inhibits proliferation of triple-negative breast cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzophenanthridines; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Isoenzymes; Mice; Paclitaxel; Protein Kinase C; Protein Kinase Inhibitors; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2017 |
PSMB5 is associated with proliferation and drug resistance in triple-negative breast cancer.
Topics: Aged; Apoptosis; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Middle Aged; Paclitaxel; Proteasome Endopeptidase Complex; Triple Negative Breast Neoplasms | 2018 |
Riluzole synergizes with paclitaxel to inhibit cell growth and induce apoptosis in triple-negative breast cancer.
Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Paclitaxel; Riluzole; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2017 |
Codelivery of anti-cancer agents via double-walled polymeric microparticles/injectable hydrogel: A promising approach for treatment of triple negative breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Capsules; Cell Line, Tumor; Cisplatin; Delayed-Action Preparations; Diffusion; Humans; Hydrogels; Injections; Paclitaxel; Treatment Outcome; Triple Negative Breast Neoplasms | 2017 |
Modulation of SOX2 expression delineates an end-point for paclitaxel-effectiveness in breast cancer stem cells.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Models, Biological; Neoplastic Stem Cells; Nuclear Proteins; Paclitaxel; SOXB1 Transcription Factors; Spheroids, Cellular; Transcriptome; Triple Negative Breast Neoplasms; Tumor Cells, Cultured; Twist-Related Protein 1 | 2017 |
CyclinG1 Amplification Enhances Aurora Kinase Inhibitor-Induced Polyploid Resistance and Inhibition of Bcl-2 Pathway Reverses the Resistance.
Topics: Adult; Aniline Compounds; Antineoplastic Agents, Phytogenic; bcl-X Protein; Benzamides; Cell Cycle Checkpoints; Cell Line, Tumor; Cyclin G1; Drug Resistance, Neoplasm; Female; Humans; MCF-7 Cells; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Paclitaxel; Polyploidy; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines; RNA Interference; Sulfonamides; Triple Negative Breast Neoplasms | 2017 |
DEAE-Dextran coated paclitaxel nanoparticles act as multifunctional nano system for intranuclear delivery to triple negative breast cancer through VEGF and NOTCH1 inhibition.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cell Line, Tumor; DEAE-Dextran; Drug Delivery Systems; Female; HEK293 Cells; Humans; Interferons; MCF-7 Cells; Mice; Mice, Inbred BALB C; Nanoparticles; Paclitaxel; Receptor, Notch1; Triple Negative Breast Neoplasms; Vascular Endothelial Growth Factor A | 2018 |
Therapy response testing of breast cancer in a 3D high-throughput perfused microfluidic platform.
Topics: Antineoplastic Agents; BRCA1 Protein; Cell Culture Techniques; Cell Line, Tumor; Cell Survival; Cisplatin; Collagen; Drug Combinations; Extracellular Matrix; Female; Humans; Laminin; Microfluidics; Mutation; Outcome Assessment, Health Care; Paclitaxel; Phthalazines; Piperazines; Prognosis; Proteoglycans; Triple Negative Breast Neoplasms; Tumor Suppressor Protein p53 | 2017 |
Safety and Efficacy of Low-dose Nanoparticle Albumin-bound Paclitaxel for HER2-negative Metastatic Breast Cancer.
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents; Disease-Free Survival; Female; Humans; Middle Aged; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Triple Negative Breast Neoplasms; Young Adult | 2018 |
Mesenchymal-epithelial Transition and Tumor Vascular Remodeling in Eribulin Chemotherapy for Breast Cancer.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Biomarkers, Tumor; Cadherins; Carbonic Anhydrase IX; Cell Hypoxia; Epithelial-Mesenchymal Transition; Female; Furans; Humans; Ketones; Middle Aged; Paclitaxel; Retrospective Studies; Triple Negative Breast Neoplasms; Vascular Remodeling; Vimentin | 2018 |
miR-613 inhibits cell migration and invasion by downregulating Daam1 in triple-negative breast cancer.
Topics: 3' Untranslated Regions; Adaptor Proteins, Signal Transducing; Cell Line, Tumor; Cell Movement; Cyclophosphamide; Docetaxel; Down-Regulation; Doxorubicin; Female; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Kaempferols; Lymphatic Metastasis; MCF-7 Cells; Microfilament Proteins; MicroRNAs; Neoplasm Invasiveness; Paclitaxel; rho GTP-Binding Proteins; rhoA GTP-Binding Protein; Signal Transduction; Triple Negative Breast Neoplasms | 2018 |
High-level expression of ARID1A predicts a favourable outcome in triple-negative breast cancer patients receiving paclitaxel-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Disease-Free Survival; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Indoles; Kaplan-Meier Estimate; Middle Aged; Nuclear Proteins; p38 Mitogen-Activated Protein Kinases; Paclitaxel; Transcription Factors; Triple Negative Breast Neoplasms | 2018 |
RIP2 enhances cell survival by activation of NF-ĸB in triple negative breast cancer cells.
Topics: Antineoplastic Agents; Cell Survival; Ceramides; Female; Humans; MCF-7 Cells; NF-kappa B; Paclitaxel; Receptor-Interacting Protein Serine-Threonine Kinase 2; Treatment Outcome; Triple Negative Breast Neoplasms; Tumor Cells, Cultured | 2018 |
Inhibiting the proliferation, migration and invasion of triple negative breast cancer cells through anti-tumor human serum albumin nanoparticles loading aziditaxel as a novel taxane derivative.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Delivery Systems; Drug Liberation; Drug Stability; Female; Humans; Inhibitory Concentration 50; Mice; Nanoparticles; Neoplasm Invasiveness; Paclitaxel; Particle Size; Serum Albumin, Human; Time Factors; Triple Negative Breast Neoplasms | 2017 |
In vitro cytotoxic effect of PARP inhibitor alone and in combination with nab‑paclitaxel on triple‑negative and luminal A breast cancer cells.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Female; Humans; MCF-7 Cells; Mitotic Index; Paclitaxel; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Triple Negative Breast Neoplasms | 2018 |
Activity of Indatuximab Ravtansine against Triple-Negative Breast Cancer in Preclinical Tumor Models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast; Cell Line, Tumor; Docetaxel; Female; Humans; Immunoconjugates; Maytansine; Mice; Mice, Nude; Paclitaxel; Syndecan-1; Treatment Outcome; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2018 |
[18F]FDG and [18F]FLT PET for the evaluation of response to neo-adjuvant chemotherapy in a model of triple negative breast cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Cell Line, Tumor; Female; Fluorodeoxyglucose F18; Humans; Ki-67 Antigen; Mice; Mice, Nude; Mice, SCID; Neoadjuvant Therapy; Paclitaxel; Positron-Emission Tomography; Radiopharmaceuticals; ROC Curve; Thymidine; Transplantation, Heterologous; Triple Negative Breast Neoplasms | 2018 |
Taxol Induces Brk-dependent Prosurvival Phenotypes in TNBC Cells through an AhR/GR/HIF-driven Signaling Axis.
Topics: Basic Helix-Loop-Helix Transcription Factors; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Hypoxia-Inducible Factor 1; MCF-7 Cells; Neoplasm Proteins; Paclitaxel; Phenotype; Phosphorylation; Protein-Tyrosine Kinases; Receptors, Aryl Hydrocarbon; Receptors, Glucocorticoid; Signal Transduction; Transfection; Triple Negative Breast Neoplasms | 2018 |
The inhibitory effects of plumbagin on the NF-қB pathway and CCL2 release in racially different triple-negative breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Black or African American; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemokine CCL2; Female; Humans; Naphthoquinones; NF-kappa B; Paclitaxel; RNA, Messenger; Signal Transduction; Triple Negative Breast Neoplasms; Tumor Necrosis Factor-alpha; White People | 2018 |
Interleukin-22 promotes triple negative breast cancer cells migration and paclitaxel resistance through JAK-STAT3/MAPKs/AKT signaling pathways.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Female; Humans; Interleukin-22; Interleukins; Janus Kinases; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Paclitaxel; Proto-Oncogene Proteins c-akt; Signal Transduction; STAT3 Transcription Factor; Triple Negative Breast Neoplasms | 2018 |
Dysregulation in Actin Cytoskeletal Organization Drives Increased Stiffness and Migratory Persistence in Polyploidal Giant Cancer Cells.
Topics: Actin Cytoskeleton; Antineoplastic Agents, Phytogenic; Biophysical Phenomena; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Female; Giant Cells; Humans; Neoplastic Stem Cells; Paclitaxel; Polyploidy; rho-Associated Kinases; rhoA GTP-Binding Protein; Signal Transduction; Triple Negative Breast Neoplasms | 2018 |
Inhibition of IRE1 RNase activity modulates the tumor cell secretome and enhances response to chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cell Line, Tumor; Endoribonucleases; Enzyme Inhibitors; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Mice, Nude; Paclitaxel; Protein Serine-Threonine Kinases; RNA Interference; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2018 |
A Minimal lncRNA-mRNA Signature Predicts Sensitivity to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cyclophosphamide; Databases, Genetic; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Remission Induction; RNA, Long Noncoding; RNA, Messenger; ROC Curve; Transcriptome; Triple Negative Breast Neoplasms | 2018 |
Antitumor activity of cell-penetrant kinin B1 receptor antagonists in human triple-negative breast cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bradykinin B1 Receptor Antagonists; Cell Line, Tumor; Cell Membrane Permeability; Cell-Penetrating Peptides; Chlorocebus aethiops; COS Cells; Doxorubicin; Female; Gene Expression Regulation, Neoplastic; Humans; Paclitaxel; Receptor, Bradykinin B1; Receptors, G-Protein-Coupled; Signal Transduction; Triple Negative Breast Neoplasms | 2019 |
TRIM59 overexpression correlates with poor prognosis and contributes to breast cancer progression through AKT signaling pathway.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; MCF-7 Cells; Membrane Proteins; Metalloproteins; Neoplasm Staging; Paclitaxel; Prognosis; Proto-Oncogene Proteins c-akt; Signal Transduction; Survival Analysis; Tripartite Motif Proteins; Triple Negative Breast Neoplasms; Tumor Burden; Up-Regulation | 2018 |
Endogenous albumin-mediated delivery of redox-responsive paclitaxel-loaded micelles for targeted cancer therapy.
Topics: Albumins; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Cell Survival; Drug Carriers; Female; Humans; Kinetics; Mice, Nude; Micelles; Molecular Docking Simulation; Nanocapsules; Osteonectin; Oxidation-Reduction; Paclitaxel; Protein Domains; Rats, Sprague-Dawley; Sialoglycoproteins; Triple Negative Breast Neoplasms | 2018 |
Effect of Vitamin D on Paclitaxel Efficacy in Triple-negative Breast Cancer Cell Lines.
Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Humans; Inhibitory Concentration 50; Mutation; Paclitaxel; Triple Negative Breast Neoplasms; Tumor Suppressor Protein p53; Vitamin D | 2018 |
Knockdown of lncRNA H19 restores chemo-sensitivity in paclitaxel-resistant triple-negative breast cancer through triggering apoptosis and regulating Akt signaling pathway.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Knockdown Techniques; Humans; Immunohistochemistry; Mice; Mice, Nude; Neoplasm Transplantation; Oncogene Protein v-akt; Paclitaxel; RNA, Long Noncoding; Signal Transduction; Triple Negative Breast Neoplasms | 2018 |
Jagged2 promotes cancer stem cell properties of triple negative breast cancer cells and paclitaxel resistance via regulating microRNA-200.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Jagged-2 Protein; MicroRNAs; Neoplastic Stem Cells; Paclitaxel; Triple Negative Breast Neoplasms; Up-Regulation | 2018 |
Anti-EGFR anchored paclitaxel loaded PLGA nanoparticles for the treatment of triple negative breast cancer. In-vitro and in-vivo anticancer activities.
Topics: Animals; Cell Line, Tumor; Cell Survival; Delayed-Action Preparations; Drug Carriers; ErbB Receptors; Humans; Mice; Nanoparticles; Paclitaxel; Polylactic Acid-Polyglycolic Acid Copolymer; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2018 |
Enhanced bioreduction-responsive diselenide-based dimeric prodrug nanoparticles for triple negative breast cancer therapy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Drug Carriers; Heterografts; Humans; Mice, Nude; Models, Theoretical; Molecular Targeted Therapy; Nanoparticles; Neoplasm Transplantation; Oxidation-Reduction; Paclitaxel; Prodrugs; Selenium Compounds; Treatment Outcome; Triple Negative Breast Neoplasms | 2018 |
PD-L1 Inhibitor Improves Survival in TNBC.
Topics: Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; B7-H1 Antigen; Humans; Paclitaxel; Triple Negative Breast Neoplasms | 2019 |
Role of inhibitor of yes-associated protein 1 in triple-negative breast cancer with taxol-based chemoresistance.
Topics: Adaptor Proteins, Signal Transducing; Adolescent; Adult; Aged; Aged, 80 and over; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Middle Aged; Paclitaxel; Phosphoproteins; Transcription Factors; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Young Adult | 2019 |
Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells.
Topics: Animals; Cell Differentiation; Cell Line, Tumor; Dasatinib; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Humans; Mice; Neoplastic Stem Cells; Paclitaxel; Protein Kinase Inhibitors; src-Family Kinases; Triple Negative Breast Neoplasms | 2018 |
Effects of adjuvant chemotherapy in T1N0M0 triple-negative breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Mastectomy; Mastectomy, Segmental; Middle Aged; Multivariate Analysis; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Retrospective Studies; Taxoids; Triple Negative Breast Neoplasms | 2019 |
Clinicopathological analysis of homologous recombination-deficient breast cancers with special reference to response to neoadjuvant paclitaxel followed by FEC.
Topics: Biopsy; BRCA1 Protein; Breast Neoplasms; DNA Methylation; Female; Gene Expression Profiling; Homologous Recombination; Humans; Neoadjuvant Therapy; Neoplasm Staging; Oligonucleotide Array Sequence Analysis; Paclitaxel; Prognosis; Promoter Regions, Genetic; Receptor, ErbB-2; Treatment Outcome; Triple Negative Breast Neoplasms | 2019 |
Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Immunological; B7-H1 Antigen; Cell Line, Tumor; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Female; Indoles; Kaplan-Meier Estimate; Mice; Molecular Targeted Therapy; Neoplasm Metastasis; Paclitaxel; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2019 |
Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Topics: Adult; Animals; Apoptosis; Cell Line, Tumor; Cell Survival; Cetuximab; Endocytosis; ErbB Receptors; Female; Histones; Humans; Mice, Nude; Mitosis; Nanocomposites; Nanodiamonds; Paclitaxel; Phosphorylation; Treatment Outcome; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2019 |
Reactive oxygen species modulate macrophage immunosuppressive phenotype through the up-regulation of PD-L1.
Topics: Animals; B7-H1 Antigen; Breast Neoplasms; Buthionine Sulfoximine; Cell Line, Tumor; Chemokines; Drug Therapy; Female; Glutathione; Humans; Immunosuppressive Agents; Macrophages; Mice; Paclitaxel; Phenotype; Reactive Oxygen Species; RNA, Messenger; Triple Negative Breast Neoplasms; Tumor Microenvironment; Up-Regulation | 2019 |
Inhibition of Copper Transport Induces Apoptosis in Triple-Negative Breast Cancer Cells and Suppresses Tumor Angiogenesis.
Topics: Animals; Apoptosis; Benzothiazoles; Bromobenzenes; Cell Line, Tumor; Cell Movement; Cell Proliferation; Copper; Copper Transport Proteins; Copper-Transporting ATPases; Female; Fluorobenzenes; Gene Expression Regulation, Neoplastic; Humans; Mice; Molecular Chaperones; Molybdenum; Neovascularization, Pathologic; Oxidative Stress; Paclitaxel; Small Molecule Libraries; Triple Negative Breast Neoplasms; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2019 |
Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cytokine Receptor gp130; Down-Regulation; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Indoles; Interleukin-6; Mice; Paclitaxel; Phosphorylation; Signal Transduction; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2019 |
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
Topics: Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Humans; Paclitaxel; Triple Negative Breast Neoplasms | 2019 |
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
Topics: Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Humans; Paclitaxel; Triple Negative Breast Neoplasms | 2019 |
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
Topics: Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Humans; Paclitaxel; Triple Negative Breast Neoplasms | 2019 |
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. Reply.
Topics: Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Humans; Paclitaxel; Triple Negative Breast Neoplasms | 2019 |
Anti-metastatic activity of MPT0G211, a novel HDAC6 inhibitor, in human breast cancer cells in vitro and in vivo.
Topics: Acetylation; Animals; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; Cell Line, Tumor; Cell Movement; Cell Survival; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; MCF-7 Cells; Mice; Neoplasm Metastasis; Paclitaxel; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2019 |
EGCG-Derivative G28 Shows High Efficacy Inhibiting the Mammosphere-Forming Capacity of Sensitive and Resistant TNBC Models.
Topics: Antineoplastic Agents; Catechin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Doxorubicin; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Fatty Acid Synthase, Type I; Female; Gene Expression Regulation, Neoplastic; Humans; Molecular Structure; Neoplastic Stem Cells; Paclitaxel; Triple Negative Breast Neoplasms | 2019 |
Advocacy for a New Oncology Research Paradigm: The Model of Bevacizumab in Triple-Negative Breast Cancer in a French Cohort Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomedical Research; Cost-Benefit Analysis; Female; Humans; Medical Oncology; Middle Aged; Neoplasm Metastasis; Paclitaxel; Progression-Free Survival; Receptor, ErbB-2; Triple Negative Breast Neoplasms; Vascular Endothelial Growth Factor A | 2019 |
Sarcoidosis-like reaction in metastatic triple negative breast cancer treated by anti-PD-L1.
Topics: Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Biopsy, Fine-Needle; Female; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Diseases; Molecular Targeted Therapy; Paclitaxel; Sarcoidosis; Triple Negative Breast Neoplasms | 2019 |
Synergistic enhancement of apoptosis by coralyne and paclitaxel in combination on MDA-MB-231 a triple-negative breast cancer cell line.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Berberine Alkaloids; Caspase 3; Cell Line, Tumor; DNA Damage; DNA Fragmentation; Drug Synergism; Female; G1 Phase Cell Cycle Checkpoints; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Matrix Metalloproteinase 9; Paclitaxel; Triple Negative Breast Neoplasms | 2019 |
Redox-Responsive Fluorescent Polycarbonates Based on Selenide for Chemotherapy of Triple-Negative Breast Cancer.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Doxorubicin; Drug Delivery Systems; Drug Liberation; Fluorescent Dyes; Humans; Hydrophobic and Hydrophilic Interactions; Mice; Micelles; Nanoparticles; Oxidation-Reduction; Paclitaxel; Polycarboxylate Cement; Reactive Oxygen Species; Triple Negative Breast Neoplasms | 2019 |
TS-1 add-on therapy in Japanese patients with triple-negative breast cancer after neoadjuvant or adjuvant chemotherapy: a feasibility study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Docetaxel; Epirubicin; Feasibility Studies; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prognosis; Silicates; Survival Rate; Titanium; Triple Negative Breast Neoplasms | 2020 |
Targeting MUC1-C Inhibits TWIST1 Signaling in Triple-Negative Breast Cancer.
Topics: Cell Line, Tumor; Cell Self Renewal; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Humans; Mucin-1; Neoplastic Stem Cells; Nuclear Proteins; Paclitaxel; Signal Transduction; Triple Negative Breast Neoplasms; Twist-Related Protein 1 | 2019 |
Co-targeting Bulk Tumor and CSCs in Clinically Translatable TNBC Patient-Derived Xenografts via Combination Nanotherapy.
Topics: Animals; Cell Line, Tumor; Cell Membrane Permeability; Cell Proliferation; Combined Modality Therapy; Humans; Mice; Nanomedicine; Nanoparticles; Neoplastic Stem Cells; Paclitaxel; Tissue Distribution; Translational Research, Biomedical; Treatment Outcome; Triple Negative Breast Neoplasms; Verteporfin; Xenograft Model Antitumor Assays | 2019 |
MicroRNA-5195-3p enhances the chemosensitivity of triple-negative breast cancer to paclitaxel by downregulating EIF4A2.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; Eukaryotic Initiation Factor-4A; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; MicroRNAs; Paclitaxel; Triple Negative Breast Neoplasms | 2019 |
Aurora kinase A stabilizes FOXM1 to enhance paclitaxel resistance in triple-negative breast cancer.
Topics: Aurora Kinase A; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Forkhead Box Protein M1; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Paclitaxel; Promoter Regions, Genetic; Thiostrepton; Triple Negative Breast Neoplasms | 2019 |
AMG 900, a small-molecule inhibitor of aurora kinases, potentiates the activity of microtubule-targeting agents in human metastatic breast cancer models.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinases; Cell Death; Cell Line, Tumor; Drug Resistance, Neoplasm; Epothilones; Female; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Neoplasm Metastasis; Paclitaxel; Phosphorylation; Phthalazines; Polyploidy; Protein Kinase Inhibitors; Triple Negative Breast Neoplasms; Tubulin Modulators; Xenograft Model Antitumor Assays | 2013 |
Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 3; Cell Line, Tumor; Dexamethasone; Drug Resistance, Neoplasm; Dual Specificity Phosphatase 1; Female; Gene Expression; Hormone Antagonists; Humans; Immediate-Early Proteins; Mice; Mice, SCID; Mifepristone; Neoplasm Recurrence, Local; Neoplasm Transplantation; Paclitaxel; Poly(ADP-ribose) Polymerases; Protein Serine-Threonine Kinases; Receptors, Estrogen; Receptors, Glucocorticoid; Signal Transduction; Transplantation, Heterologous; Triple Negative Breast Neoplasms | 2013 |
Establishment of a 5-fluorouracil-resistant triple-negative breast cancer cell line.
Topics: Antineoplastic Agents; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Paclitaxel; Proteome; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Triple Negative Breast Neoplasms; Vinblastine; Vinorelbine | 2013 |
Prolonged progression-free survival in a patient with triple-negative breast cancer metastatic to the liver after chemotherapy and local radiation therapy.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Intraductal, Noninfiltrating; Chemoradiotherapy; Female; Humans; Liver Neoplasms; Middle Aged; Neoplasm Grading; Paclitaxel; Prognosis; Survival Rate; Triple Negative Breast Neoplasms | 2014 |
Individual xenograft as a personalized therapeutic resort for women with metastatic triple-negative breast carcinoma.
Topics: Adult; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Cisplatin; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Mammary Neoplasms, Animal; Mice; Neoplasm Metastasis; Neoplasm Transplantation; Paclitaxel; Taxoids; Transplantation, Heterologous; Treatment Outcome; Triple Negative Breast Neoplasms | 2014 |
The TrkB+ cancer stem cells contribute to post-chemotherapy recurrence of triple-negative breast cancers in an orthotopic mouse model.
Topics: Aged; Animals; Apoptosis; Brain-Derived Neurotrophic Factor; Cell Line, Tumor; Disease Models, Animal; Female; Gene Expression Regulation, Neoplastic; Humans; Kruppel-Like Factor 4; Membrane Glycoproteins; Mice; Middle Aged; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Paclitaxel; Paracrine Communication; Protein-Tyrosine Kinases; Receptor, trkB; Signal Transduction; Triple Negative Breast Neoplasms | 2015 |
I-SPY2 trial yields first results on combination therapy for triple-negative breast cancer.
Topics: Anthracyclines; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Female; Humans; Paclitaxel; Randomized Controlled Trials as Topic; Treatment Outcome; Triple Negative Breast Neoplasms | 2014 |
microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Docetaxel; Down-Regulation; Doxorubicin; Epirubicin; ErbB Receptors; Female; Fluorouracil; Gene Expression Profiling; Humans; Kaplan-Meier Estimate; Keratin-5; Keratin-6; Methotrexate; MicroRNAs; Middle Aged; Oligonucleotide Array Sequence Analysis; Paclitaxel; Prognosis; Risk Assessment; Survival Rate; Taxoids; Triple Negative Breast Neoplasms; Up-Regulation | 2014 |
[A case of triple-negative breast cancer responding to multidisciplinary treatment containing bevacizumab].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Triple Negative Breast Neoplasms | 2014 |
Near-infrared optical imaging of cancer vascular remodeling after antiangiogenic therapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Female; Hemoglobins; Humans; Mammary Glands, Human; Middle Aged; Neovascularization, Pathologic; Paclitaxel; Spectrophotometry, Infrared; Triple Negative Breast Neoplasms; Vascular Remodeling | 2014 |
In vitro chemoresponse assay based on the intrinsic subtypes in breast cancer.
Topics: Adenosine Triphosphate; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Epirubicin; Female; Gemcitabine; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; In Vitro Techniques; Ki-67 Antigen; Mastectomy; Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Triple Negative Breast Neoplasms; Vinblastine; Vinorelbine | 2014 |
[Effect of miR-342-3p on chemotherapy sensitivity in triple-negative breast cancer].
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cisplatin; Doxorubicin; Drug Resistance, Neoplasm; Humans; MicroRNAs; Paclitaxel; Transfection; Triple Negative Breast Neoplasms | 2014 |
Inhibition of Cdk2 kinase activity selectively targets the CD44⁺/CD24⁻/Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cells.
Topics: Apoptosis; CD24 Antigen; Cell Line, Tumor; Chromosomal Instability; Cyclin-Dependent Kinase 2; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Humans; Hyaluronan Receptors; Imidazoles; Indoles; Inflammatory Breast Neoplasms; MCF-7 Cells; Neoplastic Stem Cells; Paclitaxel; Triple Negative Breast Neoplasms | 2014 |
Nab-paclitaxel for the management of triple-negative metastatic breast cancer: a case study.
Topics: Albumins; Antineoplastic Agents; Bevacizumab; Female; Humans; Middle Aged; Nanoparticles; Neoplasm Metastasis; Paclitaxel; Triple Negative Breast Neoplasms | 2015 |
[A case of locally advanced and metastatic breast cancer successfully treated with combination therapy of paclitaxel and bevacizumab].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Combined Modality Therapy; Female; Humans; Lymph Node Excision; Lymphatic Metastasis; Mastectomy; Middle Aged; Paclitaxel; Triple Negative Breast Neoplasms | 2014 |
The anti-androgen drug dutasteride renders triple negative breast cancer cells more sensitive to chemotherapy via inhibition of HIF-1α-/VEGF-signaling.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Androgen Antagonists; Antineoplastic Agents; Azasteroids; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Dutasteride; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Membrane Proteins; Paclitaxel; Signal Transduction; Triple Negative Breast Neoplasms; Vascular Endothelial Growth Factor A | 2015 |
Triple negative breast cancer in BRCA1 mutation carriers with a complete radiologic response to neoadjuvant paclitaxel: a case report.
Topics: Adult; Antineoplastic Agents; Carcinoma, Ductal, Breast; Doxorubicin; Female; Genes, BRCA1; Heterozygote; Humans; Mutation; Neoadjuvant Therapy; Paclitaxel; Triple Negative Breast Neoplasms; Young Adult | 2015 |
Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells.
Topics: Analysis of Variance; Cell Line, Tumor; Deoxycytidine; DNA Primers; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation; Humans; Hypoxia-Inducible Factor 1; Image Processing, Computer-Assisted; Immunoblotting; Interleukin-6; Interleukin-8; Kaplan-Meier Estimate; Luciferases; Microscopy; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Triple Negative Breast Neoplasms | 2014 |
Pathologic complete response rates in triple-negative, HER2-positive, and hormone receptor-positive breast cancers after anthracycline-free neoadjuvant chemotherapy with carboplatin and paclitaxel with or without trastuzumab.
Topics: Adult; Aged; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Trastuzumab; Triple Negative Breast Neoplasms | 2015 |
Inhibition of CDK-mediated phosphorylation of Smad3 results in decreased oncogenesis in triple negative breast cancer cells.
Topics: Animals; Cell Line, Tumor; Cyclin-Dependent Kinases; Enzyme Inhibitors; Female; Humans; Mice; Paclitaxel; Phosphorylation; Smad3 Protein; Triple Negative Breast Neoplasms | 2014 |
The Na⁺/H⁺ exchanger (NHE1) as a novel co-adjuvant target in paclitaxel therapy of triple-negative breast cancer cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Blotting, Western; Cation Transport Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Female; Gene Knockout Techniques; Humans; MCF-7 Cells; Mice, Nude; Molecular Targeted Therapy; Neoplasm Metastasis; Paclitaxel; Sodium-Hydrogen Exchanger 1; Sodium-Hydrogen Exchangers; Time Factors; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2015 |
BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; BRCA1 Protein; Cell Line, Tumor; Cell Movement; Cell Survival; Cell Transformation, Neoplastic; Disease Models, Animal; Disease Progression; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Female; Forkhead Box Protein O3; Forkhead Transcription Factors; Gene Expression; Gene Silencing; Humans; Inhibitor of Apoptosis Proteins; Mice; Neoplastic Stem Cells; Paclitaxel; Peptide Fragments; Phenotype; Proteolysis; RNA Interference; RNA, Small Interfering; Signal Transduction; Survivin; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2015 |
[Effect of weekly paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide as neoadjuvant treatment for patients with triple-negative and luminal-type breast cancer - a multicenter study].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Triple Negative Breast Neoplasms | 2015 |
[Prolonged remission achieved by using bevacizumab plus paclitaxel therapy combined with sequential radiotherapy for a rapidly growing chest wall recurrence of triple negative breast cancer - a case report].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chemoradiotherapy; Disease Progression; Female; Humans; Mastectomy, Modified Radical; Paclitaxel; Recurrence; Remission Induction; Thoracic Wall; Triple Negative Breast Neoplasms | 2015 |
"Triple-punch" strategy for triple negative breast cancer therapy with minimized drug dosage and improved antitumor efficacy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Carriers; Endocytosis; Female; Humans; Indocyanine Green; Inhibitor of Apoptosis Proteins; Intracellular Space; Lactic Acid; Methacrylates; Mice; Mice, Inbred BALB C; Nanomedicine; Nanoparticles; Paclitaxel; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; RNA, Small Interfering; Survivin; Triple Negative Breast Neoplasms | 2015 |
Autophagy inhibition re-sensitizes pulse stimulation-selected paclitaxel-resistant triple negative breast cancer cells to chemotherapy-induced apoptosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Female; Humans; Induction Chemotherapy; Mitochondria; Paclitaxel; Treatment Outcome; Triple Negative Breast Neoplasms | 2015 |
Old drugs, new tricks for triple-negative breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Humans; Paclitaxel; Triple Negative Breast Neoplasms | 2015 |
Stress hormones reduce the efficacy of paclitaxel in triple negative breast cancer through induction of DNA damage.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Catecholamines; Cell Cycle; Cell Proliferation; DNA Damage; DNA Repair; Female; Flow Cytometry; Humans; Hydrocortisone; Mice; Mice, Nude; Paclitaxel; Receptors, Estrogen; Signal Transduction; Stress, Physiological; Triple Negative Breast Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2015 |
MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Disease Progression; Female; Humans; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Paclitaxel; Transfection; Triple Negative Breast Neoplasms | 2015 |
Chemotherapy triggers HIF-1-dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Chelating Agents; Copper; Extracellular Signal-Regulated MAP Kinases; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glutathione; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Mice; Mice, SCID; Neoplasm Transplantation; Neoplastic Stem Cells; Oligonucleotides; Paclitaxel; Phenotype; Phosphorylation; RNA, Messenger; Triple Negative Breast Neoplasms | 2015 |
A paclitaxel-loaded recombinant polypeptide nanoparticle outperforms Abraxane in multiple murine cancer models.
Topics: Albumin-Bound Paclitaxel; Animals; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Survival; Drug Delivery Systems; Female; Gene Expression Regulation, Neoplastic; Humans; In Vitro Techniques; Male; Mice; Microscopy, Confocal; Microscopy, Fluorescence; Nanoconjugates; Nanoparticles; Neoplasm Transplantation; Paclitaxel; Peptides; Prostatic Neoplasms; Recombinant Proteins; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2015 |
Ligand-dependent genomic function of glucocorticoid receptor in triple-negative breast cancer.
Topics: Acetates; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Chromatin Immunoprecipitation; Dexamethasone; Drug Resistance, Neoplasm; Electrophoretic Mobility Shift Assay; Gene Expression Regulation, Neoplastic; Glucocorticoids; Humans; Ligands; Paclitaxel; Receptors, Glucocorticoid; Response Elements; Reverse Transcriptase Polymerase Chain Reaction; Triple Negative Breast Neoplasms; Tyramine | 2015 |
Paclitaxel-induced transcriptional regulation of Fas signaling pathway is antagonized by dexamethasone.
Topics: Apoptosis; Cell Survival; Dexamethasone; fas Receptor; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; NF-kappa B; Paclitaxel; Signal Transduction; Triple Negative Breast Neoplasms | 2015 |
The combination of thymoquinone and paclitaxel shows anti-tumor activity through the interplay with apoptosis network in triple-negative breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Benzoquinones; Carcinoma, Ehrlich Tumor; Cell Line, Tumor; Cell Movement; Cell Survival; Drug Screening Assays, Antitumor; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Mammary Neoplasms, Experimental; Mice, Inbred BALB C; Neoplasm Transplantation; Paclitaxel; Triple Negative Breast Neoplasms; Tumor Burden | 2016 |
Factors Associated with the Selection of First-line Bevacizumab plus Chemotherapy and Clinical Response in HER2-negative Metastatic Breast Cancer: ONCOSUR AVALOX Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Cross-Sectional Studies; Female; Humans; Neoplasm Metastasis; Paclitaxel; Quality of Life; Receptor, ErbB-2; Triple Negative Breast Neoplasms | 2015 |
Hsp90 Inhibition Results in Glucocorticoid Receptor Degradation in Association with Increased Sensitivity to Paclitaxel in Triple-Negative Breast Cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; HSP90 Heat-Shock Proteins; Humans; Mice; Paclitaxel; Receptors, Glucocorticoid; Triazoles; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2016 |
A novel EGR-1 dependent mechanism for YB-1 modulation of paclitaxel response in a triple negative breast cancer cell line.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Drug Resistance, Neoplasm; Early Growth Response Protein 1; Female; Gene Expression; Gene Expression Profiling; Humans; Kaplan-Meier Estimate; Paclitaxel; Prognosis; RNA, Messenger; Triple Negative Breast Neoplasms; Y-Box-Binding Protein 1 | 2016 |
Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triple-negative breast cancer among BRCA1 mutation carriers and non-carriers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Cyclophosphamide; Female; Humans; Middle Aged; Mutation; Neoadjuvant Therapy; Paclitaxel; Survival Analysis; Treatment Outcome; Triple Negative Breast Neoplasms; Young Adult | 2016 |
Improved safety and efficacy of a lipid emulsion loaded with a paclitaxel-cholesterol complex for the treatment of breast tumors.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Chemistry, Pharmaceutical; Cholesterol; Drug Carriers; Drug Delivery Systems; Emulsions; Female; Humans; Lipids; Mammary Neoplasms, Animal; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Particle Size; Triple Negative Breast Neoplasms | 2016 |
MiR-18a upregulation decreases Dicer expression and confers paclitaxel resistance in triple negative breast cancer.
Topics: Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Paclitaxel; Triple Negative Breast Neoplasms; Up-Regulation | 2016 |
Value of Ki-67 expression in triple-negative breast cancer before and after neoadjuvant chemotherapy with weekly paclitaxel plus carboplatin.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Disease-Free Survival; Female; Humans; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Triple Negative Breast Neoplasms | 2016 |
Metabolomics Analysis of Hormone-Responsive and Triple-Negative Breast Cancer Cell Responses to Paclitaxel Identify Key Metabolic Differences.
Topics: Amino Acids; Carbohydrate Metabolism; Cell Line, Tumor; Female; Hormones; Humans; Lipid Metabolism; Metabolic Networks and Pathways; Metabolism; Metabolomics; Paclitaxel; Phenobarbital; Triple Negative Breast Neoplasms | 2016 |
Calcium phosphate-polymer hybrid nanoparticles for enhanced triple negative breast cancer treatment via co-delivery of paclitaxel and miR-221/222 inhibitors.
Topics: Antineoplastic Agents, Phytogenic; Calcium Phosphates; Cell Line, Tumor; Humans; MicroRNAs; Nanoparticles; Paclitaxel; Polymers; Triple Negative Breast Neoplasms | 2017 |
Guanylate-Binding Protein-1 protects ovarian cancer cell lines but not breast cancer cell lines from killing by paclitaxel.
Topics: Breast Neoplasms; Cell Death; Cell Line, Tumor; Cytoprotection; Disease-Free Survival; Female; GTP-Binding Proteins; Humans; Ovarian Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-pim-1; Triple Negative Breast Neoplasms; Tubulin | 2016 |
SH003 selectively induces p73‑dependent apoptosis in triple‑negative breast cancer cells.
Topics: Angelica; Antineoplastic Agents, Phytogenic; Apoptosis; Astragalus Plant; Breast; Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Female; Humans; Paclitaxel; Plant Extracts; Trichosanthes; Triple Negative Breast Neoplasms; Tumor Protein p73 | 2016 |
Targeted Dual pH-Sensitive Lipid ECO/siRNA Self-Assembly Nanoparticles Facilitate In Vivo Cytosolic sieIF4E Delivery and Overcome Paclitaxel Resistance in Breast Cancer Therapy.
Topics: Animals; Cell Line, Tumor; Cytosol; Drug Delivery Systems; Drug Resistance, Neoplasm; Eukaryotic Initiation Factor-4E; Female; Gene Silencing; Humans; Hydrogen-Ion Concentration; Lipids; Mice; Mice, Nude; Nanoparticles; Paclitaxel; RNA Interference; RNA, Small Interfering; Triple Negative Breast Neoplasms | 2016 |
MENA Confers Resistance to Paclitaxel in Triple-Negative Breast Cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Survival; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; MAP Kinase Signaling System; Mice; Microfilament Proteins; Microtubules; Neoplasm Metastasis; Paclitaxel; Protein Isoforms; Triple Negative Breast Neoplasms; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
High-metastatic triple-negative breast-cancer variants selected in vivo become chemoresistant in vitro.
Topics: Cell Line, Tumor; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Triple Negative Breast Neoplasms | 2017 |
Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Fluorescent Antibody Technique; Hedgehog Proteins; Humans; Molecular Targeted Therapy; Neoplastic Stem Cells; Nuclear Proteins; Paclitaxel; Pyridines; Pyrimidines; Signal Transduction; Spheroids, Cellular; Triple Negative Breast Neoplasms; Zinc Finger Protein GLI1; Zinc Finger Protein Gli2 | 2017 |
Targeting of apoptotic pathways by SMAC or BH3 mimetics distinctly sensitizes paclitaxel-resistant triple negative breast cancer cells.
Topics: Aniline Compounds; Apoptosis; Apoptosis Regulatory Proteins; Biomimetic Materials; Biphenyl Compounds; Cell Line, Tumor; Dipeptides; Drug Resistance, Neoplasm; Female; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Mitochondrial Proteins; Molecular Targeted Therapy; Nitrophenols; Oligopeptides; Paclitaxel; Peptide Fragments; Piperazines; Proto-Oncogene Proteins; Signal Transduction; Sulfonamides; Triple Negative Breast Neoplasms | 2017 |
Ginsenoside Rg3 promotes cytotoxicity of Paclitaxel through inhibiting NF-κB signaling and regulating Bax/Bcl-2 expression on triple-negative breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Ginsenosides; Humans; Neoplasm Recurrence, Local; NF-kappa B; Paclitaxel; Panax; Signal Transduction; Triple Negative Breast Neoplasms | 2017 |
Sulforaphane enhances the anticancer activity of taxanes against triple negative breast cancer by killing cancer stem cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cell Line, Tumor; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Female; Gene Expression Regulation, Neoplastic; Humans; Inflammation Mediators; Interleukin-6; Interleukin-8; Isothiocyanates; Mice, Inbred NOD; Mice, SCID; Neoplastic Stem Cells; NF-kappa B p52 Subunit; Paclitaxel; Phenotype; Signal Transduction; Sulfoxides; Taxoids; Time Factors; Transcription Factor RelA; Transcription, Genetic; Transfection; Triple Negative Breast Neoplasms; Tubulin Modulators; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
The tyrosine kinase inhibitor E-3810 combined with paclitaxel inhibits the growth of advanced-stage triple-negative breast cancer xenografts.
Topics: Alanine; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Synergism; Female; Humans; Indoles; Mice; Mice, Nude; Paclitaxel; Protein Kinase Inhibitors; Pyrroles; Rabeprazole; Random Allocation; Sunitinib; Triazines; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2013 |
[Analysis of chemotherapeutic efficacies in metastatic triple-negative breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Platinum Compounds; Prognosis; Survival Analysis; Treatment Outcome; Triple Negative Breast Neoplasms; Vinblastine; Vinorelbine; Young Adult | 2012 |